---
document_datetime: 2023-09-21 21:11:23
document_pages: 102
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/yescarta-h-c-004480-ii-0042-epar-assessment-report-variation_en.pdf
document_name: yescarta-h-c-004480-ii-0042-epar-assessment-report-variation_en.pdf
version: success
processing_time: 72.7738609
conversion_datetime: 2025-12-27 22:20:35.637767
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 April 2022 EMA/622447/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Yescarta

International non-proprietary name: axicabtagene ciloleucel

Procedure No. EMEA/H/C/004480/II/0042

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                  | 6                                                                                                         |
|---------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Steps taken for the assessment of the product                                                                        | ........................................................7                                                 |
| 2. Scientific discussion................................................................................                  | 8                                                                                                         |
| 2.1. Introduction                                                                                                         | ........................................................................................................8 |
| 2.1.1. Problem statement                                                                                                  | ............................................................................................8             |
| 2.1.2. About the product                                                                                                  | ........................................................................................... 11            |
| 2.1.3. General comments on compliance with GCP........................................................                    | 11                                                                                                        |
| 2.2. Quality aspects                                                                                                      | .................................................................................................. 11     |
| 2.3. Non-clinical aspects............................................................................................     | 11                                                                                                        |
| 2.3.1. Ecotoxicity/environmental risk assessment.........................................................                 | 12                                                                                                        |
| 2.3.2. Conclusion on the non-clinical aspects                                                                             | ............................................................... 12                                        |
| 2.4. Clinical aspects                                                                                                     | .................................................................................................. 12     |
| 2.4.1. Introduction....................................................................................................   | 12                                                                                                        |
| 2.4.2. Pharmacokinetics                                                                                                   | ............................................................................................ 13           |
| 2.4.3. Pharmacodynamics (Serum).............................................................................              | 24                                                                                                        |
| 2.4.4. Discussion on clinical pharmacology...................................................................             | 28                                                                                                        |
| 2.4.5. Conclusions on clinical pharmacology.................................................................              | 29                                                                                                        |
| 2.5. Clinical efficacy                                                                                                    | .................................................................................................. 29     |
| 2.5.1. Main study                                                                                                         | ..................................................................................................... 29  |
| 2.5.2. Discussion on clinical efficacy............................................................................        | 55                                                                                                        |
| 2.5.3. Conclusions on the clinical efficacy ....................................................................          | 57                                                                                                        |
| 2.6. Clinical safety                                                                                                      | .................................................................................................... 58   |
| Introduction............................................................................................................. | 58                                                                                                        |
| Patient exposure.......................................................................................................   | 58                                                                                                        |
| Adverse events.........................................................................................................   | 64                                                                                                        |
| Serious adverse event/deaths/other significant events                                                                     | .................................................. 65                                                     |
| AEs of Special Interest                                                                                                   | .............................................................................................. 67         |
| Laboratory findings                                                                                                       | ................................................................................................... 74    |
| Safety in special populations                                                                                             | ...................................................................................... 75                 |
| Safety related to drug-drug interactions and other interactions                                                           | ...................................... 75                                                                 |
| Discontinuation due to adverse events ........................................................................            | 75                                                                                                        |
| Post marketing experience.........................................................................................        | 75                                                                                                        |
| 2.6.1. Discussion on clinical safety..............................................................................        | 76                                                                                                        |
| 2.6.2. Conclusions on clinical safety............................................................................         | 77                                                                                                        |
| 2.6.3. PSUR cycle                                                                                                         | ..................................................................................................... 77  |
| 2.7. Risk management plan .......................................................................................         | 77                                                                                                        |
| Safety Specification                                                                                                      | .................................................................................................. 78     |
| Summary of the safety concerns ................................................................................           | 79                                                                                                        |
| Pharmacovigilance plan                                                                                                    | ............................................................................................. 79          |
| Routine pharmacovigilance activities                                                                                      | ........................................................................... 79                            |
| Additional pharmacovigilance activities........................................................................           | 80                                                                                                        |
| Risk minimisation measures.......................................................................................         | 82                                                                                                        |
| Elements for a public summary of the RMP ..................................................................               | 96                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Annexes ..................................................................................................................   | 96                                                                                                        |
|------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Overall conclusion on the RMP....................................................................................            | 97                                                                                                        |
| 2.8. Update of the Product Information .......................................................................               | 97                                                                                                        |
| 2.8.1. User consultation ............................................................................................        | 97                                                                                                        |
| 3. Benefit-Risk Balance.............................................................................                         | 97                                                                                                        |
| 3.1. Therapeutic Context ...........................................................................................         | 97                                                                                                        |
| 3.1.1. Disease or condition ........................................................................................         | 97                                                                                                        |
| 3.1.2. Available therapies and unmet medical need.......................................................                     | 97                                                                                                        |
| 3.1.3. Main clinical studies.........................................................................................        | 98                                                                                                        |
| 3.2. Favourable effects..............................................................................................        | 98                                                                                                        |
| 3.3. Uncertainties and limitations about favourable effects.............................................                     | 98                                                                                                        |
| 3.4. Unfavourable effects...........................................................................................         | 98                                                                                                        |
| 3.5. Uncertainties and limitations about unfavourable effects .........................................                      | 99                                                                                                        |
| 3.6. Effects Table......................................................................................................     | 99                                                                                                        |
| 3.7. Benefit-risk assessment and discussion...............................................................                   | 100                                                                                                       |
| 3.7.1. Importance of favourable and unfavourable effects............................................                         | 100                                                                                                       |
| 3.7.2. Balance of benefits and risks ..........................................................................              | 100                                                                                                       |
| 3.7.3. Additional considerations on the benefit-risk balance .........................................                       | 100                                                                                                       |
| 3.8. Conclusions                                                                                                             | ..................................................................................................... 100 |
| 4. Recommendations...............................................................................                            | 101                                                                                                       |
| 5. EPAR changes .....................................................................................                        | 101                                                                                                       |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE

Allo-SCT

adverse event

allogeneic SCT

ADR

adverse drug reaction

AUC0-28

area-under-the-curve from Day 0 to Day 28

Auto-SCT

autologous stem cell transplant

CAR

chimeric antigen receptor

CI

confidence interval

CR

complete response

CRP

C-reactive protein

CRS

cytokine release syndrome

CSR

clinical study report

CTCAE

CXCL 10

Common Terminology Criteria for Adverse Events

C-X-C motif chemokine 10

DLBCL

diffuse large B-cell lymphoma

DOR

duration of response

EU

European Union

EZH2

enhancer of zeste homolog 2

FAS

full analysis set

FL

FLIPI

GM-CSF

follicular lymphoma

follicular lymphoma international prognostic index

granulocyte-macrophage colony-stimulation factor

GVHD

graft-versus-host disease

IAS

inferential analysis set

iNHL

indolent non-Hodgkin lymphoma

ICAM

Intercellular adhesion molecule

IFN- γ

Interferon-gamma

IL

IWG

Interleukin

International Working Group

KM

Kaplan-Meier

LLOQ

lower limit of quantification

MAA

market authorisation application

MedDRA

Medical Dictionary for Regulatory Activities

MZL

marginal zone lymphoma

NCI

National Cancer Institute

NHL

non-Hodgkin lymphoma

ORR

objective response rate

OS

overall survival

PBMC

PD

peripheral blood mononuclear cell

progressive disease

PFS

progression-free survival

PI3K

R-CHOP

R-CVP

phosphatidylinositol 3-kinase

rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone

rituximab plus cyclophosphamide, vincristine and prednisone

<div style=\"page-break-after: always\"></div>

| PR        | partial response                  |
|-----------|-----------------------------------|
| r/r       | relapsed/refractory               |
| RCR       | replication-competent retrovirus  |
| SAE       | serious adverse event             |
| SMR       | standardized mortality ratio      |
| SOC       | system organ class                |
| TNF-alpha | tumor necrosis factor alpha       |
| TTNT      | time to next therapy              |
| US        | United States                     |
| VCAM-1    | Vascular cell adhesion molecule-1 |
| VIS       | vector integration sites          |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Kite Pharma EU B.V. submitted to the European Medicines Agency on 23 July 2021 an application for a variation.

The following changes were proposed:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIA and IIIB   |

Extension of indication to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy. Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC and Package Leaflet are proposed to be updated. As a consequence, the RMP (version 5.1) has been updated to align with the indication extension.

In addition, the applicant has taken the opportunity to make minor editorial corrections throughout the SmPC and package leaflet to align with the current Quality Review of Documents (QRD) template.

The requested variation proposed amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP).

## Information relating to orphan designation

Yescarta was designated as an orphan medicinal product EU/3/15/1579 on 11 November 2015 in the following indication: Treatment of follicular lymphoma.

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0132/2020 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0132/2020 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the application included a critical report addressing the possible similarity with authorised orphan medicinal products.

## MAH request for additional market protection

The MAH requested consideration of its application in accordance with Article 14(11) of Regulation (EC) 726/2004 - one year of market protection for a new indication.

<div style=\"page-break-after: always\"></div>

## Protocol assistance

The MAH did not seek Protocol assistance at the CHMP.

## 1.1. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CAT were:

Rapporteur:

Jan Mueller-Berghaus

Co-Rapporteur:

Claire Beuneu

| Timetable                                                                                                                    | Actual dates     |
|------------------------------------------------------------------------------------------------------------------------------|------------------|
| Submission date                                                                                                              | 23 July 2021     |
| Start of procedure:                                                                                                          | 14 August 2021   |
| CAT Rapporteur Assessment Report                                                                                             | 11 October 2021  |
| CAT Co-Rapporteur Assessment Report                                                                                          | 20 October 2021  |
| PRAC Rapporteur Assessment Report                                                                                            | 15 October 2021  |
| PRAC members comments                                                                                                        | 20 October 2021  |
| CAT and CHMP members comments                                                                                                | 26 October 2021  |
| PRAC Outcome                                                                                                                 | 28 October 2021  |
| Updated CAT Rapporteur(s) (Joint) Assessment Report                                                                          | 29 October 2021  |
| CAT Request for Supplementary Information (RSI)                                                                              | 5 November 2021  |
| CAT Rapporteur Assessment Report                                                                                             | 25 January 2022  |
| PRAC Rapporteur Assessment Report                                                                                            | 27 January 2022  |
| PRAC members comments                                                                                                        | 01 February 2022 |
| CAT and CHMP members comments                                                                                                | 08 February 2022 |
| PRAC Outcome                                                                                                                 | 10 February 2022 |
| Updated CAT Rapporteur Assessment Report                                                                                     | 14 February 2022 |
| CAT Request for Supplementary Information (RSI)                                                                              | 17 February 2022 |
| CAT Rapporteur Assessment Report                                                                                             | 4 April 2022     |
| CAT and CHMP members comments                                                                                                | 6 April 2022     |
| Updated CAT Rapporteur Assessment Report                                                                                     | 14 February 2022 |
| CAT Opinion                                                                                                                  | 13 April 2022    |
| CHMP Opinion                                                                                                                 | 22 April 2022    |
| The CAT adopted a report on similarity of Yescarta with Gazyvaro and Kymriah (Appendix 1)                                    | 13 April 2022    |
| The CAT adopted a report on the significant clinical benefit for Yescarta in comparison with existing therapies (Appendix 2) | 13 April 2022    |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

## 2.1.1. Problem statement

## Disease or condition

Follicular  lymphoma  (FL)  is  the  most  common  indolent  non-Hodgkin  lymphoma  (NHL)  with  increasing occurrence (1/100.000; ESMO 2020). The median age of diagnosis is approx. 60 years of age; however, occurrence  in  younger  age  is  possible  ( J  Clin  Exp  Hematop,  Vol  54,June  2014) .  FL  develops  due  to proliferation of neoplastic germinal center B cells, both centrocytes (small to medium sized cleaved cells) and centroblasts (large non-cleaved cells) that have a follicular pattern of growth ( Kahl 2016 ). FL is subject of various classifications according to the proportion of centroblastic cells, molecular genetics, immunhistochemics and clinical appearance. The current WHO edition defines FL in accordance to number of centroblastic cells as Grade 1, Grade 2, Grade 3A and Grade 3B. The distinction between Grade 3A and 3B is important due to their apparent differences in molecular genetics and prognosis; it is suggested that Grade 3A FL (no centrocytes, centroblasts only) is on the same spectrum as Grade 1-2 FL, and Grade 3B FL behaves as de novo DLBCL ( Katzenberger et al., Am J Pathol 2004; Karube et al., Blood 2007). Clinical classification and score grading are the Ann Arbor classification, which specifies stage I-IV based on lymph node  regions  and  class  A  (without  symptoms)  and  B  (with  symptoms),  and  the  Follicular  Lymphoma International Prognostic Index (FLIPI from the pre-rituximab era and FLIPI2 for rituximab-treated patients), which  is  used  for  the  stratification  of  patients  into  low-,  intermediate-,  or  high-risk  groups.  The clinicogenetic risk score m7-FLIPI, published 2015 in Lancet Oncology by Pastore A et al., is based on FLIPI score and mutation status of seven candidate genes ( EZH2, ARID1A, MEF2B, EP300, FOXO1, CREBBP and CARD11). Based on an observation of clinical characteristics of 95 patients with FL, Lockmer et al., BJHaem 2019 concluded, however that the prognostic factor may be different when applied in a context of different therapeutically agents.

## Treatment

The heterogeneity of FL in terms of clinical, histological and molecular-genetic presentation both at initial diagnosis and increasingly in the course of the disease, which is highly variable both between patients and intra-patient  ( Kahl&amp;Yang,  2016;  Fredman,  2018;  Lockmer  at  al. )  due  to  the  risk  of  histological transformations, explains the challenges, clinicians are facing. Although there are numerous therapeutically options, there seems to be a lack of robust tools for initiation of the right treatment regimen to the right time.

Newly diagnosed, low-grade, limited stage FL is often responsive to first-line treatments. Advanced stage FL generally requires multiple successive lines of therapy leading to shorter remission periods, chemorefractory  disease  and  transformation  to  diffuse  large  B-cell  lymphoma  (DLBCL)  (about  40%  of  all  FL patients).  Transformed  follicular  lymphomas  (tFL)  have  a  worse  prognosis  due  to  poorer  response  to treatment than primary DLBCL. Surgery is not used as a general treatment option; however, removing of symptomatic limited affected organs/tissue may be useful in some cases.

For patients with limited low tumor burden stages I-II, a radiotherapy-based treatment with or without combination with rituximab is clinical standard followed by consolidation/maintenance, e. g. with rituximab for 2 years. Myeloablative consolidation followed by ASCT prolongs PFS, but advantage on OS has not been

<div style=\"page-break-after: always\"></div>

observed ( Schaaf et al, Cochrane Database Syst Rev 2012). Patients in advanced stages of FL or cases where  radiotherapy  is  not  feasible  are  treated  with  systemic  (combined)  chemo-immunotherapy, immunomodulatory agents and phosphatidylinositol 3-kinase (PI3K) inhibitors. Complete response (CR) rates are low, however, ranging from 1% to 14% ( Dreyling 2017) . Autologous (auto-SCT) and allogeneic stem cell transplant (allo-SCT) may benefit only a small fraction of patients. Therefore, most of the patients will experience disease progression, relapse or refractory disease, and prognoses for these patients are poor. Despite the advances in the treatment of FL, there is an unmet need for patients with refractory and/or relapsed FL, who failed on available therapies.

Figure 1. ESMO Recommendations for low tumour burden FL (November 2020)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 2. ESMO Recommendations for high tumour burden FL (November 2020)

<!-- image -->

## Claimed therapeutic indication

The claimed indication is: 'Yescarta is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy'.

## Aetiology and pathogenesis

FL is a systemic neoplasm of the lymphoid tissue displaying germinal centre (GC) B cell differentiation. The tumorigenesis starts in precursor B cells and becomes full tumour when the cells reach the GC maturation step. FL is preceded by an asymptomatic preclinical phase in which premalignant B cells carrying a t(14;18) reciprocal chromosomal translocation develop additional genetic alterations, although not all of these cells progress to the tumour phase. The aetiology of FL is unknown; family history is important ( Br J Haematol 2009 ) and t(14;18) alone is considered not sufficient to cause FL ( Haematologica, 2014 ).

<div style=\"page-break-after: always\"></div>

## 2.1.2. About the product

Axicabtagene ciloleucel is an autologous CAR T-cell product in which a subject's T cells are engineered to express receptors consisting of a single-chain antibody fragment against CD19 linked to CD3 ζ and CD28 Tcell activating domains that result in elimination of CD19-expressing cells {Jackson 2016, Roberts 2018}. Following CAR engagement with CD19+ target cells, the CD3 ζ domain activates the downstream signaling cascade  that  leads  to  T-cell  activation,  proliferation,  and  acquisition  of  effector  functions,  such  as cytotoxicity {Roberts 2018}. The intracellular signaling domain of CD28 provides a costimulatory signal that works in concert with the primary CD3 ζ signal to augment T-cell function, including interleukin (IL)-2 production {Finney 1998}. Together, these signals stimulate proliferation of the CAR T cells and direct killing of target cells. In addition, activated T cells secrete cytokines, chemokines, and other molecules that can recruit and activate additional antitumor immune cells {Restifo 2012}.

Yescarta was approved in 2018 for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. A single dose of Yescarta contains 2 x 10 6  CAR-positive viable T cells per kg of body weight (or maximum of 2 x 10 8  CAR-positive viable T cells for patients 100 kg and above) in approximately 68 mL dispersion in an infusion bag.

## 2.1.3. General comments on compliance with GCP

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## 2.2. Quality aspects

No changes are proposed for the manufacturing of the medicinal product, which is therefore considered to be the same, including all DS and DP specifications.

## 2.3. Non-clinical aspects

One additional non-clinical genotoxicity study has been submitted in the application. The genotoxic potential of axicabtagene ciloleucel is related to the risk of insertional oncogenesis as a result of vector integration into the genome of T cells. The risk of insertional oncogenesis is not affected by the proposed extension of indication.

The  risk  of  insertional  oncogenesis  has  previously  been  assessed  by  literature  review  and  the  clinical experience gained with administration of human T cells that were transduced with γ -retroviral vectors. The newly submitted non-clinical genotoxicity study investigated the vector integration sites (VIS) in anti-CD19 CAR T cells generated using the KTE-C19 manufacturing process and T cells from three healthy donors. The data revealed an even VIS diversity for all three donors at the end of manufacturing. No over-represented VIS  could  be  detected  suggesting  that  no  transduced  T-cell  clone  had  acquired  a  significant  growth advantage resulting from the integration event.

<div style=\"page-break-after: always\"></div>

## 2.3.1. Ecotoxicity/environmental risk assessment

The environmental risk of axicabtagene ciloleucel is not affected by the proposed extension of indication.

## 2.3.2. Conclusion on the non-clinical aspects

The additional non-clinical data do not raise any concerns and complement the literature review and clinical experience gained so far.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

| Protocol Number       | Study Title                                                                                                                                                                                                                                                                           | Third Country                                    |
|-----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------|
| KTE-C19-105 (ZUMA-5)  | A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) Ongoing                                                                                                                                              | United States                                    |
| KTE-C19-101 (ZUMA-1)  | A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma Ongoing                                                                                                                                       | Canada, Israel, United States                    |
| KTE-C19-109 (ZUMA-9)  | A Multicenter, Open-label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects with Relapsed/Refractory Large B-cell Lymphoma Ongoing Cohort 2 is enrolling subjects whose commercially manufacture products do not meet commercial release specifications | Canada, United States                            |
| KTE-C19-112 (ZUMA-12) | A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma Ongoing                                                                                                              | Australia, Canada, United Kingdom, United States |

<div style=\"page-break-after: always\"></div>

## 2.4.2. Pharmacokinetics

## General

## Methods, endpoints and objectives for primary/secondary Analysis on PK/PD

The pharmacokinetic and pharmacodynamic data for axicabtagene ciloleucel in this application are based on 1 clinical study: KTE-C19-105 (ZUMA-5). ZUMA-5 is a Phase 2, multicenter, ongoing open-label study evaluating the efficacy of axicabtagene ciloleucel in subjects with r/r B-cell iNHL of FL or MZL histological subtypes. Evaluations of pharmacokinetics (PK) and pharmacodynamics (PD) of axicabtagene ciloleucel were included as secondary endpoints. The results on PD are provided in the primary analysis report with the data cutoff date of 12 March 2020 only, and PK-parameters are evaluated and provided both in the primary analysis report with the data cutoff date of 12 March 2020 and in the 18-months analysis addendum with DCO 14 September 2020. The assessments were based on known or hypothesized aspects of the axicabtagene  ciloleucel  mechanism  of  action,  and  the  current  knowledge  of  the  safety  profile  of  the lymphodepleting chemotherapy regimen and of axicabtagene ciloleucel infusion. The number, frequency, and timing  of  blood  or  serum  samples  collected  for  PK  and  PD  analyses  were  based  on  the  expected concentration-time profile of axicabtagene ciloleucel. Presented subgroup analyses should be considered descriptive only, as the study was not designed to test for differences between groups.

The safety analysis set was used for summary analyses of PK and PD and correlation to safety outcomes. At the cut-off date of 12 March 2020 and 14 September 2020, the safety analysis set comprised respectively 146 and 148 subjects with iNHL treated with any dose of axicabtagene ciloleucel, including 124 subjects with FL and 22 (24 for 18-month update) subjects with MZL.

The inferential analysis set was used for correlation to clinical efficacy outcomes. The inferential analysis set comprised 104 subjects, including 84 subjects with FL and 20 subjects with MZL.

Assessments at the time of the primary analysis (data cut-off date of 12 March 2020) included presence, expansion, and persistence of gene-marked anti-CD19 CAR T cells in blood (PK parameters), levels of B cells in blood over time (to monitor on-target/off-tumor effect), and levels of key soluble analytes (cytokines and chemokines) in serum over time (PD parameters). Exploratory correlative analyses of PK and PD results with baseline characteristics and clinical outcomes were also performed.

The  presence,  expansion,  and  persistence  of  anti-CD19  chimeric  antigen  receptor  (CAR)  T  cells  were measured  in  cryopreserved  peripheral  blood  mononuclear  cells  (PBMCs)  derived  from  whole  blood  of subjects treated in ZUMA-5. Serial blood samples were taken after cell infusion and subjected to a validated quantitative polymerase chain reaction (qPCR) assay. The qPCR assay was based on the method developed by Kochenderfer and colleagues {Kochenderfer 2012, Kochenderfer 2015, Kochenderfer 2017a} and was further optimized and validated by the University of Rochester Medical Center (URMC) Central Lab Services. The qPCR assay was demonstrated to be specific for cells with a stably integrated anti-CD19 CAR transgene. The lower limit of detection was established at 1 cell equivalent per 100,000 PBMCs (0.001%), and the lower  limit  of  quantification  (LLOQ)  was  established  at  8  to  110  cell  equivalents  per  100,000  PBMCs depending on DNA sample load.

Table 1: Pharmacological Methods Used in ZUMA-5

| Category/Method   | Description   |
|-------------------|---------------|

## Pharmacokinetics

Sampling times

- At enrollment/leukapheresis (prior to lymphodepleting chemotherapy), after infusion on Day 7, Week 2, Week 4, Month 3, Month 6, then every 6 months through Month 24 and annually thereafter

- On the day of unscheduled hospital re-admission with any axicabtagene ciloleucel-related AE, then weekly during hospitalization, and on the day of discharge

- At the time of disease progression

Assay for anti-CD19 CAR T cells in PBMCs

Validated qPCR method adapted from NCI method {Kochenderfer 2012, Kochenderfer 2015, Kochenderfer 2017a}, see m5.3.1.4

## Pharmacodynamics

Serum sampling times

- At enrollment/leukapheresis (prior to lymphodepleting chemotherapy), Day 0, and after infusion on Day 3, Day 7, Week 2, and Week 4

- At the time of Grade 3 axicabtagene ciloleucel-related toxicity

- On the day of unscheduled hospital re-admission with any axicabtagene ciloleucel-related AE, then weekly during hospitalization (every other day during hospitalization for a new or ongoing Grade 3 or higher neurological event), and on the day of discharge

## Methods (see m5.3.1.4)

MSD ®  V-PLEX ®  Plus panels (Rockville, MD)

IL-7, IL-15 (BED-02454, REP-00255)

CRP, ICAM-1, VCAM-1 (BED-01484, REP-00256)

TNF-

α

, IL-2, IL-10, IL-6, IFN-

γ

, IL-8 (BED-02361, REP-00257)

CXCL10 (BED-01482, REP-00258)

Simple Plex™ ELISA (ProteinSimple ® ; San Jose, CA)

IL-1RA (SOP-00572, REP-00380) IL-2R α (BED-02157, REP-17900) Ferritin (SOP-00476)

MILLIPLEX ®  MAP human CD8 + T-cell panel (EMD Millipore ® )

Granzyme B, perforin (SOP-00332)

## Table 2: Pharmacologic Objectives and Endpoints for ZUMA-5

Category

Description

Phase

2

Study design

Open-label efficacy; multicenter

Study population

Adult subjects with relapsed or refractory B-cell indolent non-Hodgkin lymphoma of FL or MZL histological subtypes

Analysis population for pharmacokinetics and pharmacodynamics a

Safety analysis set (all subjects treated with any dose of axicabtagene ciloleucel):

- iNHL: N = 146

- [ ]  FL: N = 124

- [ ]  MZL: N = 22

Inferential analysis set (all subjects enrolled [and who met the eligibility criteria for the pivotal cohort, ie, had 2 or more prior therapies] and treated with any dose of axicabtagene ciloleucel):

- iNHL: N = 104

- [ ]  FL: N = 84

- [ ]  MZL: N = 20

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| Study pharmacokinetic and pharmacodynamic objectives   | Secondary: • To assess levels of anti-CD19 CAR T cells in blood and levels of cytokines in serum and association with clinical outcomes                                         |
|--------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study pharmacokinetic and pharmacodynamic endpoints    | Secondary: • Levels of anti-CD19 CAR T cells in blood • Levels of cytokines in serum                                                                                            |
| Lymphodepleting chemotherapy regimen                   | Cyclophosphamide 500 mg/m 2 and fludarabine 30 mg/m 2 given concurrently for 3 consecutive days (Days -5, -4, and -3 relative to the axicabtagene ciloleucel infusion on Day 0) |
| Axicabtagene ciloleucel dose, route, regimen           | Target dose of 2 x 10 6 anti-CD19 CAR T cells/kg body weight b in a single intravenous infusion on Day 0                                                                        |
| Duration of follow-up                                  | Up to 15 years                                                                                                                                                                  |

- a Sample sizes are based on a data cutoff date of 12 March 2020 for primary analysis.
- b Among subjects with FL, the median weight-adjusted dose of axicabtagene ciloleucel was 2.0 x 10 6  anti-CD19 CAR T cells/kg (range: 1.3 x 10 6  to 2.1 x 10 6  cells/kg). Among subjects with MZL, the median weight-adjusted dose of axicabtagene ciloleucel was 2.0 x 10 6  anti-CD19 CAR T cells/kg (range: 1.6 x 10 6  to 2.0 x 10 6  cells/kg)

## Results on Pharmacokinetics

Pharmacokinetic results over time are shown in Table 3.  Of the 114 subjects evaluable at Month 3, 15 (12.10%) had anti-CD19 CAR T-cell levels below the LLOQ, ie, no cells detected. Anti-CD19 CAR T cells remain detectable at Month 6 in the majority of subjects with evaluable samples at the time of the data cutoff date (83 of 106 subjects, 66.94%). Anti-CD19 CAR T cells remain detectable at Month 12 in 65 of 85 subjects (52.42%) with evaluable samples at the time of the data cutoff date. Anti-CD19 CAR T cells remain detectable at Month 18 in 26 of 36 subjects (20.92%) with evaluable samples at the time of the data cutoff date. At Month 24, anti-CD19 CAR T cells were detectable in 18 of 25 subjects (14.52%) with evaluable samples at the time of the data cutoff date (14 Sep 2020).

Table 3: Pharmacokinetic Results Over Time (Safety Analysis Set)

|                          | Follicular Lymphoma (N = 124)   | Marginal Zone Lymphoma (N = 24)   | Overall (N = 148)        |
|--------------------------|---------------------------------|-----------------------------------|--------------------------|
| AUC 0-28 (cells/μL*days) |                                 |                                   |                          |
| n                        | 124                             | 24                                | 148                      |
| Mean (STDEV)             | 1248.58 (2404.84)               | 1509.51 (1735.23)                 | 1290.89 (2306.40)        |
| Median (Q1, Q3)          | 422.48 (142.92, 1192.55)        | 630.31 (327.37, 2754.02)          | 454.77 (150.32, 1323.90) |
| Min, Max                 | 5.93, 1.99E+04                  | 23.75, 6468.17                    | 5.93, 1.99E+04           |
| Peak (cells/μL)          |                                 |                                   |                          |
| n                        | 124                             | 24                                | 148                      |
| Mean (STDEV)             | 121.30 (219.29)                 | 139.10 (158.14)                   | 124.19 (210.22)          |
| Median (Q1, Q3)          | 37.6 (12.02, 125.07)            | 52.56 (24.26, 299.14)             | 39.38 (13.97, 127.32)    |
| Min, Max                 | 0.49, 1415.40                   | 1.76, 453.09                      | 0.49, 1415.40            |

<div style=\"page-break-after: always\"></div>

## Time To Peak (Days)

| n               | 124                 | 24                   | 148                 |
|-----------------|---------------------|----------------------|---------------------|
| Mean (STDEV)    | 15.90 (36.81)       | 13.46 (4.85)         | 15.50 (33.74)       |
| Median (Q1, Q3) | 8 (8, 15)           | 15 (8, 16)           | 9 (8, 15)           |
| Min, Max        | 8, 371              | 8, 29                | 8, 371              |
| Baseline        |                     |                      |                     |
| n               | 124                 | 24                   | 148                 |
| Mean (STDEV)    | 0.00 (0.00)         | 0.00 (0.00)          | 0.00 (0.00)         |
| Median (Q1, Q3) | 0.00 (0.00, 0.00)   | 0.00 (0.00, 0.00)    | 0.00 (0.00, 0.00)   |
| Min, Max        | 0.00, 0.00          | 0.00, 0.00           | 0.00, 0.00          |
| Day 7           |                     |                      |                     |
| n               | 124                 | 24                   | 148                 |
| Mean (STDEV)    | 101.52 (220.03)     | 69.50 (127.86)       | 96.32 (207.87)      |
| Median (Q1, Q3) | 17.41 (3.20, 71.94) | 13.87 (2.49, 48.13)  | 17.12 (3.15, 66.84) |
| Min, Max        | 0.01, 1415.40       | 0.53, 422.35         | 0.01, 1415.40       |
| Week 2          |                     |                      |                     |
| n               | 112                 | 22                   | 134                 |
| Mean (STDEV)    | 41.62 (64.45)       | 98.64 (136.19)       | 50.99 (82.73)       |
| Median (Q1, Q3) | 14.14 (4.54, 52.26) | 39.38 (20.70, 97.02) | 20.17 (5.22, 56.97) |
| Min, Max        | 0.00, 322.58        | 0.31, 453.09         | 0.00, 453.09        |
| Week 4          |                     |                      |                     |
| n               | 117                 | 22                   | 139                 |
| Mean (STDEV)    | 7.79 (20.27)        | 15.22 (25.51)        | 8.97 (21.26)        |
| Median (Q1, Q3) | 1.49 (0.35, 4.21)   | 4.64 (1.62, 15.72)   | 1.90 (0.41, 6.05)   |
| Min, Max        | 0.00, 140.22        | 0.09, 103.94         | 0.00, 140.22        |
| Month 3         |                     |                      |                     |
| n               | 114                 | 20                   | 134                 |
| Mean (STDEV)    | 0.78 (1.91)         | 0.59 (0.53)          | 0.75 (1.78)         |
| Median (Q1, Q3) | 0.34 (0.05, 0.72)   | 0.57 (0.06, 0.98)    | 0.36 (0.05, 0.76)   |
| Min, Max        | 0.00, 15.75         | 0.00, 1.81           | 0.00, 15.75         |
| Month 6         |                     |                      |                     |
| n               | 106                 | 16                   | 122                 |
| Mean (STDEV)    | 3.49 (28.89)        | 0.75 (2.29)          | 3.13 (26.94)        |
| Median (Q1, Q3) | 0.24 (0.01, 0.62)   | 0.15 (0.00, 0.34)    | 0.24 (0.01, 0.59)   |

<div style=\"page-break-after: always\"></div>

| Min, Max        | 0.00, 297.21          | 0.00, 9.29        | 0.00, 297.21          |
|-----------------|-----------------------|-------------------|-----------------------|
| Month 12        |                       |                   |                       |
| n               | 85                    | 8                 | 93                    |
| Mean (STDEV)    | 1.19 (7.30)           | 0.16 (0.27)       | 1.10 (6.98)           |
| Median (Q1, Q3) | 0.13 (4.63E-03, 0.39) | 0.03 (0.00, 0.26) | 0.13 (4.31E-03, 0.39) |
| Min, Max        | 0.00, 67.27           | 0.00, 0.72        | 0.00, 67.27           |
| Month 18        |                       |                   |                       |
| n               | 35                    | 2                 | 37                    |
| Mean (STDEV)    | 0.74 (2.04)           | 0.01 (0.02)       | 0.70 (1.99)           |
| Median (Q1, Q3) | 0.09 (0.00, 0.70)     | 0.01 (0.00, 0.03) | 0.03 (0.00, 0.63)     |
| Min, Max        | 0.00, 11.94           | 0.00, 0.03        | 0.00, 11.94           |
| Month 24        |                       |                   |                       |
| n               | 25                    | 0                 | 25                    |
| Mean (STDEV)    | 0.67 (1.24)           |                   | 0.67 (1.24)           |
| Median (Q1, Q3) | 0.14 (0.00, 0.65)     |                   | 0.14 (0.00, 0.65)     |
| Min, Max        | 0.00, 5.71            |                   | 0.00, 5.71            |

Data cutoff date = 14Sep2020

Figure 3. Median Line Plot of Number of Anti-CD19 CAR T Cells in Blood by Disease Type (Safety Analysis Set)

Figure 4. Peak and AUC0-28 of Number of Anti-CD19 CAR T Cells in Blood by Disease Type (Safety Analysis Set)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<!-- image -->

## Pharmacokinetics in Special Populations and Subgroups

ZUMA-5 was not designed to test for differences between subgroups and formal comparisons were not prespecified. The statistical results of the subgroup analyses are descriptive in nature.

## Age

Pediatric subjects were not enrolled. Among subjects with FL, 86 evaluable subjects were &lt; 65 years of age and 38 subjects were ≥ 65 years of age. For subjects &lt; 65 years of age, the median peak anti -CD19 CAR  T-cell  level  and  AUC0-28  were  36.90  cells/ μ L  (range:  1.05  to  1415.40  cells/ μ L)  and  410.75 cells/ μ L·days (range: 10.91 to 1.99 x 10 4  cells/ μL·days), respectively. For subjects ≥ 65 years of age, the median peak anti-CD19 CAR T-cell level and AUC0-28 were 35.73 cells/ μ L (range: 0.49 to 1026.32 cells/ μ L) and 459.84 cells/ μ L·days (range: 5.93 to 7996.06 cells/ μ L·days), respectively.  Anti-CD19  CAR  T  cells remain detectable at Month 12 in 65 of 85 subjects (52.42%) with evaluable samples at the time of the data cut-off date.

## Gender

Among subjects with FL, 51 subjects were female and 73 subjects were male. For female subjects, the median peak anti-CD19 CAR T-cell level and AUC0-28 were 37.62 cells/ μ L (range: 0.49 to 529.57 cells/ μ L) and 473.27 cells/ μ L·days (range: 5.93 to 5985.07 cells/ μ L·days), respectively. For male subjects, the median peak anti-CD19 CAR T-cell level and AUC0-28 were 35.37 cells/ μ L (range: 1.05 to 1415.40 cells/ μ L) and 406.83 cells/ μ L·days (range: 10.91 to 1.99 x 104 cells/ μ L·days), respectively.

## Race

Among subjects with FL, 115 subjects were white, 4 subjects were black or African American, 2 subjects were Asian, and 3 subjects self-reported their race as other. For white subjects, the median peak anti-CD19 CAR  T-cell  level  and  AUC0-28  were  35.37  cells/ μ L  (range:  0.49  to  1415.40  cells/ μ L)  and  410.63 cells/ μ L·days (range: 5.93 to 1.99 x 104 cells/ μ L·days), respectively. In the 9 nonwhite subjects, peak anti-CD19 CAR T-cell levels ranged from 1.80 to 696.83 cells/ μ L,  and  AUC0-28 ranged from 23.61 to 5247.56 cells/ μ L·days.

<div style=\"page-break-after: always\"></div>

## Baseline tumor burden

Pharmacokinetic parameters were summarized by baseline tumor burden per central assessment. Tumor burden was measured as the sum of the cross product diameters of target lesions, ie, the sum of the products of the longest perpendicular diameters of tumors (SPD), per the International Working Group (IWG)  Lugano  Classification  {Cheson  2014}.  The  association  of  anti-CD19  CAR  T-cell  expansion  with baseline tumor burden was assessed according to quartiles of SPD as well as by median SPD. Among subjects with FL, median peak anti-CD19 CAR T-cell levels were 35.78 cells/ μ L in the first (lowest) tumor burden quartile, 60.13 cells/ μ L in the second quartile, 31.62 cells/ μ L in the third quartile, and 31.31 cells/ μ L in the fourth (highest) quartile. Median values for AUC0-28 were 422.37 cells/ μ L·days in the first quartile, 528.76  cells/ μ L·days  in  the  second  quartile,  364.55  cells/ μ L·days  in  the  third  quartile,  and  249.73 cells/ μ L·days in the fourth quartile (Table 4).

Pharmacokinetic parameters were also summarized for subgroups of subjects with baseline tumor SPD ≤ median as compared to subjects with SPD &gt; median (Table 5) . For subjects with FL with SPD ≤ median, the median peak anti-CD19 CAR T-cell level and AUC0-28 were 42.46 cells/ μ L (range: 1.08 to 1026.32 cells/ μ L) and 451.17 cells/ μ L·days (range: 19.08 to 7996.06 cells/ μ L·days), respectively. For subjects with SPD &gt; median, the median peak anti-CD19 CAR T-cell level and AUC0-28 were 31.46 cells/ μ L (range: 0.49 to 1415.40 cells/ μ L) and 331.09 cells/ μ L·days (range: 5.93 to 1.99 x 104 cells/ μ L·days), respectively.

Table 4. PK parameters by quartile of baseline tumor volume (SPD) (safety analysis set)

|                         | Follicular Lymphoma (N = 124)                                         | Follicular Lymphoma (N = 124)   | Follicular Lymphoma (N = 124)                             | Follicular Lymphoma (N = 124)           |
|-------------------------|-----------------------------------------------------------------------|---------------------------------|-----------------------------------------------------------|-----------------------------------------|
|                         | Q1:[Min = 289.2,1108.1, Median Q1 =1108.1] (N =30)                    | Q2:(Q1 = = 2517.5] (N =29)      | Q3:(Median = 2517.5,Q3= 4151.3] (N = 29)                  | Q4:Q3 = 4151.3, Max = 34675.0] (N = 29) |
| AUCo-28 (cells/μL*days) |                                                                       |                                 |                                                           |                                         |
| n                       | 30                                                                    | 29                              | 29                                                        | 29                                      |
| Mean (STDEV)            | 1363.45 (2088.17)                                                     | 921.14 (1157.51)                | 1417.86 (3682.67)                                         | 1155.98 (2190.66)                       |
| Median (Ql, Q3)         | 422.37 (149.58,528.76 (143.63, 364.55 (148.30,249.73 (68.29, 1145.67) | 974.72)                         | 985.64)                                                   | 1254.93)                                |
| Min, Max                |                                                                       |                                 | 19.08,7996.06 23.75,4797.90 16.34,1.99E+04 5.93,1.02E+04: |                                         |
| Peak (cells/μL)         |                                                                       |                                 |                                                           |                                         |
|                         | 30                                                                    | 29                              | 29                                                        | 29                                      |
| Mean (STDEV)            | 160.96 (271.09)                                                       | 85.50 (94.31)                   |                                                           | 118.24 (268.53) 107.76(208.54)1         |
| Median (Ql, Q3)         | 35.78 (11.27, 135.29)                                                 | 60.13 (17.10, 127.34)           | 31.62 (13.05, 98.72)                                      | 31.31 (4.36, 117.93)                    |
| Min, Max                | 1.08,1026.32                                                          | 2.36, 341.61                    | 1.59, 1415.40                                             | 0.49, 968.91                            |
| TimeToPeak (Days)       |                                                                       |                                 |                                                           |                                         |
| n                       | 30                                                                    | 29                              | 29                                                        | 29                                      |
| Mean (STDEV)            | 11.00 (3.67)                                                          | 18.17 (36.08)                   | 11.97 (5.88)                                              | 24.17 (66.87)                           |
| Median (Ql, Q3)         | 8 (8,15)                                                              | 13 (8, 15)                      | 8 (8, 15)                                                 | 9 (8, 15)                               |
| Min, Max                | 8,17                                                                  | 8,205                           | 8,29                                                      | 8, 371                                  |

Datacutoffdate=12Mar2020

<div style=\"page-break-after: always\"></div>

Table 5. PK parameters by median of baseline tumor volume (SPD) (safety analysis set)

|                         | Follicular Lymphoma (N = 124)            | Follicular Lymphoma (N = 124)   |
|-------------------------|------------------------------------------|---------------------------------|
|                         | SPD<=Mediana (2517.5) (N = 59)           | SPD>Median (2517.5) (N = 58)    |
| AUCo-28 (cells/μL*days) |                                          |                                 |
| n                       | 59                                       | 58                              |
| Mean (STDEV)            | 1146.04 (1696.11)                        | 1286.92 (3006.14)               |
| Median (Q1, Q3)         | 451.17(143.63, 1145.67)                  | 331.09 (113.59, 1254.93)        |
| Min, Max                | 19.08, 7996.06                           | 5.93,1.99E+04                   |
| Peak (cells/μL)         |                                          |                                 |
| n                       | 59                                       | 58                              |
| Mean (STDEV)            | 123.87 (206.12)                          | 113.00 (238.35)                 |
| Median (Q1, Q3)         | 42.46 (13.66,130.63) 31.46 (8.61,103.90) |                                 |
| Min, Max                | 1.08,1026.32                             | 0.49, 1415.40                   |
| Time To Peak (Days)     |                                          |                                 |
| n                       | 59                                       | 58                              |
| Mean (STDEV)            | 14.53 (25.46)                            | 18.07 (47.45)                   |
| Median (Q1, Q3)         | 9 (8, 15)                                | 8 (8, 15)                       |
| Min, Max                | 8,205                                    | 8,371                           |

Data cutoff date =12Mar2020

## Impact of concomitant use of tocilizumab and/or systemic corticosteroids

Among subjects with FL, 18 subjects (14.5%) received tocilizumab alone, 12 subjects (9.7%) received corticosteroids alone, 38 subjects (30.6%) received both tocilizumab and corticosteroids, and 56 subjects (45.2%)  received  neither  tocilizumab  nor  corticosteroids.  The  timing  and  dose  of  corticosteroids administered following axicabtagene ciloleucel infusion were variable. Median peak anti-CD19 CAR T-cell levels and AUC0-28 were progressively higher in the following order: the lowest expansion was in subjects who received neither tocilizumab nor corticosteroids (peak: 21.38 cells/ μ L; AUC0-28: 221.28 cells/ μ L·days); similar expansion was observed in subjects who received either tocilizumab alone (peak: 25.71 cells/ μ L; AUC0-28: 373.54 cells/ μ L·days) or corticosteroids alone (peak: 29.64 cells/ μ L; AUC0-28: 468.05  cells/ μ L·days);  the  highest  expansion  was  in  subjects  who  received  both  tocilizumab  and corticosteroids (peak: 120.39 cells/ μ L; AUC0-28: 1120.29 cells/ μ L·days).

## B-cell levels (on-target off-tumor toxicity)

B cell levels were calculated as a percentage of CD19+, CD20+, or CD19+CD20+ B cells relative to viable CD45+ leukocytes in a flow cytometry assay. Among subjects with FL, 85 of 112 subjects (75.9%) in the safety analysis set had detectable B cells at baseline (enrollment/leukapheresis), with a median B cell level of 4.84% of viable leukocytes (range: 0.02% to 78.34%). At Month 3, the first time point at which B cells were measured after axicabtagene ciloleucel infusion, 41 of 102 subjects (40.2%) had detectable B cells, and the median B cell level declined to 0.47% (range: 0.02% to 47.35%). At Month 12, of 74 subjects 42 subjects  (56.8%)  with  evaluable  samples  had  detectable  B  cells  (median:  6.53%,  range:  0.03%  to 48.49%). At Month 18, 24 of 35 subjects (68.57%) with evaluable samples had detectable B cells (median, 11.84%; range: 0.03% to 43.91%). At Month 24, 12 of 20 subjects (60.0%) with evaluable samples had detectable B cells (median, 9.05%; range: 0.14% to 46.06%).

<div style=\"page-break-after: always\"></div>

## Associations of PK with key efficacy and safety endpoints

## Objective Response

Among 84 subjects with FL in the inferential analysis set, 79 subjects (94.0%) had an objective response (CR or PR) and 3 subjects (3.6%) were nonresponders. One subject who had died prior to the first scheduled disease assessment was excluded from the analysis, and 1 subject was excluded due to undefined/no disease response by central assessment. Due to the limited number of nonresponders, no formal statistical comparisons were performed. The median peak anti-CD19 CAR T-cell levels in responders (n=112) versus nonresponders (n=5) were 38.0cells/ μ L (range: 0.49 to 1415.40 cells/ μ L) and 31.3 cells/ μ L (range: 1.80 to  60.24  cells/ μ L),  respectively.  The  median  AUC0-28  in  responders  versus  nonresponders  was  454.8 cells/ μ L·days (range: 5.93 to 1.99 x 104 cells/ μ L·days) and 247.14 cells/ μ L·days (range: 23.61 to 804.42 cells/ μ L·days), respectively.

## Best Overall Response

Among 84 evaluable subjects with FL, 67 subjects (79.8%) achieved a best response of CR, 12 subjects (14.3%) achieved PR, and 3 subjects (3.6%) were nonresponders per central read. Neither peak nor AUC028 were significantly different between the CR and PR groups. The median peak anti-CD19 CAR T-cell levels in subjects with CR versus PR were 38.33 cells/ μ L (range: 1.05 to 1415.40 cells/ μ L) and 35.78 cells/ μ L (range: 0.49 to 364.79 cells/ μ L), respectively (Wilcoxon rank sum nominal p = 0.4403). The median AUC028 in subjects with CR versus PR was 458.37 cells/ μ L·days (range: 12.00 to 1.99 x 104 cells/ μ L·days) and 374.12 cells/ μ L·days (range: 5.93 to 2800.43 cells/ μ L·days). In the nonresponder group, the median peak anti-CD19 CAR T-cell level and AUC0-28 were 35.31 cells/ μ L (range: 1.80 to 60.24 cells/ μ L) and 247.14 cells/ μ L·days (range: 23.61 to 804.42 cells/ μ L·days), respectively.

Figure 5. Peak Number of Anti-CD19 CAR T Cells in Blood by Best Overall Response per Central Assessment (Inferential Analysis Set)

<!-- image -->

Data cutoff date = 12MAR2020.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 6. AUC0-28 of Number of Anti-CD19 CAR T Cells in Blood by Best Overall Response per Central Assessment (Inferential Analysis Set)

<!-- image -->

Data cutoff date = 12MAR2020.

## Ongoing Response

Among 84 evaluable subjects with FL, 53 subjects (63.1%) were in ongoing response at the data cutoff date, 19 subjects (22.6%) had relapsed, and 3 subjects (3.6%) were nonresponders. Neither peak nor AUC0-28 were significantly associated with ongoing response, although a trend toward higher anti-CD19 CAR T-cell levels was observed in subjects with durable responses. The median peak anti-CD19 CAR T-cell levels  in  subjects  with  ongoing  response  versus  relapse  were  42.46  cells/ μ L  (range:  1.05  to  1415.40 cells/ μ L) and 31.87 cells/ μ L (range: 0.49 to 364.79 cells/ μ L), respectively. The median AUC0-28 in subjects with ongoing response versus relapse was 473.27 cells/ μ L·days (range: 12.00 to 1.99 x 104 cells/ μ L·days) and 337.61 cells/ μ L·days (range: 5.93 to 2636.04 cells/ μ L·days), respectively. In the nonresponder group, the  median  peak  anti-CD19  CAR  T-cell  level  and  AUC0-28  were  35.31  cells/ μ L  (range:  1.80  to  60.24 cells/ μ L) and 247.14 cells/ μ L·days (range: 23.61 to 804.42 cells/ μ L·days), respectively.

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 7. Peak Number of Anti-CD19 CAR T Cells in Blood by Ongoing Response (Inferential Analysis Set)

<!-- image -->

Data cutoff date = 12MAR2020

## Associations of PK with CRS and neurologic events

## CRS

Among 124 evaluable subjects with FL, 8 subjects (6.5%) had Grade 3 or higher CRS and 116 subjects (93.5%) had Grade 2, Grade 1, or no CRS. The median peak anti-CD19 CAR T-cell level was 7.7-fold higher for subjects with Grade 3 or higher CRS compared with subjects with Grade 2, Grade 1, or no CRS (272.99 vs 35.34 cells/ μ L; Wilcoxon rank sum nominal p = 0.0307). Similarly, the median AUC0-28 was 7.7-fold higher for subjects with Grade 3 or higher CRS compared with subjects with Grade 2, Grade 1, or no CRS (3155.66 vs 408.73 cells/ μ L·days; Wilcoxon rank sum nominal p = 0.0394).

## Neurologic events

Among 124 evaluable subjects with FL, 19 subjects (15.3%) had Grade 3 or higher neurologic events, and 105 subjects (84.7%) had Grade 2, Grade 1, or no neurologic events. The median peak anti-CD19 CAR Tcell level was 3.7-fold higher for subjects with Grade 3 or higher neurologic events compared with subjects with Grade 2, Grade 1, or no neurologic events (122.85 vs 33.56 cells/μL; Wilcoxon rank sum nominal p = 0.0053). Similarly, the median AUC0-28 was 2.9-fold higher for subjects with Grade 3 or higher neurologic events  compared  with  subjects  with  Grade  2,  Grade  1,  or  no  neurologic  events  (1145.67  vs  394.77 cells/μL·days; Wilcoxon rank sum nominal p = 0.0022).

## Associations of product characteristics with PK

The following key characteristics showed potential associations (p ≤ 0.05) with peak post -infusion levels of anti-CD19 CAR T cells:

- Percentage of Tnaïve cells
- (Tnaïve + Tcm)/(Tem + Teff) ratio
- Total number of Tnaïve cells infused

<!-- image -->

<div style=\"page-break-after: always\"></div>

- Percentage of CCR7+ (Tnaïve + Tcm) cells
- Total number of CCR7+ T cells infused
- -Percentage of CCR7- (Tem + Teff) cells

Table 6: Potential Associations of Post-infusion Peak Anti-CD19 CAR T-cell Levels in Blood With Product Characteristics (Safety Analysis Set: FL)

| Product Characteristic                         |   Number of Evaluable Subjects | Regression Coefficient (95% CI)   |   P-value |
|------------------------------------------------|--------------------------------|-----------------------------------|-----------|
| Transduction Rate (%)                          |                            124 | -0.00 (-0.02, 0.02)               |    0.8073 |
| IFN-gamma Level (pg/mL)                        |                            124 | 0.00 (-0.00, 0.00)                |    0.456  |
| CD4/CD8 Ratio                                  |                            104 | -0.03 (-0.13, 0.06)               |    0.5167 |
| Tnaive (% of viable CD3+ cells)                |                            105 | 0.02 (0.00, 0.04)                 |    0.0466 |
| Tcm (% of viable CD3+ cells)                   |                            105 | 0.01 (-0.02, 0.04)                |    0.464  |
| Tem (% of viable CD3+ cells)                   |                            105 | -0.02 (-0.04, 0.00)               |    0.0849 |
| Teff (% of viable CD3+ cells)                  |                            105 | -0.01 (-0.03, 0.01)               |    0.2824 |
| (Tnaive + Tcm)/(Tem + Teff) Ratio              |                            105 | 0.25 (0.00, 0.50)                 |    0.0466 |
| Total Number of T Cells Infused (x 10^6)       |                            124 | 0.00 (-0.00, 0.00)                |    0.3365 |
| Total Number of Tnaive Cells Infused (x 10^6)  |                            105 | 0.01 (0.00, 0.01)                 |    0.0077 |
| CCR7+ (Tnaive + Tcm) (%)                       |                            105 | 0.02 (0.00, 0.04)                 |    0.0247 |
| Total Number of CCR7+ T Cells Infused (x 10^6) |                            105 | 0.01 (0.00, 0.01)                 |    0.0019 |
| CCR7- (Tem + Teff) (%)                         |                            105 | -0.02 (-0.04, -0.00)              |    0.0247 |

Data cutoff date = 12MAR2020

## 2.4.3. Pharmacodynamics (Serum)

## Methods

Please refer to section 2.4.2.

Levels  of  key  analytes  (pro-inflammatory  and  immune-modulating  cytokines,  chemokines,  and  effector molecules) were to be evaluated in serum samples at multiple time points. Assays for 14 of the 17 key analytes have been qualified; assays for granzyme B, perforin and ferritin were performed in accordance to the manufacturer's recommended protocols. Analytes were to be measured at baseline (enrollment/leukapheresis), Day 0, and on Day 3, Day 7, Week 2, and Week 4 after axicabtagene ciloleucel infusion. The following 17 analytes (preselected from a larger panel of 40 analytes), which are known to be involved in mediation the antitumor activity of CAR T cells and treatment-related toxicities according to literature ( Kochendorffer 2017a; Neepalu 2017 ) are presented:

- Homeostatic/proliferative: interleukin (IL)-15, IL-2, and IL-7

<div style=\"page-break-after: always\"></div>

- Inflammatory/immune-modulating: C-reactive protein (CRP), interferon (IFN)γ , IL-1 receptor antagonist (IL-1RA), IL-2 receptor alpha (IL-2R α ), IL-6, IL-10, and tumor necrosis factor (TNF)α
- Chemokine: C-X-C motif chemokine (CXCL)10 and IL-8
- Immune effector: granzyme B and perforin
- Other analytes: ferritin, intercellular adhesion molecule (ICAM)-1, and vascular cell adhesion molecule (VCAM)-1

## Results

## IL-15

Serum IL-15 increased following the administration of the lymphodepleting chemotherapy regimen, as indicated by elevated levels of IL-15 at Day 0 relative to baseline. At baseline, the median IL-15 level was 2.10  pg/mL.  At  Day  0,  following  lymphodepleting  chemotherapy,  median  IL-15  levels  had  increased approximately 14-fold to 28.90 pg/mL. Levels of IL-15 continued to rise after the infusion of axicabtagene ciloleucel,  reaching  a  median  peak  value  of  33.75  pg/mL.  The  median  time  to  peak  was  4  days  after axicabtagene ciloleucel infusion. A 2-fold or higher change of IL-15 levels at the peak relative to baseline was observed in 122 of 124 subjects (98.4%) in the safety analysis set. At Week 4, median IL-15 levels declined to 4.10 pg/mL, with 65 of 118 subjects (55.1%) still demonstrating a 2-fold or higher change in the level of IL-15 relative to baseline.

## IL-2

IL-2 levels in the serum increased rapidly after axicabtagene ciloleucel infusion in the safety analysis set. Median levels of IL-2 at baseline, Day 0, peak, and Week 4 were 0.90 pg/mL (imputed LLOQ), 0.90 pg/mL (imputed LLOQ), 3.05 pg/mL, and 0.90 pg/mL (imputed LLOQ), respectively. The median time to peak was 4 days after axicabtagene ciloleucel infusion. A 2-fold or higher change of IL-2 levels at the peak relative to baseline was observed in 79 of 124 subjects (63.7%) in the safety analysis set. At Week 4, median IL-2 levels generally returned toward baseline, with 2 of 118 subjects (1.7%) still demonstrating a 2-fold or higher change in the level of IL-2 over baseline.

## IL-7

IL-7 increased following the administration of the lymphodepleting chemotherapy regimen, as indicated by higher levels of IL-7 at Day 0 relative to baseline. At baseline, the median IL-7 level was 14.85 pg/mL. At Day 0, following lymphodepleting chemotherapy, median IL-7 levels had increased approximately 2-fold to 27.75 pg/mL. Levels of IL-7 continued to rise after the infusion of axicabtagene ciloleucel, reaching a median peak value of 31.65 pg/mL. The median time to peak was 4 days after axicabtagene ciloleucel infusion. A 2-fold or higher change of IL-7 levels at the peak relative to baseline was observed in 69 of 124 subjects (55.6%) in the safety analysis set. At Week 4, median IL-7 levels declined toward baseline (17.45 pg/mL), with 10 of 118 subjects (8.5%) still demonstrating a 2-fold or higher change in the level of IL-7 relative to baseline.

## CRP

Median serum levels of the acute phase reactant CRP in the safety analysis set at baseline, Day 0, peak, and Week 4 were 7.13 mg/L, 15.82 mg/L, 66.97 mg/L, and 0.54 mg/L, respectively. CRP appeared to be induced by lymphodepleting chemotherapy, with 64 of 120 subjects (52.9%) demonstrating a 2-fold or higher  increase  over  baseline  at  Day  0.  The  median  time  to  peak  was  5  days  after  the  infusion  of axicabtagene ciloleucel. At the peak, 100 of 124 subjects (80.6%) demonstrated a 2-fold or higher change

<div style=\"page-break-after: always\"></div>

of CRP levels over baseline. CRP levels generally decreased to baseline or below baseline at Week 4, with 6 of 118 subjects (5.1%) still demonstrating a 2-fold or higher change in the level of CRP over baseline at that time.

## IFNγ

Median serum levels of IFNγ in the safety analysis set at baseline,Day 0, peak, and Week 4 were 7.50 pg/mL  (imputed  LLOQ),  7.50  pg/mL  (imputed  LLOQ),95.50  pg/mL,  and  7.50  pg/mL  (imputed  LLOQ), respectively. The median time to peak was 7 days after infusion of axicabtagene ciloleucel. At the peak, 102 of 124 subjects (82.3%) demonstrated a 2-fold or higher change of IFNγ levels over baseline. At Week 4, 40 of 118 subjects (33.9%) still demonstrated a 2-fold or higher change in the levels of IFNγ over baseline.

## TNFα

Median levels of TNFα in the safety analysis set at baseline, Day 0, peak, and Week 4 were 3.95 pg/mL, 2.30 pg/mL, 4.60 pg/mL, and 2.10 pg/mL, respectively. The median time to peak was 4 days after infusion of axicabtagene ciloleucel. At the peak, 20 of 124 subjects (16.1%) demonstrated a 2-fold or higher change of TNFα levels over baseline. At Week 4, TNFα levels generally returned toward baseline, with 3 of 118 subjects (2.5%) still demonstrating a 2-fold or higher increase of TNFα over baseline.

## CXCL10

Median levels of CXCL10 in the safety analysis set at baseline, Day 0, peak, and Week 4 were 343.75 pg/mL, 395.40 pg/mL, 1077.25 pg/mL, and 400.70 pg/mL, respectively. The median time to peak was 8 days after infusion of axicabtagene ciloleucel. At the peak, 72 of 124 subjects (58.1%) demonstrated a 2fold  or  higher  change  of  CXCL10  levels  over  baseline.  At  Week  4,  24  of  118  subjects  (20.3%)  still demonstrated a 2-fold or higher change in the levels of CXCL10 over baseline.

## Granzyme B

Granzyme B in the safety analysis set at baseline, Day 0, peak, and Week 4 were 1.00 pg/mL (imputed LLOQ), 1.00 pg/mL (imputed LLOQ), 8.20 pg/mL,  and 1.00 pg/mL (imputed LLOQ), respectively. The median time to peak was 8 days after infusion of axicabtagene ciloleucel. At the peak, 60 of 124 subjects (48.4%) demonstrated a 2-fold or higher change of granzyme B levels over baseline. At Week 4, granzyme B levels generally returned toward baseline, with 15 of 118 subjects (12.7%) still demonstrating a 2-fold or higher increase of granzyme B over baseline.

## Summary of results

- After lymphodepleting chemotherapy treatment, median serum levels of CRP and IL-15 increased by at least 2-fold. Consistent with lymphodepletion, median serum levels of perforin decreased during this same time period.

- On Day 3 after infusion of axicabtagene ciloleucel, median serum levels of the majority of key analytes remained steady relative to baseline levels (&lt; 2-fold change; CXCL10, granzyme B, ICAM-1, IL-1RA, IL 2R α , IL-7, TNFα , and VCAM-1) or were elevated by at least 2-fold relative to baseline (CRP, ferritin, IFNγ , IL-2, IL-6, IL-8, IL-10, and IL-15).

-  With the exception of perforin, the median time to peak for all key analytes was within 8 days after infusion of axicabtagene ciloleucel (range of medians: 4 to 8 days), coinciding with the peak anti-CD19 CAR T-cell expansion at 8 days; the median time to peak for perforin was 29 days, indicative of endogenous Tcell  recovery.  The  majority  of  analytes  increased  by  2fold  or  more  at  peak  in  ≥  50%  of subjects (exceptions: granzyme B, ICAM-1, perforin, TNFα , and VCAM-1).

<div style=\"page-break-after: always\"></div>

- By Week 4 after axicabtagene ciloleucel infusion, the majority of the 17 key serum analytes had returned to near baseline levels, ie, 5 analytes remained elevated by 2-fold or more in ≥ 20% of subjects (CXCL10, ferritin, IFNγ , IL-6, and IL-15).

## Associations of PD with CRS and neurologic events

Table 7. Potential Associations of Key Analytes With Safety Endpoints (Safety Analysis Set)

|            | Follicular Lymphoma   | Follicular Lymphoma                 | Marginal Zone Lymphoma   | Marginal Zone Lymphoma              |
|------------|-----------------------|-------------------------------------|--------------------------|-------------------------------------|
| Analyte    | Grade 3 or Higher CRS | Grade 3 or Higher Neurologic Events | Grade 3 or Higher CRS a  | Grade 3 or Higher Neurologic Events |
| CRP        | No trend              | No trend                            | NA                       | No trend                            |
| CXCL10     | Positive              | Positive b                          | NA                       | Inconclusive c                      |
| Ferritin   | No trend              | No trend                            | NA                       | No trend                            |
| Granzyme B | No trend              | Positive                            | NA                       | No trend                            |
| ICAM-1     | No trend              | No trend                            | NA                       | No trend                            |
| IFN- γ     | Positive              | Positive                            | NA                       | No trend                            |
| IL-1RA     | Positive              | No trend                            | NA                       | No trend                            |
| IL-2       | Positive              | Positive                            | NA                       | No trend                            |
| IL- 2Rα    | Positive b            | Positive                            | NA                       | No trend                            |
| IL-6       | Positive              | Positive                            | NA                       | No trend                            |
| IL-7       | No trend              | No trend                            | NA                       | No trend                            |
| IL-8       | Positive b            | Positive                            | NA                       | No trend                            |
| IL-10      | Positive              | Positive                            | NA                       | No trend                            |
| IL-15      | No trend              | Positive                            | NA                       | No trend                            |
| Perforin   | No trend              | No trend                            | NA                       | No trend                            |
| TNF- α     | Positive b            | Positive b                          | NA                       | No trend                            |
| VCAM-1     | Positive b            | No trend                            | NA                       | No trend                            |

## CRS

Of the 17 key analytes, the median peak serum levels for the following analytes were nominally higher among subjects with FL who experienced Grade 3 or higher CRS versus Grade 2, Grade 1, or no CRS after infusion of axicabtagene ciloleucel: CXCL10, IFNγ ,  IL-1RA, IL-2, IL-2R α ,  IL-6,  IL-8,  IL-10,  TNFα ,  and VCAM-1.

The 3 analytes with the lowest p-values for peak serum levels with Grade 3 or higher CRS compared with Grade 2, Grade 1, or no CRS were IL-2, TNFα and IL-6. These were also the 3 analytes with the greatest fold change in median peak serum levels by grade of CRS.

## Neurologic events

Of the 17 key analytes, the median peak serum levels for the following analytes were nominally higher among subjects with FL who experienced Grade 3 or higher neurologic events versus Grade 2, Grade 1, or no neurologic events after infusion of axicabtagene ciloleucel: CXCL10, granzyme B, IFNγ , IL-2, IL-2R α ,

<div style=\"page-break-after: always\"></div>

IL-6, IL-8, IL-10, IL-15, and TNFα . These analytes also were associated with higher severity CRS with the exception of granzyme B and IL-15.

The 4 analytes with the lowest p-values for peak serum levels with Grade 3 or higher neurologic events compared with Grade 2, Grade 1, or no neurologic events were IFNγ , IL-2, IL-6 and IL-10.

The 4 analytes with the greatest fold change in median peak serum levels by grade of neurologic events were IFNγ , IL-6, IL-2 and Granzyme B.

## Associations of B-cell levels with PK and disease response

## Summary of results

Subjects with FL who were in ongoing response or whose disease had relapsed by DCO had numerically lower median B-cell levels at baseline compared with nonresponders (4.65% and 4.59% versus 11.45%, respectively).

Most subjects who were in ongoing response demonstrated B-cell aplasia at Month 3, with 28 of 44 subjects (63.6%) having B-cell levels below the LLOQ of the flow cytometry assay used for evaluation. B-cell levels slowly recovered by Month 18, with 5 of 13 subjects (38.5%) having B-cell levels below the LLOQ at that time.

Subjects in ongoing response who had B-cell aplasia (B-cell levels below the LLOQ) had numerically higher median  CAR  T-cell  levels  than  subjects  in  ongoing  response  who  did  not  have  B-cell  aplasia  (B  cells detectable) at all time points for which data exist, Month 3 to Month 18.

Anti-CD19 CAR T cells persisted at detectable levels (median CAR T-cell level: 0.01 cells/ μ L; range: &lt; LLOQ to 0.93 cells/ μ L) in 8 subjects (61.5%) in ongoing response at Month 18 in the presence of recovered Bcell levels.

## 2.4.4. Discussion on clinical pharmacology

In general, the results presented on PK and PD and on measurable associations with both the drug product and the clinical parameters on safety and efficacy can be considered in line with current knowledge in the pharmacology  of  CAR  T  cell  therapy.  The  observed  variability  in  engraftment  kinetics  is  known  to  be multifactorial (applied dose, conditioning therapy etc.), which might be an explanation for the observed differences within defined and between defined groups.

The relationship between axicabtagene ciloleucel exposure and clinical efficacy is obvious. Interestingly, in terms of OR rates, there seem to be no significant differences in the median peak anti-CD19 CAR-T cell levels between responders and non-responders in contrast to median AUC0-28 levels, whereas in terms of ongoing response, the differences in both median peak CAR T- cell levels and AUC0-28 are obvious.

Onset  and  severity  of  CRS  and  neurological  events  coincides  with  the  kinetics  of  engraftment  of axicabtagene ciloleucel and a rise in the concentration of cytokines in the serum. With regard to PK and the occurrence of CRS and/or neurological events, higher anti-CD19 CAR T-cell levels (peak and AUC0-28) were associated with Grade 3 or higher CRS and neurological events, an observation, which is known according to  scientific  publications.  Results  presented  on  PD  and  clinical  safety  endpoints  (CRS  and  neurological events) indicate a positive association of most of the 17 key cytokines, chemokines and immune effector molecules with higher grade CRS and neurological events, an observation, which is also in compliance with current scientific knowledge in the treatment with CAR T-cell products.

<div style=\"page-break-after: always\"></div>

Nearly all patients, who experienced tumor response experienced concomitant elimination of non-malignant B-cells  (on-target  off-tumor  toxicity).  The  figures  on  the  loss  of  B-cells,  associated  with  decrease  in immunoglobulin concentrations as well as the figures on the return of B-cells at the subjects with FL in ZUMA-5 indicates to be consistent with literature data on CAR T cell therapy.

## 2.4.5. Conclusions on clinical pharmacology

The data provided are presented in a detailed and comprehensive way for the target indication r/r FL. The measurement  methods  used  in  ZUMA-5  are  the  commonly  employed  to  track  the  CAR  T  cells  after administration, and they appear to show viable correlations.

The results on PK and PD and on measurable associations with both the drug product and clinical outcome can be considered in line with current knowledge in the pharmacology of CAR T cell therapy.

## 2.5. Clinical efficacy

## 2.5.1. Main study

## Title of Study

## A Phase 2 Multicenter Study of Axicabtagene Ciloluecel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (ZUMA-5)

## Methods

Study KTE-C19-105 is a Phase 2, multicenter, open-label study estimating the efficacy of axicabtagene ciloleucel in subjects with r/r iNHL.

Originally, approximately 50 subjects were planned to be enrolled and treated with cyclophosphamide and fludarabine  conditioning  chemotherapy,  followed  by  a  target  dose  of  2  x  10 6   autologous,  genetically modified, anti-CD19 CAR T cells per kg body weight.

Each subject will proceed through the following study periods:

- Screening period
- Enrollment/Leukapheresis period
- Conditioning chemotherapy period
- Investigational product (IP) treatment period
- Post treatment assessment period
- Long-term follow-up period

## Main inclusion criteria

- Histologically proven indolent NHL that is determined to be high risk as defined by one or more of the following criteria: Biopsy-proven progression of Grade 1, Grade 2, or Grade 3, a FL, within 24

<div style=\"page-break-after: always\"></div>

months of original diagnosis of disease that was subsequently treated with first-line anti-CD20 monoclonal antibody- and cytotoxic agent-containing combination chemoimmunotherapy (eg, RCHOP, R-Bendamustine, R-CVP, R-fludarabine)

## OR

Progression of Grade 1, Grade 2, or Grade 3,a FL, or other iNHL (excluding small lymphocytic lymphoma)  within  6  months  of  completion  of  second  or  greater  line therapy  with  anti-CD20 monoclonal antibody- and alkylating agent-containing chemoimmunotherapy

## OR

Progression of Grade 1, Grade 2, or Grade 3 a FL, or other iNHL at any point following autologous transplantation

- At  least  1  measurable  lesion  according  to  the  revised  IWG  Response  Criteria  for  Malignant Lymphoma  (Cheson  2007).  Lesions  that  have  been  previously  irradiated  will  be  considered measurable only if progression has been documented following completion of radiation therapy MRI of the brain showing no evidence of CNS lymphoma
- ECOG performance status of 0 or 1
- MRI of the brain showing no evidence of CNS lymphoma
- Adequate bone marrow, renal, hepatic, pulmonary, and cardiac function

## Main exclusion criteria

- Transformed FL
- Small lymphocytic lymphoma
- Histological Grade 3b FL
- Known presence of lymphoma cells in the peripheral blood
- History  of  malignancy  other  than  nonmelanoma  skin  cancer  or  carcinoma  in  situ  (eg,  cervix, bladder, breast) unless disease-free and without anticancer therapy for at least 3 years
- Autologous stem cell transplant within 6 weeks of planned axicabtagene ciloleucel infusion
- History of allogeneic stem cell transplantation
- Prior CD19 targeted therapy with the exception of subjects who received axicabtagene ciloleucel in this study and are eligible for retreatment
- Prior CAR therapy or other genetically modified T-cell therapy

As per protocol amendment 2 (19 Jan 2018), the main inclusion criterion with regard to eligible iNHL histology was revised to limit histologically proven B-cell iNHL to the FL (Grade 1, 2 or 3a) or MZL nodal or extranodal histological subtypes based on the WHO 2016 classification and to remove primary relapse and relapse  after  ASCT  high  risk  categories  of  iNHL.  An  additional  inclusion  criterion  was  added  to  require relapse or refractory disease after 2 or more prior lines of therapy and that prior therapy must have included an anti-CD20 monoclonal antibody combined with an alkylating agent (Single agent anti-CD20 antibody was not counted as line of therapy for eligibility). Additionally, it was clarified that stable disease (without relapse) &gt; 1 year from completion of last therapy is not eligible. Furthermore, the inclusion criterion with the requirement of having at least 1 measurable lesion was updated to include the more recent Lugano Response Criteria for Malignant Lymphoma (Cheson et al, 2014). And finally, the requirement for MRI of

<div style=\"page-break-after: always\"></div>

the brain to show there is no evidence of CNS lymphoma was removed and replaced by a requirement of having no known history or suspicion of central nervous system (CNS) involvement by lymphoma.

Diagnosis of FL or MZL for determination of study eligibility was made by the investigator at each site. Diagnosis was centrally confirmed retrospectively on archival tumor tissue by NeoGenomics Laboratories (Irvine,  CA).  The  retrospective  review  of  central  diagnosis  included  assessment  of  CD19  expression. Demonstration of CD19 expression was not required for study eligibility. Tumor tissue in the form of an archival  formalin-fixed  paraffin  embedded  block,  pre-cut  slides,  or  an  on-study  baseline  (prior  to lymphodepletion) biopsy, were to be submitted for the central review.

## Study participants

Adult patients with r/r follicular lymphoma (FL) and marginal zone lymphoma (MZL)

## Treatments

Lymphodepletion (days-5 through -3 before infusion with axicabtagene ciloleucel)

The 3-day conditioning regimen of fludarabine and cyclophosphamide is described below. Hydration for cyclophosphamide may alternatively be performed according to local institutional guidelines.

- IV hydration with 1 L of 0.9% NaCl given prior to cyclophosphamide on the day of infusion followed by:
- Cyclophosphamide 500mg/m2 IV over 60 minutes followed by:
- Fludarabine 30mg/m2 IV over 30 minutes followed by:
- An additional 1L of 0.9% NaCl at the completion of the cyclophosphamide infusion
- Add Mesna per institutional guidelines

## Axicabtagene Ciloleucel Premedication Dosing

The following pre axicabtagene ciloleucel infusion medications should be administered approximately 1 hour prior to infusion.

- Tylenol 650 mg PO
- Benadryl (12.5 mg IV or 25 mg PO)

## Axicabtagene Ciloleucel (Day 0 after Fludarabine and Cyclophosphamide)

Subjects will receive axicabtagene ciloleucel treatment consisting of a single infusion of CAR transduced autologous T cells administered intravenously at a target dose of 2 x 10 6  anti-CD19 CAR T cells/kg (1.0 x 10 6  anti-CD19 CAR T cells/kg to 2.4 x 10 6  anti-CD19 CAR T cells/kg). For subjects weighing greater than 100 kg, a maximum flat dose of 2 x 10 8  anti-CD19 CAR T cells will be administered.

## Toxicity management

- Tocilizumab and corticosteroids in accordance to recommendations
- Alternatives allowed, such as anti-IL-6 antibodies (siltuximab) anti-TNF-alpha monoclonal antibody (infliximab), soluble TNF-alpha receptor (etanercept), and IL-1- receptor antagonist (anakinra)
- Vasopressors

<div style=\"page-break-after: always\"></div>

| Vasopressor                                      | Dose                                                    |
|--------------------------------------------------|---------------------------------------------------------|
| Norepinephrine monotherapy                       | ≥ 20 µg/min                                             |
| Dopamine monotherapy                             | ≥ 10 µg/kg/min                                          |
| Phenylephrine monotherapy                        | ≥ 200 µg/min                                            |
| Epinephrine monotherapy                          | ≥ 10 µg/min                                             |
| If on vasopressin                                | Vasopressin + norepinephrine equivalent of ≥ 10 µg/min* |
| If on combination vasopressors (not vasopressin) | Norepinephrine equivalent of ≥ 20 µg/min*               |

- Prophylactic anti-epileptics (e. g. levetiracetam) allowed
- Gammaglobulin according institutional guidelines

## Axicabtagene Ciloleucel retreatment

Subjects who achieve a response of PR or better at the 3-month disease assessment, but subsequently experience disease progression, had the option to receive a second course of conditioning chemotherapy and axicabtagene ciloleucel.

The following criteria must be met to be considered for a repeat course of therapy:

- Subject has at least PR or CR at the Month 3 disease assessment, but subsequently experienced progression of disease at a later time.
- CD19 expression on tumor cells confirmed locally by biopsy after disease progression and prior to treatment
- Subject continues to meet the original study eligibility criteria with the exception of prior axicabtagene ciloleucel  use  in  this  study.  Screening  assessments  should  be  repeated  if  clinically  indicated,  as determined by the investigator, to confirm eligibility .
- Subject has not received subsequent therapy for the treatment of lymphoma.
- Subject did not experience Grade 4 CRS, Grade 4 neurological event, or any other life-threatening toxicity during the original course of treatment.
- Toxicities  related  to  conditioning  chemotherapy  (fludarabine  and  cyclophosphamide),  with  the exception of alopecia, have resolved to ≤ Grade 1 or returned to baseline prior to retreatment.
- Subject  does  not  have  known  neutralizing  antibodies  (exception:  if  a  non-neutralizing  KTE-C19 antibody develops, subject may be retreated if he or she meets the original study eligibility criteria).

## Outcomes/endpoints

## Primary endpoint

Objective response rate (ORR), defined as complete response (CR)+ partial response (PR) per Lugano classification and central assessment

## Key secondary endpoints

- Progression-free survival (PFS), including the 12-month PFS rate (central/investigator assessment)
- ORR for those subjects who had 3 or more lines of prior therapy per central assessment

<div style=\"page-break-after: always\"></div>

- DOR (central/investigator assessment
- Overall Survival (OS)
- Incidence of AEs
- PD and PK

## Sample size

Up to approximately 160 subjects, including up to approximately 125 subjects with FL with at least 80 subjects with FL in the inferential analysis set, were to be enrolled and treated. The trial used a single-arm design to estimate the ORR in subjects with r/r iNHL treated with axicabtagene ciloleucel.

The primary analysis was to be performed when at least 80 subjects in the FL inferential analysis set had had the opportunity to be followed for 12 months after the first disease assessment. The primary efficacy endpoint for this study in the inferential analysis set had 93% power to reject the null hypothesis that the ORR was 40% given the ORR was 60%, with a 1-sided alpha level of 0.0237.

The analysis sets have been revised after the first round of questions by the Applicant as follows, excluding centrally confirmed non-FL:

FAS with 3 or more lines of prior therapy: n=75

IAS with 3 or more lines of prior therapy: n=55

SAS with 3 or more lines of prior therapy: n=73

## Randomisation and Blinding (masking)

The study was a single arm, open-label trial and subjects and investigators were aware of treatment received. Data handling procedures for the study were to be devised to reduce potential sources of bias and maintain the validity and credibility of the study. These procedures were to be outlined in the study statistical analysis plan, DSMB charter, and trial integrity document.

## Statistical methods

## Analysis sets

The following analysis sets were defined:

- Inferential Analysis Set (IAS): all enrolled subjects (FL or MZL) treated with any dose of axicabtagene ciloleucel who met the eligibility criteria. This analysis set was to be used as primary efficacy analysis set.
- Full Analysis Set (FAS): all enrolled (leukapheresed) subjects; this set was to be used for sensitivity analyses.
- Safety Analysis Set: all subjects treated with any dose of axicabtagene ciloleucel; the safety analysis set was used for all safety analyses.
- Retreatment Analysis Set: all subjects who underwent retreatment with axicabtagene ciloleucel; this set was used for all retreatment safety and efficacy analyses. Subjects in the re-treatment analysis set were not included in any other analysis sets.

<div style=\"page-break-after: always\"></div>

## Statistical Hypotheses

Four hypotheses were tested using a fixed sequence procedure in terms of ORR and CR rate as determined by central review to control the overall type I error at 1-sided alpha level of 0.025 with the following testing order:

- Hypothesis 1 (H1): ORR as determined by central review less than 40% in subjects with FL in the IAS
- Hypothesis 2 (H2): CR rate as determined by central review less than 15% in subjects with FL in the IAS
- Hypothesis 3 (H3): test for ORR as determined by central review less than 40% in subjects with FL in the IAS who had had 3 or more lines of prior therapy
- Hypothesis 4 (H4): test for CR rate as determined by central review less than 15% in subjects with FL in the IAS who had had 3 or more lines of prior therapy

Hypotheses H1 through H4 were to be assessed at the time of the interim analyses 3, 4, and 5 and at the time of the primary analysis. No formal hypothesis testing was planned for the MZL histological subtype. The analysis is descriptive only.

## Historical control ORR and CR rates

The historical control rate for ORR was estimated based on results of limited available data on the approved therapies for r/r FL after 2 or more prior lines of therapy. These approved therapies at the time of trial design were the PI3K inhibitors idelalisib and copanlisib. In the trial of idelalisib, the ORR and CR rate for patients with relapsed FL after 2 or more prior lines of therapy were 54% and 8%, respectively, and in the trial of copanlisib, the ORR and CR rate for patients with r/r FL after 2 or more prior lines of therapy were 59% and 14%, respectively. It was anticipated that most subjects would have had prior treatment with at least one of the aforementioned PI3K inhibitors; thus, an ORR &lt;40% or CR rate &lt;15% would not be of clinical interest. Therefore, these rates were used for hypothesis testing.

## Analyses of primary and secondary endpoints

The subject incidence of objective response and complete response together with 2-sided 95% confidence intervals were to be calculated with the Clopper-Pearson method. An exact binomial test was to be used to compare the ORR and CR per central read among the subjects with FL and among the subjects with FL who have had 3 or more lines of prior therapy to the hypothesized historical control rates of 40% and 15%, respectively.

Kaplan-Meier plots, estimates, and 2-sided 95% confidence intervals were to be generated for DOR, PFS and OS. Kaplan-Meier estimates were to be provided for the proportion of subjects who were alive and progression-free at 3-month time intervals. The number of subjects censored or having had events was to be summarized, as well as the reasons for censoring and the event type (PD or death; if applicable).

The reverse Kaplan-Meier approach (Schemper and Smith 1996) was to be used to estimate the follow-up time for DOR.

## Planned analyses

Five interim analyses were planned. An independent data and safety monitoring board (DSMB) was to be chartered to make trial conduct recommendations based on an analysis of risk versus benefit. The 5 interim analyses were as follows:

<div style=\"page-break-after: always\"></div>

- Interim analysis 1 was to be conducted after 10 subjects in the safety analysis set had been enrolled and treated with axicabtagene ciloleucel and had had an opportunity to be followed for 4 weeks. This analysis was to be for safety only.
- Interim analysis 2 was to be conducted after 30 subjects in the safety analysis set had been enrolled and treated with axicabtagene ciloleucel and had had an opportunity to be followed for 4 weeks. This analysis was to be for safety only.
- Interim analysis 3 was to be performed when 30 subjects in the FL inferential set had had the opportunity to be followed for 6 months after the axicabtagene ciloleucel infusion. This interim analysis was to be for safety and to assess early demonstration of efficacy.
- Interim analysis 4 was to be performed when 80 subjects in the FL inferential analysis set had had the opportunity to be followed for 6 months after axicabtagene ciloleucel infusion.
- Interim analysis 5 was to be performed when at least 80 subjects with FL in the inferential analysis set had had the opportunity to be followed for 9 months after the first disease response assessment.
- The primary analysis was to be performed when at least 80 subjects with FL in the inferential analysis set have had the opportunity to be followed for 12 months after the first disease response assessment.

Additionally the following updated analyses were planned:

- Follow-up analysis 1 was planned to be performed when 80 subject in the FL inferential analysis set have had the opportunity to be followed for 18 months after axicabtagene ciloleucel infusion. This analysis was to be for safety and efficacy and was to be descriptive.
- Follow-up analysis 2 was planned to be performed when 80 subjects in the FL inferential analysis set have had the opportunity to be followed for 24 months after axicabtagene ciloleucel infusion. This analysis was to be for safety and efficacy and was to be descriptive.
- The final analysis was to occur after all subjects have completed the study.

It should be noted that subjects with MZL were included in the fifth interim analysis and the primary analysis if they had had the opportunity to undergo the Week 4 disease assessment.

An alpha spending function was to be used to allocate the alpha level between interim analyses 3, 4, and 5, and the primary analysis. Using the O'Brien-Fleming boundary of the Lan-DeMets family of alpha spending functions, the nominal 1-sided alpha used to test for efficacy at interim analyses 3 was 0.0003.With Protocol Amendment 5 the remaining alpha was split for interim analyses 4, 5 and primary analysis as 0.0005, 0.0005, and 0.0237.

## Multiplicity control over endpoints

If the criteria for early efficacy were met for H1, the same alpha spending function was to be applied to test H2 at this interim analysis; otherwise, H2 through H4 was not be tested until the subsequent analysis. If the criteria for early efficacy were met for H1 and H2, the same alpha spending function was to be applied to test H3; otherwise, H3 and H4 were not to be tested until the subsequent analysis. If the criteria for early efficacy were met for H1, H2, and H3, the same alpha spending function was to be applied to test H4; otherwise, H4 was not be tested until the subsequent analysis. The study was not to be stopped if early efficacy was demonstrated.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

## Figure 8. Participant flow

<!-- image -->

## Recruitment

In total, 154 subjects with iNHL were assessed for eligibility.

Among these 154 subjects, 127 subjects were diagnosed with FL according to local histopathological assessment. Although central confirmation of diagnosis was retrospective and was not required for treatment or continued enrolment on the study per protocol and statistical analysis plan (SAP), the number of enrolled subjects with histologic confirmation of FL by central assessment was 101 subjects in the FAS. For the majority of the 26 subjects for which local diagnosis of FL could retrospectively not be confirmed per central assessment ('inconclusive'/'other'), this was due to the following: 1) the protocol did not mandate that the same tissue specimens had to be reviewed by local and central review pathologists, 2) the majority of the non-confirmed FL by central assessment were due to insufficient tissue, and 3) insufficient tumor in the samples provided. Only for 5 of the 26 subjects central lab assessment was highly suggestive of an alternative non-FL diagnosis (3 subjects with transformed FL, 1 subject with small B-cell lymphoma, and 1 subject with MZL per central assessment). These 5 subjects were subsequently excluded from the FAS.

Among subjects with FL (subjects with centrally confirmed non-FL excluded), the full analysis set (FAS) comprised 122 subjects. Of these subjects, 119 were included in the safety analysis set, 81 were included

<div style=\"page-break-after: always\"></div>

in  the inferential analysis set, 75 were included in the subset of subjects with 3 or more lines of prior therapy in the FAS. No additional subjects were enrolled/treated after the primary analysis data cutoff date.

No manufacturing failures occurred. The median time from leukapheresis to the products release from the manufacturing site was 12.0 days (range: 10 to 37 days). Axicabtagene ciloleucel was delivered to the study site a median of 17.0 days (range: 13 to 72 days) after leukapheresis and was administered to the subject a median of 27.0 days (range: 19 to 330 days) after leukapheresis. Delays that occurred (&gt; 50 days) from manufacturing of the product to delivery to the clinical site or from leukapheresis to infusion of the product were due to the clinical course of the disease.

## Conduct of the study

On June 2017, the first subject was screened in this study and the first subject was enrolled on 20 Jun 2017. The data cutoff date for the primary analysis (12-month follow-up) was 12 March 2020. The data cut-off date of the 18-month follow-up analysis, also included in the submission, was 14 September 2020. The data cut-off date of the 24 month follow-up analysis, provided at the time of Day 120 responses and the data to be presented in the SmPC, is 31 March 2021.

## Study protocol amendments

The original protocol, dated 26 November 2016, was amended 5 times before the data cutoff date of the primary analysis of the study. The amendments made related to iNHL in general and/or MZL/FL in particular.

## Study protocol deviations

In the safety analysis set (SAS), important protocol deviations (IPDs) were reported for 23 subjects (19%) during the course of the trial. Most of IPDs were missing data (n=20; 16%).

## Baseline data

Table 8. Demographics and Baseline Characteristics in FAS and IAS of Subjects With FL or of Subjects With FL Who Received 3 or More Lines of Prior Therapy (Excluding Centrally Confirmed Non-FL; based on 24 months analyses, DCO 31 Mar 2021)

|                      | FAS               | FAS                                               | IAS               | IAS                                               |
|----------------------|-------------------|---------------------------------------------------|-------------------|---------------------------------------------------|
|                      | FL (N = 122)      | FL With 3 or More Lines of Prior Therapy (N = 75) | FL (N = 81)       | FL With 3 or More Lines of Prior Therapy (N = 55) |
| Age (years)          |                   |                                                   |                   |                                                   |
| n                    | 122               | 75                                                | 81                | 55                                                |
| Mean (STDEV)         | 58.9 (9.8)        | 59.8 (9.1)                                        | 59.4 (10.5)       | 59.8 (9.8)                                        |
| Median (Q1, Q3)      | 60.0 (53.0, 67.0) | 60.0 (54.0, 67.0)                                 | 62.0 (53.0, 69.0) | 62.0 (54.0, 69.0)                                 |
| Min, Max             | 34, 79            | 34, 79                                            | 34, 79            | 34, 79                                            |
| Age category - n (%) |                   |                                                   |                   |                                                   |
| < 65 Years           | 85 (70)           | 52 (69)                                           | 53 (65)           | 37 (67)                                           |

<div style=\"page-break-after: always\"></div>

|                                                            | FAS          | FAS                                               | IAS         | IAS                                               |
|------------------------------------------------------------|--------------|---------------------------------------------------|-------------|---------------------------------------------------|
|                                                            | FL (N = 122) | FL With 3 or More Lines of Prior Therapy (N = 75) | FL (N = 81) | FL With 3 or More Lines of Prior Therapy (N = 55) |
| >= 65 Years                                                | 37 (30)      | 23 (31)                                           | 28 (35)     | 18 (33)                                           |
| Sex - n (%)                                                |              |                                                   |             |                                                   |
| Male                                                       | 73 (60)      | 47 (63)                                           | 46 (57)     | 35 (64)                                           |
| Female                                                     | 49 (40)      | 28 (37)                                           | 35 (43)     | 20 (36)                                           |
| Ethnicity - n (%)                                          |              |                                                   |             |                                                   |
| Hispanic or Latino                                         | 6 (5)        | 4 (5)                                             | 4 (5)       | 4 (7)                                             |
| Not Hispanic or Latino                                     | 116 (95)     | 71 (95)                                           | 77 (95)     | 51 (93)                                           |
| Missing                                                    | 0 (0)        |                                                   | 0 (0)       | 0 (0)                                             |
| Race - n (%)                                               |              |                                                   |             |                                                   |
| Asian                                                      | 3 (2)        | 3 (4)                                             | 2 (2)       | 2 (4)                                             |
| Black or African American                                  | 3 (2)        | 1 (1)                                             | 2 (2)       | 1 (2)                                             |
| White                                                      | 113 (93)     | 70 (93)                                           | 76 (94)     | 51 (93)                                           |
| Other                                                      | 3 (2)        | 1 (1)                                             | 1 (1)       | 1 (2)                                             |
| Country - n (%)                                            |              |                                                   |             |                                                   |
| United States                                              | 112 (92)     | 67 (89)                                           | 77 (95)     | 51 (93)                                           |
| France                                                     | 10 (8)       | 8 (11)                                            | 4 (5)       | 4 (7)                                             |
| ECOG performance status, n (%)                             |              |                                                   |             |                                                   |
| 0                                                          | 77 (63)      | 44 (59)                                           | 49 (60)     | 32 (58)                                           |
| 1                                                          | 45 (37)      | 31 (41)                                           | 32 (40)     | 23 (42)                                           |
| Histologically diagnosed disease type per local lab, n (%) |              |                                                   |             |                                                   |
| FL                                                         | 122 (100)    | 75 (100)                                          | 81 (100)    | 55 (100)                                          |
| FL histological category at study entry, n (%)             |              |                                                   |             |                                                   |
| Grade 1                                                    | 32 (26)      | 22 (29)                                           | 18 (22)     | 11 (20)                                           |
| Grade 2                                                    | 61 (50)      | 38 (51)                                           | 41 (51)     | 30 (55)                                           |
| Grade 3a                                                   | 29 (24)      | 15 (20)                                           | 22 (27)     | 14 (25)                                           |
| Disease stage f , n (%)                                    |              |                                                   |             |                                                   |
| I                                                          | 5 (4)        | 3 (4)                                             | 2 (2)       | 2 (4)                                             |
| II                                                         | 13 (11)      | 7 (9)                                             | 9 (11)      | 6 (11)                                            |

<div style=\"page-break-after: always\"></div>

|                                            | FAS               | FAS                                               | IAS               | IAS                                               |
|--------------------------------------------|-------------------|---------------------------------------------------|-------------------|---------------------------------------------------|
|                                            | FL (N = 122)      | FL With 3 or More Lines of Prior Therapy (N = 75) | FL (N = 81)       | FL With 3 or More Lines of Prior Therapy (N = 55) |
| III                                        | 46 (38)           | 34 (45)                                           | 35 (43)           | 25 (45)                                           |
| IV                                         | 58 (48)           | 31 (41)                                           | 35 (43)           | 22 (40)                                           |
| FLIPI total score g , n (%)                |                   |                                                   |                   |                                                   |
| 0                                          | 4 (3)             | 2 (3)                                             | 3 (4)             | 2 (4)                                             |
| 1                                          | 18 (15)           | 9 (12)                                            | 10 (12)           | 7 (13)                                            |
| 2                                          | 48 (39)           | 30 (40)                                           | 32 (40)           | 20 (36)                                           |
| 3                                          | 34 (28)           | 22 (29)                                           | 23 (28)           | 17 (31)                                           |
| 4                                          | 15 (12)           | 11 (15)                                           | 11 (14)           | 8 (15)                                            |
| 5                                          | 3 (2)             | 1 (1)                                             | 2 (2)             | 1 (2)                                             |
| Low risk (0 - 1)                           | 22 (18)           | 11 (15)                                           | 13 (16)           | 9 (16)                                            |
| Intermediate risk (2)                      | 48 (39)           | 30 (40)                                           | 32 (40)           | 20 (36)                                           |
| High risk (3 - 5)                          | 52 (43)           | 34 (45)                                           | 36 (44)           | 26 (47)                                           |
| Relapsed/refractory subgroup a , n (%)     |                   |                                                   |                   |                                                   |
| Relapsed                                   | 40 (33)           | 17 (23)                                           | 23 (28)           | 12 (22)                                           |
| Refractory                                 | 82 (67)           | 58 (77)                                           | 58 (72)           | 43 (78)                                           |
| Double refractory subgroup a , n (%)       |                   |                                                   |                   |                                                   |
| Yes                                        | 36 (30)           | 18 (24)                                           | 28 (35)           | 17 (31)                                           |
| No                                         | 86 (70)           | 57 (76)                                           | 53 (65)           | 38 (69)                                           |
| Number of prior lines of therapy e , n (%) |                   |                                                   |                   |                                                   |
| 1                                          | 3 (2)             | -                                                 | -                 | -                                                 |
| 2                                          | 43 (35)           | -                                                 | 26 (32)           | -                                                 |
| 3                                          | 30 (25)           | 30 (40)                                           | 17 (21)           | 17 (31)                                           |
| 4                                          | 25 (20)           | 25 (33)                                           | 20 (25)           | 20 (36)                                           |
| ≥ 5                                        | 20 (16)           | 20 (27)                                           | 18 (22)           | 18 (33)                                           |
| n                                          | 121               | 75                                                | 81                | 55                                                |
| Mean (STDEV)                               | 3.31 (1.59)       | 4.16 (1.47)                                       | 3.58 (1.59)       | 4.33 (1.40)                                       |
| Median (Q1, Q3)                            | 3.00 (2.00, 4.00) | 4.00 (3.00, 5.00)                                 | 3.00 (2.00, 4.00) | 4.00 (3.00, 5.00)                                 |
| Min, Max                                   | 1.0, 10.0         | 3.0, 10.0                                         | 2.0, 9.0          | 3.0, 9.0                                          |
| Response to last line of therapy, n (%)    |                   |                                                   |                   |                                                   |

<div style=\"page-break-after: always\"></div>

|                                                                                  | FAS          | FAS                                               | IAS         | IAS                                               |
|----------------------------------------------------------------------------------|--------------|---------------------------------------------------|-------------|---------------------------------------------------|
|                                                                                  | FL (N = 122) | FL With 3 or More Lines of Prior Therapy (N = 75) | FL (N = 81) | FL With 3 or More Lines of Prior Therapy (N = 55) |
| Complete response                                                                | 34 (28)      | 17 (22)                                           | 21 (26)     | 11 (20)                                           |
| Partial response                                                                 | 24 (20)      | 11 (15)                                           | 15 (19)     | 8 (15)                                            |
| Stable disease                                                                   | 22 (18)      | 19 (25)                                           | 17 (21)     | 16 (29)                                           |
| Progressive disease                                                              | 23 (19)      | 16 (21)                                           | 16 (20)     | 11 (20)                                           |
| Not evaluable                                                                    | 4 (3)        | 4 (5)                                             | 3 (4)       | 3 (5)                                             |
| Unknown                                                                          | 14 (11)      | 8 (11)                                            | 9 (11)      | 6 (11)                                            |
| Receiving prior autologous stem cell transplant, n (%)                           |              |                                                   |             |                                                   |
| Yes                                                                              | 30 (25)      | 22 (29)                                           | 21 (26)     | 16 (29)                                           |
| No                                                                               | 92 (75)      | 53 (71)                                           | 60 (74)     | 39 (71)                                           |
| Time to relapse from first anti-CD20- chemotherapy combination therapy b , n (%) | 121          | 75                                                | 81          | 55                                                |
| ≥ 24 months                                                                      | 41 (34)      | 31 (41)                                           | 29 (36)     | 22 (40)                                           |
| < 24 months                                                                      | 65 (54)      | 38 (51)                                           | 44 (54)     | 29 (53)                                           |
| High tumor bulk as defined by GELF criteria c , n (%)                            | 63 (52)      | 43 (57)                                           | 40 (49)     | 30 (55)                                           |
| Involvement of ≥ 3 nodal sites, each with a diameter of ≥ 3 cm                   | 31 (25)      | 24 (32)                                           | 22 (27)     | 19 (35)                                           |
| Any nodal or extranodal tumor mass with a                                        | 22 (18)      | 17 (23)                                           | 16 (20)     | 13 (24)                                           |
| diameter of ≥ 7 cm                                                               |              |                                                   |             |                                                   |
| Presence of B symptoms                                                           | 8 (7)        | 4 (5)                                             | 5 (6)       | 3 (5)                                             |
| Splenomegaly                                                                     | 22 (18)      | 14 (19)                                           | 15 (19)     | 10 (18)                                           |
| Pleural effusions or peritoneal ascites                                          | 5 (4)        | 4 (5)                                             | 2 (2)       | 2 (4)                                             |
| Cytopenias                                                                       | 15 (12)      | 11 (15)                                           | 9 (11)      | 8 (15)                                            |
| Leukemia                                                                         | 1 (1)        | 0 (0)                                             | 0 (0)       | 0 (0)                                             |
| Prior PI3K inhibitor, n (%)                                                      |              |                                                   |             |                                                   |
| Yes                                                                              | 32 (26)      | 30 (40)                                           | 24 (30)     | 22 (40)                                           |
| No                                                                               | 90 (74)      | 45 (60)                                           | 57 (70)     | 33 (60)                                           |
| Prior anti-CD20 + alkylating agent, n (%)                                        |              |                                                   |             |                                                   |
| Yes                                                                              | 121 (99)     | 75 (100)                                          | 81 (100)    | 55 (100)                                          |
| No                                                                               | 1 (1)        | 0 (0)                                             | 0 (0)       | 0 (0)                                             |

<div style=\"page-break-after: always\"></div>

|                                              | FAS          | FAS                                               | IAS         | IAS                                               |
|----------------------------------------------|--------------|---------------------------------------------------|-------------|---------------------------------------------------|
|                                              | FL (N = 122) | FL With 3 or More Lines of Prior Therapy (N = 75) | FL (N = 81) | FL With 3 or More Lines of Prior Therapy (N = 55) |
| Prior lenalidomide, n (%)                    |              |                                                   |             |                                                   |
| Yes                                          | 34 (28)      | 28 (37)                                           | 23 (28)     | 20 (36)                                           |
| No                                           | 88 (72)      | 47 (63)                                           | 58 (72)     | 35 (64)                                           |
| Bone marrow assessment at baseline d , n (%) |              |                                                   |             |                                                   |
| Lymphoma present                             | 34 (28)      | 24 (32)                                           | 19 (23)     | 15 (27)                                           |
| Lymphoma present but not FL                  | 1 (1)        | 1 (1)                                             | 1 (1)       | 1 (2)                                             |
| Lymphoma not present                         | 86 (70)      | 50 (67)                                           | 61 (75)     | 39 (71)                                           |
| Unknown                                      | 1 (1)        | -                                                 | -           | -                                                 |

a. Subjects with iNHL who progressed within 6 months of completion of the most recent prior treatment are defined as refractory. Subjects with iNHL who progressed &gt; 6 months of completion of the most recent prior treatment are defined as relapsed.

- b. Time to relapse is defined as the time from initiation of the first line anti-CD20-chemotherapy combination therapy to progression. Number of subjects with time to relapse is based on those who had progressed with date of progression. Percentages are based on number of subjects who ever received anti-CD20-chemotherapy combination therapy.
- c. Disease burden, as defined by any of Groupe d Etude des Lymphomes Folliculaires (GELF) criteria (subject meets the criteria for high tumor bulk versus subject does not meet the criteria for high tumor bulk): Involvement of ≥ 3 nodal sites, each with a diameter of ≥ 3 cm, Any nodal or e xtranodal tumor mass with a diameter of ≥ 7 cm, B symptoms, Splenomegaly, Pleural effusions or peritoneal ascites, Cytopenias, or Leukemia.
- d. Bone marrow assessment at baseline for lymphoma presence is based on investigator reported Lugano bone marrow assessment/ bone marrow assessment using aspirate or core biopsy at screening. If these are not available, lymphoma presence is based on diagnosis history of bone marrow involvement.

e. Prior anti-CD20 single agent includes rituximab, ofatumumab, obinutuzumab.

## Retrospective Analysis of Tumor CD19 Status

Among 122 subjects with FL in the FAS excluding centrally confirmed non-FL, 113 subjects were with available samples at baseline; of these, 95 subjects had confirmed CD19 +  antigen status, 8 subjects had confirmed CD19 -status, and 10 subjects' CD19 antigen status were missing/inconclusive at baseline.

## Outcomes and estimation

## Primary analysis (DCO 12 Mar 2020)

Among the 84 subjects with FL (per investigator assessment) in the IAS who had the opportunity to be followed for 12 months after the first disease response assessment, the ORR was 94% (79/84 subjects), with a 95% CI of (87%, 98%). This ORR was significantly greater (p &lt; 0.0001; less than the alpha level of 0.0237 allocated at the primary analysis) than the prespecified historical control rate of 40%. Therefore, the null hypothesis was rejected and the primary efficacy endpoint for ZUMA-5 was met (Hypothesis 1).

The CR rate was 80% (67/84 subjects, 95% CI: 70%, 88%), which was significantly greater (p &lt; 0.0001) than the prespecified control rate of 15%. Therefore, the null hypothesis was rejected and the criteria for the key secondary endpoint of CR rate was met (Hypothesis 2).

Among the 58 subjects with FL who had 3 or more lines of prior therapy, the ORR was 95% (55 of 58 subjects, 95% CI: 86%, 99%), with a CR rate of 81% (47 of 58 subjects, 95% CI: 69%, 90%). The ORR of 95% was significantly greater (p &lt; 0.0001) than the prespecified control rate of 40%; therefore, the

<div style=\"page-break-after: always\"></div>

criteria for efficacy for the secondary endpoint of ORR in subjects who had 3 or more lines of prior therapy was met (Hypothesis 3).

The CR rate among subjects with FL who had 3 or more lines of prior therapy was tested because the ORR among these subjects was significant. The CR rate of 81% was significantly greater (p &lt; 0.0001) than the prespecified control rate of 15%; therefore, the criteria for efficacy for the secondary endpoint of CR rate in subjects who had 3 or more lines of prior therapy was met (Hypothesis 4).

## 24 month FU analysis (DCO 31 Mar 2021)

Based on the 24-month data cutoff date, the ORR and CR rate of subjects with FL who received 3 or more lines of therapy in the FAS and IAS excluding centrally confirmed non-FL were similar (ORR: 91% versus 95% respectively; CR rate: 77% versus 78%, respectively). Among the subjects with FL who received 3 or more lines of therapy in the FAS excluding centrally confirmed non-FL and who achieved a CR or PR, the median time to first objective response was 0.99 month (range: 0.8 to 3.1 months). Among the 58 subjects who achieved a CR, the median time to first CR was 1.05 month (range: 0.8 to 12.1 months). Twenty nine out of 75 FL patients who had 3 or more prior lines of therapy initially achieved a PR, 19 of whom later achieved CR. The KM median estimates of DOR, PFS, OS, and TTNT in the FAS and IAS were similar (DOR: 38.6 months in each analysis set; PFS: 40.2 versus 28.0 months, respectively; OS: not estimable in each analysis set; TTNT: 40.2 versus 39.6 months, respectively). The pattern of the KM PFS plots in the FAS and IAS are parallel. Median follow-up time for DOR was 22.6 months (95% CI: 18.8, 23.0 months).

Table 9.Summary of Key Efficacy Results of Subjects With FL Who Received 3 or More Lines of Prior Therapy Excluding Centrally Confirmed Non-FL (FAS and IAS); DCO 31Mar2021

<div style=\"page-break-after: always\"></div>

Figure 9. KM Plot of DOR Per central Assessment of Subjects With FL and OR Who received 3 or More Lines of Therapy (FAS Excluding centrally Confirmed Non-FL)

|                                                                  | FAS               | FAS                                               | IAS                       | IAS                                              |
|------------------------------------------------------------------|-------------------|---------------------------------------------------|---------------------------|--------------------------------------------------|
|                                                                  | FL (N = 122)      | FL With 3 or More Lines of Prior Therapy (N = 75) | FL (N=81)                 | FL With 3or More Lines of Prior Therapy (N = 55) |
| ORR (95% CJ): p-value                                            | 92% (85%, 96%);   | 91% (82%, 96%);                                   | 94% (86%, 98%); p <0.0001 | 95% (85%, 99%); p < 0.0001                       |
| CR (95% CJ); p-value                                             | 77% (69%, 84%);   | 77% (66%, 86%)                                    | 78% (67%, 86%); p<0.0001  | 78% (65%, 88%); p < 0.0001                       |
| PR (95% CI)                                                      | 15% (9%, 22%)     | 13% (7%, 23%)                                     | 16% (9%, 26%)             | 16% (8%, 29%)                                    |
| DORb                                                             |                   |                                                   |                           |                                                  |
| KM Median (95% CI) (months)                                      | 38.6 (NE, NE)     | 38.6 (24.7, NE)                                   | 38.6 (24.7, NE)           | 38.6 (22.7, NE)                                  |
| KM estimate of proportion in response at 24 months (95% CI)      | 71.0 (60.3, 79.3) | 67.6 (52.7, 78.7)                                 | 68.1 (55.5, 77.8)         | 62.8 (46.9, .75.2)                               |
| PES                                                              |                   |                                                   |                           |                                                  |
| KM Median (95% CI) (months)                                      | 40.2 (28.9, NE)   | 40.2 (26.6, NE)                                   | 39.6 (25.7, NE)           | 28.0 (23.5, NE)                                  |
| KM estimate of proportion progression-free at 24 months (95% CI) | 71.9 (62.4, 79.5) | 71.8 (58.6, 81.4)                                 | 65.1 (53.0, 74.9)         | 61.3 (46.0, 73.5)                                |
| KM Median (95% CI) (months)                                      | NE (40.2, NE)     | NE (40.2, NE)                                     | NE (39.6, NE)             | NE (39.6, NE)                                    |
| KM estimate of proportion allive at 24 months (95% CI)           | 87.9 (80.3, 92.7) | 85.5 (74.6, 91.9)                                 | 81.3 (71.0, 88.3)         | 79.8 (66.5, 88.3)                                |
| TTNTe                                                            |                   |                                                   |                           |                                                  |
| KM Median (95% CI) (months)                                      | 40.2 (40.2, NE)   | 40.2 (26.6, NE)                                   | 39.6 (28.0, NE)           | 39.6 (22.8, NE)                                  |
| KM estimate of proportion event-free at 24 months (95% CI)       | 70.8 (61.7, 78.1) | 67.0 (54.8, 76.6)                                 | 64.0 (52.6, 73.4)         | 59.7 (45.5, 71.3)                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 10. KM Plot of PFS Per Central Assessment of Subjects With FL Who Received 3 or More Lines of Prior Therapy (FAS Excluding Centrally Confirmed Non-FL)

<!-- image -->

<div style=\"page-break-after: always\"></div>

Figure 11. KM Plot of OS of Subjects With FL Who Received 3 or More Lines of Prior Therapy (FAS Excluding Centrally Confirmed Non-FL)

<!-- image -->

Ancillary analyses (based on 24 months analysis; CDO 31 MAR 2021)

Sensitivity analyses for DOR and PFS according to EMA censoring rules (FAS with FL subjects who received ≥ 3 prior lines of therapy , excluding centrally confirmed non-FL)

In the primary analysis for DOR based on the 24-months data cut-off date, 3 subjects were censored due to starting new anticancer therapy and 1 subject due to retreatment. In the primary analysis for PFS, 4 subjects were censored due to starting new anticancer therapy and 2 subjects due to retreatment. These subjects started new anticancer therapy or retreatment in the absence of prior documented progression confirmed by central assessment, however the decision to start another treatment or to retreat was based on the investigator's assessment reporting disease progression. All subjects who received subsequent HSCT had disease progression reported by both central and investigator's assessment. Upon request, sensitivity analyses for DOR and PFS in the FL FAS excluding centrally confirmed non-FL who received ≥ 3 prior lines of therapy, considering the start of other new anticancer therapies or axi-cel retreatment in the absence of prior documented progression as an event (EMA censoring rules), were provided.

## Response to retreatment

<div style=\"page-break-after: always\"></div>

Figure 12. KM Plot of DOR Per Central Assessment - Sensitivity Analysis with New Anticancer Therapy and Retreatment as Event in Subjects with Objective Response and 3 or more prior lines of therapy (FAS Excluding Centrally Confirmed Non-FL)

<!-- image -->

Data cutoff date = 31MAR2021

<div style=\"page-break-after: always\"></div>

Table 10. PFS Per Central Assessment Based on Primary Analysis Versus Sensitivity Analysis With New Anticancer Therapy and Retreatment as Event (FAS Excluding Centrally Confirmed Non-Follicular Lymphoma, Subjects with 3 or More Lines of Prior Therapy)

|                                                               | Primary Analvsisa (N = 75)   | Sensitivity Aualysist (N = 75)   |
|---------------------------------------------------------------|------------------------------|----------------------------------|
| Number of subjects                                            | 75                           | 75                               |
| Events, n (%)                                                 | 23 (31)                      | 29 (39)                          |
| Censored, n (%)                                               | 52 (69)                      | 46 (61)                          |
| KM Median (95% CI) PFS time (months)                          | 40.2 (26.6, NE)              | 28.9 (24.2, NE)                  |
| Min, Max PFS time (months)                                    | 0.0, 40.2                    | 0.0, 40.2                        |
| Events                                                        |                              |                                  |
| Disease progression, n (%)                                    | 14 (19)                      | 14 (19)                          |
| Death from any cause, n (%)                                   | 9 (12)                       | 9 (12)                           |
| Started new anticancer therapy, n (%)                         | 一                            | 4 (5)                            |
| Retreatment, n (%)                                            |                              | 2 (3)                            |
| Censoring reason                                              |                              |                                  |
| Response ongoing. n (%)                                       | 42 (56)e                     | 42 (56)                          |
| Lost to follow-up, n (%)                                      | 1 (1)                        | 1 (1)                            |
| Withdrawal of consent, n (%)                                  | 1 (1)                        | 1 (1)                            |
| Investigator decision, n (%)                                  | 1 (1)                        | 1 (1)                            |
| Stem cell transplant, n (%)                                   | 0 (0)                        | 0 (0)                            |
| Response assessed but no disease, n (%)                       | 1 (1)                        | 0 (0)                            |
| Response not yet assessed, n (%)                              | 1 (1)                        | 1 (1)                            |
| Started new anticancer therapy, n (%)                         | 4 (5)e                       |                                  |
| Retreatment, n (%)                                            | 2 (3)f                       | 一                                |
| Progression-free rate % (95% CI) by KME                       |                              |                                  |
| 3 Month                                                       | 97.2 (89.3, 99.3)            | 94.5 (86.1, 97.9)                |
| 6 Month                                                       | 92.9 (83.7, 97.0)            | 90.4 (80.9, 95.3)                |
| 9 Month                                                       | 83.8 (72.6, 90.7)            | 77.7 (66.3, 85.7)                |
| 12 Month                                                      | 82.3 (70.8, 89.5)            | 76.3 (64.7, 84.6)                |
| 15 Month                                                      | 77.2 (65.0, 85.6)            | 70.5 (58.4, 79.7)                |
| 18 Month                                                      | 75.2 (62.5, 84.1)            | 69.0 (56.8, 78.4)                |
| 24 Month                                                      | 71.0 (55.9, 81.7)            | 65.0 (52.3, 75.2)                |
| Median (95% CI) follow-up time (months) (reverse KM approach) | 18.8 (15.9, 19.4)            | 24.6 (21.3, 25.2)                |

Data cutoff date = 31MAR2021.

## Summary of main study

The  following  tables  summarise  the  efficacy  results  from  the  main  studies  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

<div style=\"page-break-after: always\"></div>

| Table 11.                                                                                                                               | Summary of Efficacy for ZUMA-5                                                                                                                                                                                                                                                                                                                                                                                                                    | Summary of Efficacy for ZUMA-5                                                                                                                                                                                                                                                                                                                                                                                                                    |
|-----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) | Title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)                                                                                                                                                                                                                                                                                                           | Title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)                                                                                                                                                                                                                                                                                                           |
| Study identifier                                                                                                                        | KTE-C19-105                                                                                                                                                                                                                                                                                                                                                                                                                                       | KTE-C19-105                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Design                                                                                                                                  | Phase II, multicenter, open-label, study in adults with r/r B-cell iNHL of FL or MZL                                                                                                                                                                                                                                                                                                                                                              | Phase II, multicenter, open-label, study in adults with r/r B-cell iNHL of FL or MZL                                                                                                                                                                                                                                                                                                                                                              |
| Design                                                                                                                                  | Duration:                                                                                                                                                                                                                                                                                                                                                                                                                                         | After completing anti-CD19 CAR T-cell infusion, all subjects will be followed in the post-treatment assessment period counting from Day 0 to Month 3 visit                                                                                                                                                                                                                                                                                        |
| Design                                                                                                                                  | Duration of Run-in phase:                                                                                                                                                                                                                                                                                                                                                                                                                         | Not applicable                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Design                                                                                                                                  | Duration of Extension phase:                                                                                                                                                                                                                                                                                                                                                                                                                      | After Month 3 visit, all treated subjects will be followed in a long-term follow-up period for survival and disease status. The duration of the study is planned to be up to 15 years.                                                                                                                                                                                                                                                            |
| Hypothesis                                                                                                                              | The hypothesis is that the ORR of subjects with FL or subjects with FL and 3 or more prior lines of therapy, determined by central assessment, to axicabtagene ciloleucel was significantly higher than the pre-specified historical ORR of 40% and the CR rate of subjects with FL or subjects with FL and 3 or more prior lines of therapy, determined by central assessment, to axicabtagene ciloleucel was significantly higher than the pre- | The hypothesis is that the ORR of subjects with FL or subjects with FL and 3 or more prior lines of therapy, determined by central assessment, to axicabtagene ciloleucel was significantly higher than the pre-specified historical ORR of 40% and the CR rate of subjects with FL or subjects with FL and 3 or more prior lines of therapy, determined by central assessment, to axicabtagene ciloleucel was significantly higher than the pre- |
| Treatments groups (per DCO 31 March 2021 = 24 months analysis)                                                                          | FL in the FAS                                                                                                                                                                                                                                                                                                                                                                                                                                     | Subjects with FL (based on ZUMA-5 24-month Follow-up CSR Addendum): Number enrolled (ie, underwent leukapheresis): n = 127 Number treated: n = 124 Median actual follow-up a : 26.55 months (range: 0.3 to 44.3 months) Median potential follow-up b : 28.80 months (range: 18.2 to 44.3 months)                                                                                                                                                  |
| Treatments groups (per DCO 31 March 2021 = 24 months analysis)                                                                          | FL in the FAS                                                                                                                                                                                                                                                                                                                                                                                                                                     | Subjects with FL and 3 or more prior lines of therapy (based on ZUMA-5 24-month Follow-up CSR Addendum): Number enrolled (ie, underwent leukapheresis): n = 80 Number treated: n = 78 Median actual follow-up a : 26.55 months (range: 0.3 to 44.3 months) Median potential follow-up b : 28.81 months (range: 19.9 to 44.3 months)                                                                                                               |
| Treatments groups (per DCO 31 March 2021 = 24 months analysis)                                                                          | FL in the FAS                                                                                                                                                                                                                                                                                                                                                                                                                                     | Subjects with FL excluding centrally confirmed non-FL (based on Kite's newly proposed analysis set): Number enrolled (ie, underwent leukapheresis): n = 122 Number treated: n = 119 Median actual follow-up a : 25.86 months (range: 0.3 to 44.3 months) Median potential follow-up b : 28.52 months (range: 18.2 to 44.3 months)                                                                                                                 |
| Treatments groups (per DCO 31 March 2021 = 24 months analysis)                                                                          | FL in the FAS                                                                                                                                                                                                                                                                                                                                                                                                                                     | Subjects with FL and 3 or more prior lines of excluding centrally confirmed non-FL (based on Kite's newly proposed analysis set): Number enrolled (ie, underwent leukapheresis): n = 75 Number treated: n = 73 Median actual follow-up a : 26.55 months (range: 0.3 to 44.3 months) Median potential follow-up b : 28.06 months (range: 19.9 to 44.3 months)                                                                                      |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions   | Primary endpoint                                                                                                                 | ORR in subjects with FL                                                                                                          | ORR was defined as the incidence of CR or PR using central assessment per the Lugano Classification {Cheson 2014}                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------------------------|----------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions   | Secondary endpoints                                                                                                              | ORR in subjects with FL and 3 or more prior lines of therapy                                                                     | ORR in subjects with 3 or more prior lines of therapy is defined as the incidence of a CR or a PR by the Lugano Classification {Cheson 2014} as determined by central assessment for those subjects who had 3 or more lines of prior therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Endpoints and definitions   | Secondary endpoints                                                                                                              | CR rate in subjects with FL and 3 or more prior lines of therapy                                                                 | CR rate in subjects with 3 or more prior lines of therapy is defined as the incidence of CR as best response to treatment by the Lugano Classification {Cheson 2014} as determined by central assessment for those subjects who had 3 or more lines of prior therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Endpoints and definitions   | Secondary endpoints                                                                                                              | DOR                                                                                                                              | DOR was defined as the time from first objective response (CR or PR) to disease progression or death. Subjects not meeting the criteria by the analysis data cutoff date were censored at their last evaluable disease assessment date prior to the data cutoff date or new anticancer therapy start date (including SCT or retreatment of axicabtagene ciloleucel), whichever was earlier                                                                                                                                                                                                                                                                                                                        |
| Endpoints and definitions   | Secondary endpoints                                                                                                              | PFS                                                                                                                              | PFS was defined as the time from the axicabtagene ciloleucel infusion date (analyses based on the IAS and the safety analysis set) or the enrollment/leukapheresis date (analysis based on the FAS) to the date of disease progression per {Cheson 2014} or death due to any cause. The main analysis of PFS was based on progression defined per central assessment. PFS for subjects who received any subsequent anticancer therapy (including SCT or retreatment with axicabtagene ciloleucel) in the absence of prior documented progression was censored at the date of the last evaluable disease assessment prior to subsequent anti-cancer therapy or the last evaluable disease assessment prior to SCT. |
| Endpoints and definitions   | Secondary endpoints                                                                                                              | OS                                                                                                                               | OS was defined as the time from the axicabtagene ciloleucel infusion for the analyses based on the IAS and the safety analysis set or the enrollment/leukapheresis date for the analysis based on the FAS to the date of death due to any cause.                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Endpoints and definitions   | Secondary endpoints                                                                                                              | TTNT c                                                                                                                           | TTNT is defined as the time from the leukapheresis date (for FAS) or the axicabtagene ciloleucel infusion date (for IAS and safety analysis set) to the start of subsequent anticancer therapy or death from any cause. Subjects who had not received subsequent anticancer therapy, or were still alive by the data cutoff date, or had died after the data cutoff date were to be censored at their last new therapy status date prior to the data cutoff date. Subjects who were alive after the data cutoff date were to be censored at the data cutoff date.                                                                                                                                                 |
| Database lock               | For the primary analysis: 12 March 2020 For the                                                                                  | 18-month follow-up:                                                                                                              | 14 September 2020                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Results and Analysis        | Results and Analysis                                                                                                             | Results and Analysis                                                                                                             | Results and Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Analysis description        | Primary Analysis                                                                                                                 | Primary Analysis                                                                                                                 | Primary Analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Analysis population         | FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non-FL | FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non-FL | FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non-FL                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| and time point description                      |                                                                             |                    |                                                 |                                                                                              |                                                                                              |                                                                                              |
|-------------------------------------------------|-----------------------------------------------------------------------------|--------------------|-------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Descriptive statistics and estimate variability | Treatment group                                                             | FL in FAS          | FL with 3 or more prior lines of therapy in FAS | FL with 3 or more prior lines of therapy in FAS                                              | FL in IAS                                                                                    | FL with 3 or more prior lines of therapy in IAS                                              |
| Descriptive statistics and estimate variability | Number of subjects (N)                                                      | 122                | 75                                              | 75                                                                                           | 79                                                                                           | 53                                                                                           |
| Descriptive statistics and estimate variability | ORR (CR+PR) n (%), [95% CI per the Clopper- Pearson Method]                 | 111 (91), [84, 95] | 68 (91), [82, 96]                               | 68 (91), [82, 96]                                                                            | 74 (94), [86, 98]                                                                            | 50 (94), [84, 99]                                                                            |
| Descriptive statistics and estimate variability | CR n (%), [95% CI per the Clopper- Pearson Method]                          | 92 (75), [67, 83]  | 58 (77), [66, 86]                               | 58 (77), [66, 86]                                                                            | 62 (78), [68, 87]                                                                            | 42 (79), [66, 89]                                                                            |
| Descriptive statistics and estimate variability | DOR median in months, [95% CI]                                              | NE [NE, NE]        | NE [20.8, NE]                                   | NE [20.8, NE]                                                                                | NE [20.8, NE]                                                                                | NE [20.8, NE]                                                                                |
| Descriptive statistics and estimate variability | PFS median in months, [95% CI]                                              | NE [NE, NE]        | NE [24.2, NE]                                   | NE [24.2, NE]                                                                                | NE [23.5, NE]                                                                                | NE [23.5, NE]                                                                                |
| Descriptive statistics and estimate variability | OS median in months, [95% CI]                                               | NE [NE, NE]        | NE [NE, NE]                                     | NE [NE, NE]                                                                                  | NE [23.5, NE]                                                                                | NE [23.5, NE]                                                                                |
| Effect estimate per comparison                  | ORR in subjects with FL in the IAS                                          | Comparison         | Comparison                                      | ORR in subjects with FL versus 40% historic ORR                                              | ORR in subjects with FL versus 40% historic ORR                                              | ORR in subjects with FL versus 40% historic ORR                                              |
| Effect estimate per comparison                  | ORR in subjects with FL in the IAS                                          | P-value            | P-value                                         | < 0.0001                                                                                     | < 0.0001                                                                                     | < 0.0001                                                                                     |
| Effect estimate per comparison                  | ORR in subjects with FL and 3 or more prior lines of therapy in the IAS     | Comparison groups  | Comparison groups                               | ORR in subjects with FL and 3 or more prior lines of therapy versus 40% historic ORR         | ORR in subjects with FL and 3 or more prior lines of therapy versus 40% historic ORR         | ORR in subjects with FL and 3 or more prior lines of therapy versus 40% historic ORR         |
| Effect estimate per comparison                  | ORR in subjects with FL and 3 or more prior lines of therapy in the IAS     | P-value            | P-value                                         | < 0.0001                                                                                     | < 0.0001                                                                                     | < 0.0001                                                                                     |
| Effect estimate per comparison                  | CR rate in subjects with FL in the IAS                                      | Comparison groups  | Comparison groups                               | CR in subjects with FL versus 15% historic CR rate                                           | CR in subjects with FL versus 15% historic CR rate                                           | CR in subjects with FL versus 15% historic CR rate                                           |
| Effect estimate per comparison                  | CR rate in subjects with FL in the IAS                                      | P-value            | P-value                                         | < 0.0001                                                                                     | < 0.0001                                                                                     | < 0.0001                                                                                     |
| Effect estimate per comparison                  | CR rate in subjects with FL and 3 or more prior lines of therapy in the IAS | Comparison groups  | Comparison groups                               | CR rate in subjects with FL and 3 or more prior lines of therapy versus 15% historic CR rate | CR rate in subjects with FL and 3 or more prior lines of therapy versus 15% historic CR rate | CR rate in subjects with FL and 3 or more prior lines of therapy versus 15% historic CR rate |
| Effect estimate per comparison                  | CR rate in subjects with FL and 3 or more prior lines of therapy in the IAS | P-value            | P-value                                         | < 0.0001                                                                                     | < 0.0001                                                                                     | < 0.0001                                                                                     |

<div style=\"page-break-after: always\"></div>

| Notes                                                       | Results presented above are from analyses in the FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non- FL using the central assessment of disease based on the Lugano Classification {Cheson 2014}.   | Results presented above are from analyses in the FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non- FL using the central assessment of disease based on the Lugano Classification {Cheson 2014}.   | Results presented above are from analyses in the FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non- FL using the central assessment of disease based on the Lugano Classification {Cheson 2014}.   | Results presented above are from analyses in the FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non- FL using the central assessment of disease based on the Lugano Classification {Cheson 2014}.   | Results presented above are from analyses in the FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non- FL using the central assessment of disease based on the Lugano Classification {Cheson 2014}.   |
|-------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Analysis description                                        | 24-month Follow-up Analysis                                                                                                                                                                                                                                                    | 24-month Follow-up Analysis                                                                                                                                                                                                                                                    | 24-month Follow-up Analysis                                                                                                                                                                                                                                                    | 24-month Follow-up Analysis                                                                                                                                                                                                                                                    | 24-month Follow-up Analysis                                                                                                                                                                                                                                                    |
| Analysis population and time point                          | FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non-FL                                                                                                                                               | FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non-FL                                                                                                                                               | FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non-FL                                                                                                                                               | FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non-FL                                                                                                                                               | FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non-FL                                                                                                                                               |
| description Descriptive statistics and estimate variability | Treatment group                                                                                                                                                                                                                                                                | FL in FAS                                                                                                                                                                                                                                                                      | FL with 3 or more prior lines of therapy in FAS                                                                                                                                                                                                                                | FL in IAS                                                                                                                                                                                                                                                                      | FL with 3 or more prior lines of therapy in IAS                                                                                                                                                                                                                                |
| description Descriptive statistics and estimate variability | Number of subjects (N)                                                                                                                                                                                                                                                         | 122                                                                                                                                                                                                                                                                            | 75                                                                                                                                                                                                                                                                             | 81                                                                                                                                                                                                                                                                             | 55                                                                                                                                                                                                                                                                             |
| description Descriptive statistics and estimate variability | ORR (CR+PR) n (%), [95% CI per the Clopper- Pearson Method]                                                                                                                                                                                                                    | 112 (92), [85, 96]                                                                                                                                                                                                                                                             | 68 (91), [82, 96]                                                                                                                                                                                                                                                              | 76 (94), [86, 98]                                                                                                                                                                                                                                                              | 52 (95), [85, 99]                                                                                                                                                                                                                                                              |
| description Descriptive statistics and estimate variability | CR n (%), [95% CI per the Clopper- Pearson Method]                                                                                                                                                                                                                             | 94 (77), [69, 84]                                                                                                                                                                                                                                                              | 58 (77), [66, 86]                                                                                                                                                                                                                                                              | 63 (78), [67, 86]                                                                                                                                                                                                                                                              | 43 (78), [65, 88]                                                                                                                                                                                                                                                              |
| description Descriptive statistics and estimate variability | DOR median in months, [95% CI]                                                                                                                                                                                                                                                 | 38.6 [NE, NE]                                                                                                                                                                                                                                                                  | 38.6 [24.7, NE]                                                                                                                                                                                                                                                                | 38.6 [24.7, NE]                                                                                                                                                                                                                                                                | 38.6 [22.7, NE]                                                                                                                                                                                                                                                                |
| description Descriptive statistics and estimate variability | PFS median in months, [95% CI]                                                                                                                                                                                                                                                 | 40.2 [28.9, NE]                                                                                                                                                                                                                                                                | 40.2 [26.6, NE]                                                                                                                                                                                                                                                                | 39.6 [25.7, NE]                                                                                                                                                                                                                                                                | 28.0 [23.5, NE]                                                                                                                                                                                                                                                                |
| description Descriptive statistics and estimate variability | OS median in months, [95% CI]                                                                                                                                                                                                                                                  | NE [40.2, NE]                                                                                                                                                                                                                                                                  | NE [40.2, NE]                                                                                                                                                                                                                                                                  | NE [39.6, NE]                                                                                                                                                                                                                                                                  | NE [39.6, NE]                                                                                                                                                                                                                                                                  |
| description Descriptive statistics and estimate variability | TTNT c median in months, [95% CI]                                                                                                                                                                                                                                              | 40.2 [40.2, NE]                                                                                                                                                                                                                                                                | 40.2 [26.6, NE]                                                                                                                                                                                                                                                                | 39.6 [28.0, NE]                                                                                                                                                                                                                                                                | 39.6 [22.8, NE]                                                                                                                                                                                                                                                                |
| Notes                                                       | Results presented above are from analyses in the FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non- FL using the central assessment of disease based on the Lugano Classification {Cheson          | Results presented above are from analyses in the FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non- FL using the central assessment of disease based on the Lugano Classification {Cheson          | Results presented above are from analyses in the FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non- FL using the central assessment of disease based on the Lugano Classification {Cheson          | Results presented above are from analyses in the FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non- FL using the central assessment of disease based on the Lugano Classification {Cheson          | Results presented above are from analyses in the FAS and IAS in subjects with FL or in subjects with FL and 3 or more prior lines of therapy excluding centrally confirmed non- FL using the central assessment of disease based on the Lugano Classification {Cheson          |

- a Actual follow-up time was calculated as (death date or last date known live - the axicabtagene ciloleucel infusion date + 1)/30.4375.
- b Potential follow-up time was calculated as (the data cutoff date - the axicabtagene ciloleucel infusion date +

<div style=\"page-break-after: always\"></div>

## 1)/30.4375.

- c TTNT was added after the primary analysis.

## Supportive study

As supportive study (external control) served the SCHOLAR-5 trial.

## Title

A comparison of clinical outcomes from ZUMA-5 and the internal SCHOLAR-5 external control cohort in r/r FL (grades 1-3A).

## Trial design

A multicenter, international observational retrospective study based on EMR and clinical trial data.

## Objectives

- To describe clinical and demographic characteristics and treatment patterns in patients with r/r iNHL in the real-world setting, who would be eligible for CAR-T.
- To estimate overall response rate (ORR) among patients with r/r iNHL in the real-world setting. complete response (CR), Partial Response (PR), Overall survival (OS), duration of response (DoR), progression-free survival (PFS) and time to next treatment (TTNT) will be secondary endpoints.
- To compare selected outcomes from the external comparator cohort to those from the Zuma- 5 clinical trial.
- To describe patient's quality of life based on available patient reported outcomes (PROs) as an exploratory objective.

## Main inclusion criteria

- Patients aged ≥18 years
- Patients with histologically confirmed diagnosis of iNHL, with histological subtype limited to FL Grade 1, Grade 2, or Grade 3a or MZL nodal / extranodal based on criteria established by the World Health Organization (WHO) 2016 classification (restricted to patients with FL in the analysis stage)
- Patients with r/r disease (i.e., r/r iNHL) starting third or higher line of therapy on or after 23rd July 2014 (exact date differed according to individual cohort component protocols)

## Main Exclusion criteria

- Transformed FL
- FL Histological Grade 3b
- Prior anti-CD19 CAR T-cell therapy or other genetically modified T-cell therapy
- Eligible within 12 months before of the end of the study database cut-off

## Trial conduct

- In total, 82 patients were included in the overall SCHOLAR-5 cohort, which comprised the following subcohorts:
- Subcohort A (IQVIA): 56 patients and 78 eligible lines of therapy

<div style=\"page-break-after: always\"></div>

- Subcohort B (Vanderbilt): 2 patients and 4 eligible lines of therapy
- Subcohort C (DELTA): 24 patients and 24 eligible lines of therapy
- From the 86 patients ZUMA-5 followup 1 IAS cohort, the 60 patients who had received ≥3 prior lines of therapy were the focus of this report.

## Results

Comparative analyses are provided in the following tables:

Table 12: Number of patients available for analysis from each study

|                                            | SCHOLAR-5        | SCHOLAR-5        | SCHOLAR-5        | SCHOLAR-5        |                  |
|--------------------------------------------|------------------|------------------|------------------|------------------|------------------|
| Analysis                                   | IQVIA            | Vanderbilt       | DELTA            | Total SCHOLAR-5  | ZUMA-5           |
| ≥3 prior                                   | lines of therapy | lines of therapy | lines of therapy | lines of therapy | lines of therapy |
| Primary comparative analysis               | 56               | 2                | 24               | 82               | 60               |
| Excluding patients from DELTA              | 56               | 2                | 0                | 58               | 60               |
| Modified effectiveness analysis set (mEAS) | 42               | 2                | 23               | 67               | 60               |
| Analysis without multiple imputation       | 55               | 2                | 24               | 81               | 60               |
| ZUMA-5 Safety analysis set                 | 56               | 2                | 24               | 82               | 78               |
| Patients with positive POD24 status        | 17               | 0                | 0                | 17               | 34               |
| Patients refractory at index date          | 43               | 2                | 24               | 69               | 48               |
| Patients with prior SCT                    | 15               | 0                | 4                | 19               | 16               |

Note: In the primary comparative analysis, the ZUMA-5 is from the Inferential Analysis set, whereas the Safety Analysis Set is used to obtained data when not restricted to 18 months of follow-up. POD24: progressed disease within 24 months after initiation of first line anti-CD20 chemo combination therapy.

Table 13 : Propensity score variables, prior to weighting (≥3 prior lines of therapy)

|                        |         | SCHOLAR-5   | ZUMA-5     | p-value   | SMD   |
|------------------------|---------|-------------|------------|-----------|-------|
| Number of patients     |         | 82          | 60         |           |       |
| POD24                  | Yes     | 29 (35.4%)  | 34 (56.7%) | 0.014     | 0.437 |
|                        | No      | 53 (64.6%)  | 26 (43.3%) |           |       |
|                        | Missing | 0 (0%)      | 0 (0%)     |           |       |
| Prior lines of therapy | Mean    | 3.72        | 4.30       | 0.009     | 0.446 |
|                        | SD      | 1.20        | 1.39       |           |       |
|                        | Median  | 3.00        | 4.00       |           |       |
|                        | Q1      | 3.00        | 3.00       |           |       |
|                        | Q3      | 4.00        | 5.00       |           |       |
|                        | Min     | 3.00        | 3.00       |           |       |

<div style=\"page-break-after: always\"></div>

|                                                       | Max        | 8.00       | 9.00       |       |       |
|-------------------------------------------------------|------------|------------|------------|-------|-------|
|                                                       | N          | 82         | 60         |       |       |
|                                                       | Missing    | 0          | 0          |       |       |
| Relapsed/refractory to prior line of therapy          | Relapsed   | 16 (19.5%) | 12 (20.0%) | 0.943 | 0.012 |
|                                                       | Refractory | 66 (80.5%) | 48 (80.0%) |       |       |
|                                                       | Missing    | 0 (0%)     | 0 (0%)     |       |       |
| Prior SCT                                             | Yes        | 21 (25.6%) | 16 (26.7%) | 0.888 | 0.024 |
|                                                       | No         | 61 (74.4%) | 44 (73.3%) |       |       |
|                                                       | Missing    | 0 (0%)     | 0 (0%)     |       |       |
| Tumor bulk 7cm or greater                             | Yes        | 16 (19.4%) | 14 (23.3%) | 0.589 | 0.097 |
|                                                       | No         | 66 (80.6%) | 46 (76.7%) |       |       |
|                                                       | Missing    | 0 (0%)     | 0 (0%)     |       |       |
| Time since last treatment (months)                    | Mean       | 11.94      | 7.54       | 0.222 | 0.220 |
|                                                       | SD         | 26.12      | 10.90      |       |       |
|                                                       | Median     | 2.02       | 2.94       |       |       |
|                                                       | Q1         | 0.75       | 1.63       |       |       |
|                                                       | Q3         | 10.63      | 6.53       |       |       |
|                                                       | Min        | 0          | 0          |       |       |
|                                                       | Max        | 172.93     | 51.06      |       |       |
|                                                       | N          | 82         | 60         |       |       |
|                                                       | Missing    | 0          | 0          |       |       |
| Complete or partial response to prior line of therapy | Yes        | 44 (53.7%) | 24 (40.2%) | 0.130 | 0.273 |
|                                                       | No         | 38 (46.3%) | 36 (59.8%) |       |       |
|                                                       | Missing    | 0 (0%)     | 0 (0%)     |       |       |
| Age 65+                                               | Yes        | 42 (51.2%) | 21 (35.0%) | 0.058 | 0.332 |
|                                                       | No         | 40 (48.8%) | 39 (65.0%) |       |       |
|                                                       | Missing    | 0 (0%)     | 0 (0%)     |       |       |
| Prior anti-CD20 + alkylator combination treatment     | Yes        | 74 (90.2%) | 60 (100%)  | 0.673 | 0.465 |
|                                                       | No         | 8 (9.8%)   | 0 (0%)     |       |       |
|                                                       | Missing    | 0 (0%)     | 0 (0%)     |       |       |

The response rates (ORR and CR) in ZUMA-5 after propensity score weighing were higher than in SCHOLAR5, which can be seen in Table 15.

Table 14: Response rates for ZUMA-5 versus SCHOLAR5 after propensity score weighting (≥3 prior lines of therapy, primary comparative analysis)

|                    |     | SCHOLAR-5 (n=59)   | ZUMA-5 (n=60)   | Odds Ratio (95% CI)   | p-value   |
|--------------------|-----|--------------------|-----------------|-----------------------|-----------|
| Objective response | Yes | 24 (40.3%)         | 57 (95.0%)      | 28.13 (7.37, 107.30)  | <0.001    |
|                    | No  | 35 (59.7%)         | 3 (5.0%)        |                       |           |
| Complete response  | Yes | 12 (20.6%)         | 48 (80.0%)      | 15.42 (5.83, 40.84)   | <0.001    |
|                    | No  | 47 (79.4%)         | 12 (20.0%)      |                       |           |
| Partial response   | Yes | 12 (19.7%)         | 9 (15.0%)       | 0.72 (0.26, 2.00)     | 0.525     |
|                    | No  | 48 (80.3%)         | 51 (85.0%)      |                       |           |
| Stable disease     | Yes | 7 (11.6%)          | 1 (1.7%)        | 0.13 (0.01, 1.24)     | 0.076     |
|                    | No  | 52 (88.4%)         | 59 (98.3%)      |                       |           |

<div style=\"page-break-after: always\"></div>

## 2.5.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

Initially, the ZUMA-5 trial was designed as a single-arm open-label phase 2 multicenter trial in subjects with r/r iNHL, and initially patients with biopsy proven progression of r/r follicular lymphoma Grade 1, Grade 2 or Grade 3a have been enrolled. Between the original trial protocol, dated 26 November 2016 and the current  valid  version  of  amendment  5,  dated  24  July  2019,  a  couple  of  important  changes  have  been introduced,  including  the addition  of  patients  with  r/r  marginal  zone  lymphoma.  According  to  the  final protocol, the two cohorts (FL and MZL) were analysed together with very different follow up criteria. The minimum follow-up for MZL patients for the primary analysis was 4 weeks, while the minimum follow-up for FL patients was 12 months. As the sought indication is only for FL pooling of MZL and FL patients is not considered sensible.

The trial was a single-arm open-label trial, and therefore sensitive to selection bias and assessment bias. A DSMB was tasked with the interim review of data. The Applicant further planned to protect the conduct of study via limited access of company members to the data of the ongoing trial which was defined in a 'Trial Integrity Document'. However, the document showed that many subjects had broad access to raw and aggregated data at all times. No firewall was in place. Functions such as biostatisticians were granted full  access to the data at any time and were involved in drafting protocol amendments which included substantial changes to the confirmatory analyses (including changes in endpoints, analysis populations, number and timing of interim analyses and type 1 error control over interim analyses). Interim analyses 4 and 5 were furthermore defined only after the successful interim analysis 3 was conducted. This shows that the  conduct  of  trial  was  not  to  the  usual  standards  for  a  well  conducted  confirmatory  trial,  but  is  not expected to have a major negative impact on general data integrity.

The high number of relevant changes and adaptations of the study protocol (6 protocol amendments) and the SAP during the conduct of the trial is noticeable, and may result from the clinical trial initially not having been planned as a pivotal and/or supportive clinical trial for the indication extension on r/r FL. However, no major impact on the data is estimated. The change to add prior therapy with an anti-CD20 monoclonal antibody combined with an alkylating agent as inclusion criterion, e.g., was required in order to ensure that subjects have received standard first line therapy prior to enrollment.

As requested, the Applicant provided data on clinical efficacy of axicabtagene ciloleucel in the indication of r/r FL after 3 or more prior lines of therapy, excluding subjects with centrally confirmed non-FL and for a recent  data  cutoff  date  (24-month  follow-up  analysis  data  cutoff  date:  31 March 2021).  The  originally reported results for ORR, CR and duration of response in subjects treated with axicabtagene ciloleucel after 3L+ therapy remain compelling, although uncertainties related to a single arm trial may be raised. Most of the included patients had not received prior HDT and autologous ASCT. Due to the safety and the logistic issues of CAR-T therapy, this treatment should be reserved to FL grade 1-3a patients following at least 34 prior therapies, including HDT. Patients with FL Grade 3B have been excluded from the pivotal trial, while the  proposed  target  indication  in  r/r  FL  actually  includes  all  grade  FL,  including  FL  Grade  3B.  The extrapolation to patients with FL Grade 3B is considered permissible, as in clinical practice FL Grade 3B is often treated as DLBCL, for which axi-cel is also indicated.

A relatively large proportion of subjects (n=23; 19%) reported an important protocol deviation (IPD), from which  only  a  minority  [n  =  3;2  %)]  could  be  explained  as  related  to  the  outbreak  of  the  COVID-19 pandemic.  Most  of  the  IPDs  related  to  missing  data  were  missed  FU-antibody  samples,  missed  two

<div style=\"page-break-after: always\"></div>

consecutive  exams  and  missed  post  treatment  PET-CT  and/or  diagnostic  CTs.  Moreover,  there  were important  differences  in  number  and  nature  of  protocol  deviations  between  study  sites,  requiring  the Applicant's remote observation of one site, were n=111 PDs occurred in 7 subjects included. However, no major risks were identified and it was concluded that these IPD may not had a negative impact on general data integrity.

Bridging therapy between leukapheresis and LDC based on investigator decision was not excluded according to the ZUMA-5 clinical trial protocol and 4 subjects with FL excluding centrally confirmed non-FL received bridging therapy. For subjects who received bridging chemotherapy, PET-CT scan was to be performed to establish a new baseline before the start of the lymphodepleting chemotherapy, which ensured that bridging chemotherapy did not impact the analysis of the disease response.

## Efficacy data and additional analyses (based on 24-month DCO)

## ZUMA-5

The full analysis set (FAS) of subjects with FL excluding subjects with centrally confirmed non-FL and who received ≥ 3 lines of prior therapy, which is the claimed target indication of this MAA, comprised 75 subjects. The majority of subjects presented with disease stage Grade III (n=34; 45%) and Grade IV (n=31; 41%), and with intermediate (FLIPI total score of 2) (n=30; 40%) and high risk (FLIPI total score of 3-5) (n=34; 45%) disease.  The  retrospective  CD19  status  for  n=69/75  evaluable  subjects  per  central  assessment revealed  that  56  subjects  of  these  69  (90.3%)  were  confirmed  CD19  positive,  6 subjects  were  CD19 negative, and 7 subjects' CD19 antigen status were missing/inconclusive at baseline. The median number of prior therapy lines was 4 (range: 3 to 10), and 45 subjects (60%) had received 4 or more lines of therapy.  Twenty  two  subjects  (29%)  had  previously  received  auto-SCT  and  30  subjects  (40%)  had previously been treated with a PI3K inhibitor. With 91% of subjects with at least 1 high-risk prognostic factor (progression within 24 months from the first anti-CD20-chemotherapy combination therapy, within 6 months after the last line of prior therapy, or after auto-SCT), overall this population can been considered at high risk with a medical need for alternative treatment options.

Response rates at 24 months follow-up in the FAS for subjects with FL who received ≥ 3 lines of prior therapy, excluding subjects with centrally confirmed non-FL (n = 75): the primary and secondary endpoints ORR and CR were 91% (68 of 75 subjects, 95% CI: 82%, 96%) and 77% (58 of 75 subjects, 95% CI: 66%, 86%).

With regard to DOR the KM-median was 38.6 months (95% CI: 24.7, NE) in the FAS for subjects with FL who received ≥ 3 lines of prior therapy, excluding subjects with centrally confirmed non-FL. The subjects with FL had a median follow-up time for DOR of 22.6 months (95% CI: 18.8, 23.0 months). Among the 75 subjects with FL who received ≥ 3 lines of prior therapy , KM estimates of PFS rates at 24 months was 71.8% (95% CI: 58.6%, 81.4%). The KM median for PFS was 40.2 months (95% CI: 26.6, NE). The KM median for OS was not reached (95% CI: 40.2 months, NE), with a median follow-up time of 29.7 months (95% CI: 26.9, 31.87 months). Estimates of OS at 24 months was 85.5% (95% CI: 74.6, 91.9%).

With regard to analyses for DOR and PFS, patients who received other anticancer therapies (including HSCT and axi-cel retreatment) were censored. As this kind of analysis might be prone to informative censoring, upon request, sensitivity analyses for DOR and PFS in the FL FAS excluding centrally confirmed non-FL who received  ≥  3  prior  lines  of  therapy ,  considering  the  start  of  other  new  anticancer  therapies  or  axi-cel retreatment in the absence of prior documented progression as an event (EMA censoring rules), were provided.  Although  a  larger  difference in  median  PFS  has  been  noted  between  primary  and  sensitivity analysis (40.2 months and 28.9 months, respectively), outcomes for DOR were very similar (both median and K-M plots) and K-M curves for PFS also followed a similar pattern. In conclusion, censoring patients

<div style=\"page-break-after: always\"></div>

who started a new anticancer therapies or were retreated with axi-cel retreatment in the absence of prior documented progression as reported by central assessment on DOR and PFS outcomes, is not considered impactful for the interpretation of data. Median follow-up time for TTNT was 29.3 months (95% CI: 25.7, 33.6 months). The KM median TTNT was 40.2 months (95% CI: 26.6, NE). The longest TTNT was 43.3 months as of the data cutoff date. The KM estimates of the proportion of subjects who had not commenced subsequent therapy at Months 24 was 67.0% (95% CI: 54.8%, 76.6%).

Although the number of subjects with CD19 negative status at baseline is small, and thus results should be interpreted with caution, efficacy outcomes (CR rate, ORR and DOR) and PK in patients with baseline CD19 status seemed to be at least non-inferior compared to the efficacy outcomes and PK in patients with CD19 + status. In addition, although the data on confirmed CD19 antigen status at relapse are few, there is no evidence of CD19 -escape.

Only n=8/75 subjects (11%) in FAS with FL excluding subjects with centrally confirmed non-FL and who received  ≥  3  lines  of  prior  therapy were  non-US  subjects  (in  particular  from  France),  which  might compromise the external validity  of  the  ZUMA-5  study.  A  significant  difference  observed  is  the  higher number of prior auto-SCT (65%/EU versus 25%/US). However, response (CR rate) and safety profile seem consistent between subjects from EU and US.

The results provided for the requested revised analysis sets, and for the 24-month data cut-off date indicate that the ORR and CR rate of subjects with FL who received 3 or more lines of therapy in the FAS and IAS excluding centrally confirmed non-FL were similar (ORR: 91% versus 95% respectively; CR rate: 77% versus 78%, respectively). The KM median estimates of DOR, PFS, OS, and TTNT in the FAS and IAS were similar  (DOR:  38.6 months  in  each  analysis  set;  PFS:  40.2 versus  28.0 months,  respectively;  OS:  not estimable in each analysis set; TTNT: 40.2 versus 39.6 months, respectively).

## SCHOLAR-5

SCHOLAR-5 as a synthetic supportive trial can be acknowledged in general. In a comparative analysis ORR and CR in SCHOLAR-5 was lower than in ZUMA-5. The statistical challenges such as potential bias (due to different sources) which are inherent to single-arm trials with external controls make further conclusions from this data impossible. OS and PFS from single-arm trials should not be compared with external controls due to an unknown magnitude of bias. The data from SCHOLAR-5 overall is considered overall supportive.

## 2.5.3. Conclusions on the clinical efficacy

The data presented on primary and secondary endpoints in subjects with r/r FL, the target indication in the ZUMA-5 trial, indicate a benefit for the patients. The trial was a single-arm open label trial without a good firewall in place to protect decision making to be influenced by the available data. Decisions to include further interim analyses (IA4 and 5) were even made post hoc after the results from interim analysis 3 were known. Given that the first efficacy interim analysis (IA3) was significant and given the very high effects both for ORR as well as CRR at all analyses this is not considered of major relevance for the overall extension of indication procedure. The trial is considered to have met the primary objective at IA3, which is then numerically supported by analyses with more subjects and longer follow up. The conduct of trial was not up to the usual standards, however, this is not expected to have a negative impact on general data integrity.

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical safety

## Introduction

The important identified risks and the potential risks identified for axicabtagene ciloleucel are similar to the AEs identified for this product class. No further risks and AEs could be identified which would be specific for axicabtagene ciloleucel or for the indications to be treated with axicabtagene ciloleucel. The important identified risks are CRS, neurotoxicity, cytopenias, infections, hypogammaglobulinemia.

A new indication is being sought for the treatment of adult patients with r/r FL after three or more lines of systemic therapy with this submission. The evaluation of safety is based on the ZUMA-5 study. The initial analysis cutoff date is March 12, 2020, which represents the 12 months follow-up data. Additional safety data were from the follow-up analysis 1, with a data cutoff date of 14 September 2020, (hereafter referred to as the 18-month analysis) of ZUMA-5. This prespecified analysis was performed when at least 80 subjects with FL had had the opportunity to be followed for 18 months after axicabtagene ciloleucel infusion.

Supporting  safety  data  are  also  presented  from  3  studies  of  axicabtagene  ciloleucel  in  subjects  with aggressive large B-cell lymphomas: KTE-C19-101 (ZUMA-1), KTE-C19-109 (ZUMA-9), and KTE-C19-112 (ZUMA-12). The additional safety data are provided with a data cutoff date of 11 August 2020.

## Patient exposure

Throughout the documents, the Applicant presented data for patients with FL, but also for patients with Marginal Zone Lymphoma (MZL), sometimes combining these patients in an indolent NHL group. For the primary safety evaluation in this AR, the data obtained in FL patients were considered as main data (18month follow-up, data cutoff 14 September 2020), and data from MZL patients were considered supportive.

The safety analysis set is defined as all subjects treated with any dose of axicabtagene ciloleucel.

Table 15. Analysis sets (data cutoff 14 Sept 2020)

|                                                         | Follicular (N=127)   | Marginal Zone Lymphoma (N=25)   | Overall* (N=153)   |
|---------------------------------------------------------|----------------------|---------------------------------|--------------------|
| Full amalysis set, n (%)                                | 127 (100)            | 25 (100)                        | 153 (100)          |
| Subjects with 3 or more lines of prior therapy, n (%6)  | 80 (63)              | 16 (64)                         | 97 (63)            |
| Safety analysis set, n (%6)                             | 124 (98)             | 24 (96)                         | 148 (97)           |
| Subjects with 3 or more lines of prior therapy, n (%6)  | 78 (61)              | 16 (64)                         | 94 (61)            |
| Imferential amalysis set, n (%6)                        | 86 (68)              | 23 (92)                         | 109 (71)           |
| Subjects with 3 or more lines of prior therapy, n (9%6) | 60 (47)              | 16 (64)                         | 76 (50)            |
| Safety retreatment analysis set, n (%6)                 | 11 (9)               | 2 (8)                           | 13 (8)             |

Data cutoff date: 14Sep2020.

Note: There are 181 subjects screened and 153 emrolled.

The full amalysis set consists of all enrolled subjects.

The safety analysis set is defined as all subjects treated with any dose of axicabtagene ciloleucel.

criteria for the pivotal cohort), treated with any dose of axicabtagene ciloleucel, and had opporhmity to be followed for

18monthsfrom theaxicabtagene ciloleucelinfision

The safety retreatment analysis set consists of all subjects who underwent retreatment with axicabtagene ciloleucel.

a. One subject was found to have disease type diffuse lrge B-cell lymphoma affer emrollment, did not receive axicabtagene ciloleucel infusion, and then discontinued the study. This subjectis only included in the Oveall column.

In total, as of the 18-month follow-up (cutoff 14 September 2020), 153 subjects with iNHL were enrolled (ie, underwent leukapheresis): 127 subjects with FL , 25 subjects with MZL, and 1 subject with DLBCL. The  DLBCL  was  discovered  via  a  pretreatment  biopsy  that  was  examined  after  the  subject  enrolled;

<div style=\"page-break-after: always\"></div>

consequently, the subject was deemed ineligible and was withdrawn from the study. A total of 148 subjects ( 124  subjects  with  FL and  24  subjects  with  MZL)  had  received  lymphodepleting  chemotherapy  and axicabtagene  ciloleucel;  5  subjects  had  not  received  lymphodepleting  chemotherapy  or  axicabtagene ciloleucel. One of these 5 subjects was the aforementioned subject with DLBCL who was deemed ineligible; the reasons for not receiving lymphodepleting chemotherapy or axicabtagene ciloleucel for the other 4 subjects were as follows:

- One subject with FL died due to cardiac arrest before having the opportunity to be treated on study.
- One subject with FL was found to be ineligible after enrollment but prior to treatment due to inadequate platelet levels (&lt; 75,000 per mm3); this subject was treated under a compassionate use protocol and was not included in the safety analysis set.
-  One  subject  with  FL  was  leukapheresed,  but  experienced  a  CR  prior  to  lymphodepleting chemotherapy and had partially withdrawn at the time of data cutoff; the subject remains in followup.
-  One  subject  with  MZL  was  leukapheresed,  but  experienced  a  CR  prior  to  lymphodepleting chemotherapy and was considered ineligible to receive infusion based on inclusion criteria; the subject remains in follow-up.

Six subjects with FL received bridging therapy between enrollment and lymphodepleting chemotherapy. New baseline scans were obtained after bridging treatment and before lymphodepleting chemotherapy.

Thirteen subjects (11 subjects with FL and 2 subjects with MZL) were retreated with axicabtagene ciloleucel. These subjects are included in the retreatment analysis set. The outcome of retreatment for these subjects is not part of the main inferential analysis and is analysed separately. (For the retreated patients the safety profile was similar to that observed for the main analysis.)

As  of  the  data  cutoff  date,  18  subjects  (14  subjects  with  FL  and  4  subjects  with  MZL)  who  received axicabtagene ciloleucel had died. One additional subject with FL who received axicabtagene ciloleucel was removed from the study due to investigator decision and ultimately died.

For the 124 subjects with FL who received axicabtagene ciloleucel, the median actual study follow-up time was 20.34 months (range: 0.3 to 37.7 months); 91 of 127 subjects (73%) had a potential study follow-up time of at least 18 months.

Table 16: Demographics (Safety Analysis Set)

|                 | Follicular Lymphoma (N=124)   |
|-----------------|-------------------------------|
| Age (years)     |                               |
| N               | 124                           |
| Mean (STDEV)    | 59.0 (9.9)                    |
| Median (Q1, Q3) | 60.0 (53.0, 67.0)             |
| Min, Max        | 34, 79                        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

Table 17: Baseline Characteristics (Safety analysis set)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Involvement of ≥ 3 nodal sites, each with a diameter of≥3 cm   | 32 (26)   |
|----------------------------------------------------------------|-----------|
| Anynodalorextranodal tumormass withadiameterof7cm              | 22 (18)   |
| Presence of B symptoms                                         | 8(0)      |
| Splenomegaly                                                   | 22 (18)   |
| Pleuwral effusions or peritoneal ascites                       | 5(4)      |
| Cytopemias                                                     | 15 (12)   |
| Leukemia                                                       | 1 (1)     |
| Prior PI3K inhibitor, n (%6)                                   |           |
|                                                                | 34 (27)   |
| No                                                             | 90 (73)   |
| Prior anti-CD20 single agent, n (%6)                           |           |
|                                                                | 39 (31)   |
| No                                                             | 85 (69)   |
| Prior alkylating single agent, n (%6)                          |           |
| 1                                                              | 16 (13)   |
| No                                                             | 108 (87)  |
| Prior snti-CD20 + allkylating agent, n (%6)                    |           |
|                                                                | 123 (99)  |
| No\"                                                            | 1(1)      |
| Prior lenalidomide, n (%)                                      |           |
|                                                                | 38 (31)   |
| No                                                             | 86 (69)   |
| Bone marrow assessment at baselineh, n (96)                    |           |
| Lymphoma present                                               | 33 (27)   |
| Lymphoma present but not FL MZL8                               | 1 (1)     |
| Lymphoma not present                                           | 89 (72)   |
| Unknown                                                        | 1(1)      |

## Data cutoff date: 14Sep2020.

- reffactory. Subjects with iNHL who progressed &gt; 6 mouths from conpletion of the most recent prior treatment are defined as relapsed. Subjects with iNHL who progressed within 6 months of completion each of the first 2 lines of prior treatment are defined as double reffactory.
- b.
- C. Subjects were emrolled before the implementation of Protocol Amendment 2, which required subjects to have had at least 2 prior lines of therapy.
- e. Disease buuden, as defined by any of GELF criteria (subjects who meet the criteria for high tumor bullk versus subjects who cytopenias,or leukemia.
- d Time to relapse is defined as the time from initiation of the first line anti-CD20-chemotherapy combination therapy to progression The nummber of subjects with time to relapse is based on those who had progressed with date of progression. Percentages are based on the mumber of subjects who ever received anti-CD20-chemotherapy combination therapy.
- f Prior anti-CD20 single agent includes ritximab, ofatumumab, or obinuhzumab.
- h. Bone marrow assessment at baseline for lymphoma presence is based on investigator reported Lugano bone marrow assessment/ bone marrow assessment using aspirate or core biopsy at screening. If these are not available, lymphoma presence is based on diaguosis history of bone marow involvement.
- 名 One subject did not have documentation to support that prior lines of therapy were administered for FL. The date of FL at the time any of the therapies were administered, the site was asked to remove all lines of therapy. The absence of docuwmentation to support an FL diaguosis when prior therapies were administered is considered an important protocol deviation. This subject is not included in the inferential amalysis set. One subject with MZL did not receive anti-CD20 therapy cue to the disease being previously documented as CD20 negative. This subjectis included in the inferential analysis set.

<div style=\"page-break-after: always\"></div>

## Exposure to LD

All  subjects  in  the  ZUMA-5  safety  analysis  set  received  the  planned  total  BSA-adjusted  dose  of cyclophosphamide (1500 mg/m 2 ) and fludarabine (90 mg/m 2 ).

## Exposure to Axicabtagene Ciloleucel

Among subjects with FL, the median weight-adjusted dose of axicabtagene ciloleucel was 2.0 x 10 6  antiCD19 CAR T cells/kg (range: 1.3 x 10 6  to 2.1 x 10 6  cells/kg). The median total number of anti-CD19 CAR T cells in the axicabtagene ciloleucel infusion was 170.0 x 10 6  cells (range: 100.0 x 10 6  to 200.0 x 10 6 cells), and the median total number of T cells infused was 283.70 x 10 6  cells (range: 123.5 x 10 6  to 769.2 x 10 6  cells). The majority of subjects (120 subjects, 97%) received within 10% of the planned total dose.

The median duration for hospitalization after the axicabtagene ciloleucel infusion was 13.0 days (range: 8.0 to 40 days) for subjects with FL. The median duration in the intensive care unit was 6 days for subjects with FL (range: 2 to 24 days).

## Adverse events

The overall summary of AEs at the 18 months cutoff is displayed in Table 19.

As of the data cutoff date, 3 subjects with FL (2%) who received axicabtagene ciloleucel had died due to AEs:

- 1 subject died due multiple organ dysfunction syndrome on Day 7 that was secondary to CRS (the death was deemed related to axicabtagene ciloleucel),
- 1 subject died due to cardiopulmonary arrest that followed an aortic dissection on Day 399 (the death was deemed unrelated to axicabtagene ciloleucel),
- 1 subject died due to disease progression on Day 47 that was categorized as an AE (Grade 5 Bcell lymphoma) because it occurred within the 3-month AE reporting window.

Overall, safety results were generally similar in the subset of subjects who had 3 or more lines of prior therapy  (99%  subjects  with  TEAE,  47%  with  SAEs,  79%  with  CRS,  and  55%  with  neurologic  events) compared with those found for the larger safety analysis set in subjects with 2 or more lines of prior therapy.

Table 18: Overall Summary of AEs (data cutoff 14 Sept 2020)

<div style=\"page-break-after: always\"></div>

|                                                 | Follicular Lymphoma (N=124) (%) I   |
|-------------------------------------------------|-------------------------------------|
| Worst Grade 5                                   | 3(2)                                |
| Worst Grade ≥ 3                                 | 44 (35)                             |
| Any axicabtagene ciloleucel-related TEAE        | 118 (95)                            |
| Worst Grade 5                                   | 1(1)                                |
| Worst Grade ≥ 3                                 | 71 (57)                             |
| Any serious axicabtagene ciloleucel-relatedTEAE | 38 (31)                             |
| Worst Grade5                                    | 1(1)                                |
| Worst Grade ≥ 3                                 | 26 (21)                             |
| Any TE neurologic event                         | 70 (56)                             |
| Worst Grade5                                    | (0)                                 |
| Worst Grade≥3                                   | 19 (15)                             |
| Any senious TE neurologic event                 | 19 (15)                             |
| Worst Grade 5                                   | (0)                                 |
| Worst Grade ≥ 3                                 | 14 (11)                             |
| Any TE CRS                                      | 97 (78)                             |
| Worst Grade 5                                   | 1(1)                                |
| Worst Grade ≥ 3                                 | 8(6)                                |
| Any senious TE CRS                              | 15 (12)                             |
| Worst Grade 5                                   | 1(1)                                |
| Worst Grade≥3                                   | 8(6)                                |
| Any TE hypogammaglobulinemia                    | 24 (19)                             |
| Worst Grade 5                                   | (0)                                 |
| Worst Grade ≥ 3                                 | 1(1)                                |
| Any TE cytopenias                               | 91 (73)                             |
| Worst Grade 5                                   | (0)                                 |
| Worst Grade ≥ 3                                 | 86 (69)                             |
| AnyTE infections                                | 64 (52)                             |
| Worst Grade 5                                   | (0)                                 |
| Worst Grade ≥ 3                                 | 19 (15)                             |
| Any TE tumor lysis syndrome                     | (0)                                 |
| Any TEgraft-versus-host-disease                 | (0)                                 |

Data cutoff date: 14Sep2020

Among subjects with FL, the most common AEs by preferred terms were pyrexia (103 subjects, 83%), hypotension (59 subjects, 48%), and headache (55 subjects, 44%). The most common AEs (&gt;60% of subjects) by SOC were general disorders and administration site conditions (113 subjects, 91%), nervous system disorders (90 subjects, 73%), and gastrointestinal disorders (88 subjects, 71%).

Twenty-nine subjects (23%) had worst Grade 3 AEs, 73 subjects (59%) had worst Grade 4 AEs, and 3 subjects (2%) had worst Grade 5 AEs. The most common worst Grade 3 or higher AEs were neutropenia (44 subjects, 35%), and neutrophil count decreased and anemia (29 subjects each, 23%).

## Serious adverse event/deaths/other significant events

## SAEs

Among subjects with FL, 57 subjects (46%) had at least 1 SAE, the most frequently reported of which were pyrexia  (16  subjects,  13%),  encephalopathy  (8  subjects,  6%),  pneumonia  (8  subjects,  6%),  and confusional state (7 subjects, 6%). The most common worst Grade 3 or higher SAEs were encephalopathy (8 subjects, 6%), pneumonia (7 subjects, 6%), and confusional state (4 subjects, 3%).

<div style=\"page-break-after: always\"></div>

## Deaths

Among all subjects who received axicabtagene ciloleucel, 15 FL subjects had died as of the data cutoff date (14 September 2020), including 2 which occurred within 3 months of axicabtagene ciloleucel infusion, and 13 occurred &gt; 3 months after the infusion):

- -Nine subjects from progressive disease (including one subject with ≥ 3 lines of prior therapy who died due to PD on Day 47 that was reported as Grade 5 B-cell lymphoma because it occurred within the AE reporting window)
- -Two subjects from AE (both in subjects with ≥ 3 lines of prior therapy): One subject died on Day 7 due to multiple organ dysfunction syndrome that was secondary to CRS, both of which were attributed to the axicabtagene ciloleucel infusion. One subject died on Day 399 due to cardiopulmonary arrest that followed an aortic dissection; the subject remained in CR at Month 12 (the last visit before her death) per central assessment. The death was deemed unrelated to axicabtagene ciloleucel.
- -One from secondary malignancy: This subject died on Day 337 due to acute myeloid leukemia (not attributable to axicabtagene ciloleucel) after having partially withdrawn consent from the study and having agreed to be followed for survival.
- -One from infection (who died after partial withdrawal of consent) (in subject with ≥ 3 lines of prior therapy): The subject died on Day 715 due to an infection (coccidioidomycosis) that was not attributable to axicabtagene ciloleucel. The subject was in CR at Month 18 (the last visit before his death) per central assessment.
- -Two from unknown causes: One subject died due to unknown reasons on Day 692; this subject had been removed from the study by the investigator. The investigator discovered the death in public records without any details. One additional subject died due to unknown reasons on Day 697.

Table 19: Summary of Deaths, Including Cause of Deaths (Safety Analysis Set, 14 Sep 2020 cutoff)

|                                                                                            | Follicular Lymphoma (N=124) (%) I   |
|--------------------------------------------------------------------------------------------|-------------------------------------|
| Subjects who died                                                                          | 15 (12)                             |
| Deaths that occuured -= 30 days of axicabtagene ciloleucel infusion                        | 1()                                 |
| Deaths that occured →30 days through3 months (92 days) of axicabtagene ciloleucel infusion | 1(1)                                |
| Deaths that occuured > 3 months (92 days) after axicabtagene ciloleucel infusion           | 13 (10)                             |
| Primary cause of death                                                                     | 15 (12)                             |
| AE due to reasons other than PD or subsequent therapy                                      | 2(2)                                |
| Progressive disease!                                                                       | 90                                  |
| Secondary malignancy                                                                       | 1(1)                                |
| Other, infectionb                                                                          | 1(1)                                |
| Other, mkmow                                                                               | 1(1)                                |
| Other, umknown, foumd via public record                                                    | 1()                                 |

Data cutoff date: 14Sep2020.

<div style=\"page-break-after: always\"></div>

## AEs of Special Interest

## Important identified risks

## 1. CRS

CRS was graded as a syndrome according to a modification of the criteria established by Lee and Colleagues. All cases of CRS were considered related to axicabtagene ciloleucel.

Table 20: Subject Incidence of CRS and CRS Symptoms Occurring in ≥ 4% of Subjects Overall (Safety Analysis Set)

| MedDRAPreferredTerm Worst CTCAE Grade   | Follicular Lymphoma (N=124) n (%)   |
|-----------------------------------------|-------------------------------------|
| Subjects with any TE CRS                | 97 (78)                             |
| Grade 5                                 | 1(1)                                |
| Grade ≥3                                | 8(6)                                |
| CRS symptoms bypreferred tenmb          |                                     |
| Pyrexia                                 | 94 (97)                             |
| Grade5                                  | (0)                                 |
| Grade ≥3                                | 6(0                                 |
| Hypotension                             | 39 (40)                             |
| Grade 5                                 | (0)                                 |
| Grade ≥3                                | 3(3)                                |
| Chills                                  | 25 (26)                             |
| Grade 5                                 | (0)                                 |
| Grade ≥3                                | (0)                                 |
| Hypoxia                                 | 23 (24)                             |
| Grade 5                                 | (0)                                 |
| Grade ≥3                                | 6(6                                 |
| Sinus Tachycardia                       | 25 (26)                             |
| Grade 5                                 | (0)                                 |
| Grade ≥3                                | 2(2                                 |
| Headache                                | 19 (20)                             |
| Grade 5                                 | (0)                                 |

<div style=\"page-break-after: always\"></div>

Data cutoff date: 14Sep2020.

<!-- image -->

| Grade ≥3                          | (0)   |
|-----------------------------------|-------|
| Tachycardia                       | 9 (9) |
| Grade 5                           | 0(0)  |
| Grade ≥3                          | (0)   |
| Nausea                            | 70    |
| Grade 5                           | (0)   |
| Grade ≥3                          | (0)   |
| Vomiting                          | 70    |
| Grade 5                           | (0)   |
| Grade ≥3                          | (0)   |
| Fatigue                           | 6(6   |
| Grade 5                           | 0(0)  |
| Grade ≥3                          | (0)   |
| Malaise                           | 6(6   |
| Grade 5                           | (0)   |
| Grade ≥3                          | (0)   |
| AlanineAminotransferase Increased | 4(4)  |
| Grade 5                           | (0)   |
| Grade ≥3                          | 2(2)  |
| Myalgia                           | 5()   |
| Grade 5                           | (0)   |
| Grade ≥3                          | (0)   |

The median time to onset was 4 days (range: 1 to 15 days) for subjects with FL. As of the data cutoff date, CRS had resolved in all but 1 subject in ZUMA-5; the subject with unresolved CRS had FL and died on Day 7 due to multiple organ dysfunction syndrome that was secondary to CRS. For the 96 subjects with FL whose CRS had resolved, the median duration of CRS was 6 days (range: 1 to 27 days).

<div style=\"page-break-after: always\"></div>

Table 21: Concomitant medications of interest (Safety Analysis Set)

|                                                       | Follicular Lymphoma (N = 124) (%6)   |
|-------------------------------------------------------|--------------------------------------|
| Subjects with any concomitant medications of interest | 79 (64)                              |
| Steroids                                              |                                      |
| Any                                                   | 50 (40)                              |
| Used for teatment of CRS                              | 19 (15)                              |
| Used for teatment of NE                               | 38 (31)                              |
| Other AEs                                             | 12 (10)                              |
| Tocilizumab                                           |                                      |
| Any                                                   | 56 (45)                              |
| Used for reatment of CRS                              | 56 (45)                              |
| Used for tmeatment of NE                              | 7(0)                                 |
| Oter AEs                                              | 5(4)                                 |
| Steroid or tocilizumab                                |                                      |
| Any                                                   | 68 (55)                              |
| Steroid and tocilizimab                               |                                      |
| Any                                                   | 38 (31)                              |
| Vasopressors                                          |                                      |
| Any                                                   | 15 (12)                              |
| Used for teatment of CRS                              | 7(6)                                 |
| Used for reatment of NE                               | 1 (1)                                |
| Nonsteroidal immumosuppressive agenis                 |                                      |
| Any                                                   | 1 (1)                                |
| Used for teatment of CR.S                             | 1(1)                                 |
| Used for teatment of NE                               | 0 (0)                                |
| Immumoglobulins                                       |                                      |
| Any                                                   | 34 (27)                              |

Data cutoff dato: 14Sep2020.

## 2. Neurologic events

<div style=\"page-break-after: always\"></div>

Table 22: Subject Incidence of Neurologic Events (Safety Analysis Set)

| MedDRA Preferred Term Worst CTCAE Grade   | Follicular Lymphoma (N = 124) n (%)   |
|-------------------------------------------|---------------------------------------|
| Subjects with any TE neurologic event     | 70 (56)                               |
| Grade 5                                   | 0 (0)                                 |
| Grade ≥3                                  | 19 (15)                               |
| Tremor                                    | 36 (29)                               |
| Grade 5                                   | (0) 0                                 |
| Grade ≥3                                  | 1(1)                                  |
| Confiusional State                        | 28 (23)                               |
| Grade 5                                   | 0 (0)                                 |
| Grade ≥3                                  | 6 (5)                                 |
| Encephalopathy                            | 24 (19)                               |
| Grade 5                                   | 0 (0)                                 |
| Grade ≥3                                  | 10 (8)                                |
| Aphasia                                   | 16 (13)                               |
| Grade 5                                   | 0(0)                                  |
| Grade ≥3                                  | 3 (2)                                 |
| Sommolence                                | 97)                                   |
| Grade 5                                   | 0 (0)                                 |
| Grade≥3                                   | 2 (2)                                 |
| Agitation                                 | 10 (8)                                |
| Grade 5                                   | 0 (0)                                 |
| Grade ≥3                                  | 2 (2)                                 |
| Dishubance In Attention                   | 7(6)                                  |
| Grade 5                                   | 0 (0)                                 |
| Grade ≥3                                  | 0 (0)                                 |
| Dysarthria                                | 6 (5)                                 |
| Grade 5                                   | 0 (0)                                 |
| Grade ≥3                                  | 1 (1)                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Paraesthesia                                           | 6(5)   |
|--------------------------------------------------------|--------|
| Grade 5                                                | 0 (0)  |
| Grade ≥3                                               | 0 (0)  |
| Delinium                                               | 3 (2)  |
| Grade 5                                                | 0 (0)  |
| Grade ≥3                                               | 2 (2)  |
| Hallucination                                          | 6 (5)  |
| Grade 5                                                | 0 (0)  |
| Grade ≥3                                               | 2 (2)  |
| Memory Impaiment                                       | 4 (3)  |
| Grade 5                                                | 0 (0)  |
| Grade ≥3                                               | 0 (0)  |
| Amnesia                                                | 2(2)   |
| Grade 5                                                | 0 (0)  |
| Grade ≥3                                               | 0 (0)  |
| Dysgraphia                                             | 3 (2)  |
| Grade 5                                                | 0 (0)  |
| Grade ≥3                                               | 0 (0)  |
| Seizure                                                | 2 (2)  |
| Grade 5                                                | 0 (0)  |
| Grade ≥3                                               | 0 (0)  |
| Apraxia                                                | 1 (1)  |
| Grade 5                                                | 0 (0)  |
| Grade ≥3                                               | 0 (0)  |
| Ataxia                                                 | 1(1)   |
| Grade 5                                                | 0 (0)  |
| Grade ≥3                                               | 0 (0)  |
| Cognitive Disorder                                     | 1 (1)  |
| Grade 5                                                | 0 (0)  |
| Grade ≥3                                               | 0 (0)  |
| Hypoaesthesia                                          | 2 (2)  |
| Grade 5                                                | 0 (0)  |
| Grade≥3                                                | 0 (0)  |
| Immune Effector Cell-Associated Neurotoxicity Syndrome | 2 (2)  |
| Grade 5                                                | 0(0)   |
| Grade ≥3                                               | 1 (1)  |

Data cutoff date: 14Sep2020.

For subjects with FL, the median time to event onset was 7 days (range: 1 to 177 days). Six subjects with FL had neurologic events with an onset &gt; 80 days after the axicabtagene ciloleucel infusion; these events were as follows:

- -One  subject  had  worst  Grade  1  disturbance  in  attention  (which  started  on  Day  94  and  was unresolved  as  of  the  data  cutoff  date)  and  somnolence  (Day  200  through  Day  219).  Only  the disturbance in attention was deemed related to axicabtagene ciloleucel.
- -One subject had a worst Grade 1 tremor (Day 94 through Day 262) that was deemed related to axicabtagene ciloleucel.

<div style=\"page-break-after: always\"></div>

- -One subject had worst Grade 1 aphasia (Day 97 through Day 193) that was deemed unrelated to axicabtagene ciloleucel.
- -One subject had worst Grade 2 events of amnesia (Day 119 through Day 137) and confusional state (Day 124 through Day 133), neither of which were deemed related to axicabtagene ciloleucel.
- -One subject had a worst Grade 1 memory impairment (Day 176 through Day 267) that was deemed unrelated to axicabtagene ciloleucel.
- -One subject had a worst Grade 1 hypoaesthesia (Day 452 through Day 456) that was deemed unrelated to axicabtagene ciloleucel.

As of the data cutoff date Sept 2020, three subjects had unresolved neurologic events at the data cutoff: memory impairment [started on Day 59], paresthesia [started on Day 66], and the aforementioned subject with disturbance in attention [started on Day 94]; all Grade 1. These events were all assessed as nonserious and deemed related to axicabtagene ciloleucel. One additional subject with FL had disturbance in attention that was deemed related to axicabtagene ciloleucel (started on Day 94; Grade 1). The subject died due to an unknown cause on Day 692, and the event was recorded to be resolved on the same day.

Among 70 subjects with FL who had neurologic events, 67 subjects (96%) had events that resolved; the events resolved within 3 weeks after the infusion for 41 subjects (59%) and within 8 weeks after the infusion for 54 subjects (77%). Among the 67 subjects with FL whose neurologic events had resolved, the median duration of neurologic events was 14.0 days (range: 1 to 452 days). Three subjects with FL had neurologic events that were present beyond study Day 200 as follows:

- -Two subjects had Grade 1 tremor from Day 94 to Day 262 and Day 19 to Day 369, respectively (both events were deemed related to axicabtagene ciloleucel).
- -One subject had Grade 1 hypoesthesia from Day 452 to Day 456 that was deemed unrelated to axicabtagene ciloleucel.

There were 11 subjects with FL who had neurologic events that occurred &gt; 30 days but &lt; 200 days after the axicabtgene ciloleucel infusion. All of these neurologic events were Grade 1 except for the events of Grade 2 amnesia and Grade 2 confusional state in 1 FL subject.

## 3. Cytopenias

Among subjects with FL, 91 subjects (73%) had any cytopenia AEs, and 86 subjects (69%) had worst Grade 3 or higher cytopenia AEs. 79 subjects (64%) had neutropenia AEs of any grade, and 75 subjects (60%) had worst Grade 3 or higher neutropenia AEs. Forty-four subjects (35%) had thrombocytopenia AEs of  any  grade,  and  29  subjects  (23%)  had  worst  Grade  3  or  higher  thrombocytopenia  AEs.  Forty-four subjects (35%) had anemia AEs of any grade, and 29 subjects (23%) had worst Grade 3 or higher anemia AEs.

The number of subjects with FL who had worst Grade 3 or higher prolonged neutropenia, thrombocytopenia, and anemia AEs (that were present on or after Day 30 following the axicabtagene ciloleucel infusion on Day 0)  were  34  subjects  (27%),  13  subjects  (10%),  and  8  subjects  (6%),  respectively.  The  duration  of cytopenias was calculated for subjects whose events had resolved. The mean (standard deviation) and median (range) times to onset of cytopenias were 16.7 (51.7) and 3.0 (1 to 325) days after axicabtagene ciloleucel infusion, respectively. The median duration of cytopenias were 27.0 (range: 1 to 769) days.

<div style=\"page-break-after: always\"></div>

## 4. Infections

Among subjects with FL, 64 subjects (52%) had infections; 18 subjects (15%) had worst Grade 3 infections and 1 subject (1%) had worst Grade 4 infection. No subject had a worst Grade 5 infection. The most common events by preferred terms within the SOC of infections and infestations were pneumonia (15 subjects, 12%), upper respiratory tract infection (14 subjects, 11%), and oral candidiasis, sinusitis, and urinary tract infection (9 subjects, 7%). The most common bacterial infections were staphylococcal infection (3 subjects, 2%) and clostridium difficile colitis and hemophilus infection (2 subjects each, 2%); all other bacterial infections were reported for 1 subject each (1%). The most common viral infections were influenza (6 subjects, 5%), rhinovirus infection (4 subjects, 3%), and herpes zoster (3 subjects, 2%); all other viral infections  were  reported  for  1  subject  each  (1%).  Opportunistic  infections  included  cytomegalovirus viraemia, mycobacterium kansasii infection, ophthalmic herpes simplex, and systemic candida, all reported in 1 subject each (1%). The most common other types of infections were pneumonia (15 subjects, 12%), upper respiratory tract infections (14 subjects, 11%), and sinusitis and urinary tract infections (9 subjects each, 7%). Worst Grade 3 events included pneumonia (7 subjects, 6%), urinary tract infection (3 subjects, 2%),  and  staphylococcal  infection,  clostridium  difficile  colitis,  bacterial  infection,  Escherichia  infection, pneumonia streptococcal, systemic candida, herpes zoster, sinusitis, vascular device infection, bacteremia, kidney infection, prostate infection, and viremia (1 subject each, 1%). The single worst Grade 4 event was sepsis (1 subject, 1%).

## 5. Hypogammaglobulinemia

Among subjects with FL, 24 subjects (19%) had AEs of hypogammaglobulinemia (17% in of subjects who had 3 or more lines of prior therapy), and the majority were either worst Grade 1 (7 subjects, 6%) or worst Grade 2 (16 subjects, 13%). One subject (1%) had a worst Grade 3 event.

## Important potential risks

## Secondary Malignancies

All other new malignancies were assessed as being unrelated to axicabtagene ciloleucel.

In the FL patients, there were 9 secondary malignancies identified: squamous cell carcinoma (2 subjects), malignant anorectal neoplasm and secondary anal/rectal cancer (1 subject), and myelodysplastic syndrome (MDS), malignant melanoma, basal cell carcinoma, acute bilineal leukemia, and prostate cancer (1 subject each). In addition, there was 1 subject whose death was flagged as due to secondary malignancy; this subject died due to acute myeloid leukemia after having partially withdrawn consent from the study and having agreed to be followed for survival. The events of acute bilineal leukemia and MDS were deemed related to lymphodepleting chemotherapy.

## Immunogenicity

Subjects were tested for immunogenicity. In the FL patients, based on an initial screening assay, 14 subjects were antibody-positive at baseline and 14 of the 123 tested subjects (11%) had a positive antibody test result at any time point. Samples from all 14 subjects were sent for confirmatory testing via a cell-based assay. Results of the confirmatory assay indicated that all 14 subjects were antibody-negative at all time points tested.

<div style=\"page-break-after: always\"></div>

Table 23: Anti-Axicabtagene Ciloleucel Antibody Summary (Safety Analysis Set)

|                                                                                                                                                                                                                                                                                  | Follicular Lymphoma (N = 124)                                                                                                                                                                                                                                                    | Marginal Zone Lymphoma (N=24)                                                                                                                                                                                                                                                    | Overall (N = 148)                                                                                                                                                                                                                                                                |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Subjects with an on-study result, n                                                                                                                                                                                                                                              | 123                                                                                                                                                                                                                                                                              | 23                                                                                                                                                                                                                                                                               | 146                                                                                                                                                                                                                                                                              |
| Antibody-positive at anytime, n (96)                                                                                                                                                                                                                                             | 14 (11)                                                                                                                                                                                                                                                                          | 7 (29)                                                                                                                                                                                                                                                                           | 21 (14)                                                                                                                                                                                                                                                                          |
| Subjects with a result at baseline,n                                                                                                                                                                                                                                             | 121                                                                                                                                                                                                                                                                              | 23                                                                                                                                                                                                                                                                               | 144                                                                                                                                                                                                                                                                              |
| Antibody-positive at baseline, n (%6)                                                                                                                                                                                                                                            | 14 (11)                                                                                                                                                                                                                                                                          | 6 (25)                                                                                                                                                                                                                                                                           | 20 (14)                                                                                                                                                                                                                                                                          |
| Subjects with a post-baseline result, n                                                                                                                                                                                                                                          | 121                                                                                                                                                                                                                                                                              | 23                                                                                                                                                                                                                                                                               | 144                                                                                                                                                                                                                                                                              |
| Antibody-positive at post-baseline with a negative or no result at baseline, n (%6)                                                                                                                                                                                              | 3 (2)                                                                                                                                                                                                                                                                            | 1(4)                                                                                                                                                                                                                                                                             | 4 (3)                                                                                                                                                                                                                                                                            |
| Antibody-positive at post-baseline with a negative result at baseline, n (%6)                                                                                                                                                                                                    | 3 (2)                                                                                                                                                                                                                                                                            | 1(4)                                                                                                                                                                                                                                                                             | 4(3)                                                                                                                                                                                                                                                                             |
| Antibody-positive at post-baseline with no result at baseline, n (%6)                                                                                                                                                                                                            | 0(0)                                                                                                                                                                                                                                                                             | 0 (0)                                                                                                                                                                                                                                                                            | 0 (0)                                                                                                                                                                                                                                                                            |
| Transient,n(%)                                                                                                                                                                                                                                                                   | 2 (2)                                                                                                                                                                                                                                                                            | 1(4)                                                                                                                                                                                                                                                                             | 3 (2)                                                                                                                                                                                                                                                                            |
| Data culoff date: 14Sep2020. . Subject is considored on-study on or aftor cmrollmont 6. Trawsient is defined an deweloping positive post-baselino with a negative orno rsults at bareline but renult at the subject's last timepoint tested within the shdy period was negatiwe. | Data culoff date: 14Sep2020. . Subject is considored on-study on or aftor cmrollmont 6. Trawsient is defined an deweloping positive post-baselino with a negative orno rsults at bareline but renult at the subject's last timepoint tested within the shdy period was negatiwe. | Data culoff date: 14Sep2020. . Subject is considored on-study on or aftor cmrollmont 6. Trawsient is defined an deweloping positive post-baselino with a negative orno rsults at bareline but renult at the subject's last timepoint tested within the shdy period was negatiwe. | Data culoff date: 14Sep2020. . Subject is considored on-study on or aftor cmrollmont 6. Trawsient is defined an deweloping positive post-baselino with a negative orno rsults at bareline but renult at the subject's last timepoint tested within the shdy period was negatiwe. |

## RCR

No patient tested positive for RCR.

## Tumor Lysis Syndrome

No cases of tumor lysis syndrome were reported.

## Aggravation of GVHD

No subject had an aggravation of GVHD that was attributable to axicabtagene ciloleucel.

## Arrhythmia

There were 52% FL patients with cardiac arrhythmia AEs (mainly grade 1 or 2). The most common events were sinus tachycardia (33%) and tachycardia (12%). There were 2% of subjects who presented worst Grade  3  cardiac  arrhythmias  (atrial  fibrillation  in  1  subject  and  sinus  tachycardia  in  2  subjects:  all considered related to axicabtagene ciloleucel, not serious). All cardiac arrhythmia events resolved.

## Laboratory findings

Among subjects with FL, the most common increased laboratory values were creatinine (79 subjects, 64%), glucose (78 subjects, 63%), and ALT (68 subjects, 55%). The most common worst Grade 3 or higher increased laboratory values were glucose and urate (11 subjects each, 9%), ALT (7 subjects, 6%), and aspartate  aminotransferase  (AST)  and  bilirubin  (5  subjects  each,  4%).  The  most  common  decreased laboratory values were leukocytes (122 subjects, 98%), neutrophils (121 subjects, 98%), and hemoglobin (103  subjects,  83%).  The  most  common  worst  Grade  3  or  higher  decreased  laboratory  values  were leukocytes (116 subjects, 94%), neutrophils (114 subjects, 92%), and platelets (43 subjects, 35%).

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## 1. AEs by Age

Among subjects with FL, compared with subjects who were &lt; 65 years old, subjects who were ≥ 65 years old showed a trend toward a higher incidence of SAEs (42% vs 55%), axicabtagene ciloleucel-related SAEs (27% vs 39%), neurologic events (49% vs 74%), and serious neurologic events (10% vs 26%). In general, subjects ≥ 65 years old had a higher incidence of worst Grade 3 or higher events.

## 2. AEs by Sex

Among subjects with FL, compared with males, females showed a trend toward a higher incidence of hypogammaglobulinemia (14% vs 27%), worst Grade 3 or higher axicabtagene ciloleucel-related AEs (52% vs 65%), infections (47% vs 59%), and worst Grade 3 or higher infections (10% vs 24%). Across all other categories, the incidence of worst Grade 3 or higher events was similar.

## 3. AEs by R/R Subgroup

Among subjects with FL, compared with subjects who had relapsed, subjects with refractory disease showed a trend toward a higher incidence of axicabtagene ciloleucel-related SAEs (23% vs 35%) and serious CRS (5% vs 15%). Across all other categories, the incidence of worst Grade 3 or higher events was similar.

## 4. AEs by Double Refractory Subgroup

Among subjects with FL, compared with subjects who were not in the double refractory subgroup, subjects in  the  double refractory subgroup showed a trend towards a higher incidence of SAEs (42% vs 56%), axicabtagene  ciloleucel-related  SAEs  (24%  vs  47%),  worst  Grade  3  or  higher  axicabtagene  ciloleucelrelated SAEs (18% vs 28%), and serious neurologic events (11% vs 25%).

## Safety related to drug-drug interactions and other interactions

No formal drug interaction studies have been conducted.

## Discontinuation due to adverse events

N/A.

## Post marketing experience

Axicabtagene ciloleucel was first approved in the US on 18 October 2017 and is currently approved under the trade name YESCARTA ®  in 36 countries including the US, Canada, Switzerland, Australia, Israel, and the European Economic Area (31 countries).

Postmarketing data are provided in a periodic safety update report/ periodic benefit-risk evaluation report (PBRER) for axicabtagene ciloleucel that covers the 6-month period from 18 April 2020 to 17 October 2020 and summarized here.

<div style=\"page-break-after: always\"></div>

As of 17 October 2020, 789 subjects have been exposed to axicabtagene ciloleucel in company sponsored interventional clinical trials. During the reporting period (18 April 2020 to 17 October 2020) approximately 43  subjects  were  administered  axicabtagene  ciloleucel  in  company  sponsored  clinical  trials.  In  the postmarketing setting, cumulative exposure to axicabtagene ciloleucel was approximately 3666 patients as of  17  October  2020.  During  the  reporting  period,  approximately  858  patients  were  administered axicabtagene ciloleucel in the postmarketing setting.

During the reporting period 18 April 2020 to 17 October 2020, the axicabtagene ciloleucel company core data sheet was updated twice. The first update, on 13 May 2020, included opportunistic infection data that further characterizes the known axicabtagene ciloleucel risk Infections. In addition, the CRS and neurologic toxicity grading and management guidances were revised and the 9-month interim data from ZUMA-5 were added. The second update, on 24 July 2020, included the 12-month primary analysis data from ZUMA-5. These updates will be incorporated into product information globally.

No significant safety issues for axicabtagene ciloleucel emerged following the commercialization of this product, and the overall benefit-risk evaluation for axicabtagene ciloleucel continues to be positive.

## 2.6.1. Discussion on clinical safety

The safety database included 124 FL patients treated with axicabtagene ciloleucel in the ZUMA-5 trial. The initial analysis cutoff date is March 12, 2020, which represents the 12 months follow-up data. Additional safety data were provided from the follow-up analysis 1, with a data cutoff date of 14 September 2020. This prespecified analysis was performed when at least 80 subjects with FL had had the opportunity to be followed for 18 months after axicabtagene ciloleucel infusion (the median actual study follow-up time was 20.34 months, range: 0.3 to 37.7 months; 73% had a potential study follow-up time of at least 18 months). For this assessment report, mostly the data from the 18 months follow-up were used. Yet the 18 months follow up is still considered rather short.

Essentially, the AEs and risks are similar to what has been described for other CAR T cell therapies and for axicabtagene ciloleucel in the other indications. No further risks and AEs could be identified which would be specific  for  axicabtagene  ciloleucel  or  for  the  indication  to  be  treated  with  KTE-X19.  The  toxicity management plans are presented in the SmPC and are in line with the general management plans for this product class.

The important identified risks (CRS, neurologic events, cytopenias, infections, and hypogammaglobulinemia)  were  largely  reversible  and  manageable  with  supportive  care  and  medical interventions.

In general, a lower incidence of CRS (78%) and worst Grade 3 CRS (6%) was observed in the FL patients in the ZUMA-5 study (vs. 93% and 9%, respectively, in patients with aggressive lymphoma; ZUMA-1 Phase 1 and Phase 2 Cohorts 1 and 2, ZUMA-9 Cohort 1, and ZUMA-12). This aspect could be attributed to the indolent type of the disease, but also the increased awareness in the clinical sites and the experience in treating CRS patients.

In addition, the number of patients with neurologic AEs (56%) and worst Grade 3 or higher neurologic AEs (15%) in the FL patients in the ZUMA-5 study seems to be a bit lower than what is known for this drug class (vs. 68% and 31%, respectively, in patients with aggressive lymphoma; ZUMA-1 Phase 1 and Phase 2 Cohorts 1 and 2, ZUMA-9 Cohort 1, and ZUMA-12). However, six subjects with FL had Grade 1 or 2 neurologic events with an onset &gt; 80 days after the axicabtagene ciloleucel infusion, 2 of which were deemed related to axicabtagene ciloleucel. There were 11 subjects with FL who had neurologic events that occurred &gt; 30 days but &lt; 200 days after the axicabtgene ciloleucel infusion. All of these neurologic events

<div style=\"page-break-after: always\"></div>

were Grade 1 except for the events of Grade 2 amnesia and Grade 2 confusional state in 1 FL subject. Three subjects with FL had neurologic events that were present beyond study Day 200, two of which were deemed related to axicabtagene ciloleucel. Therefore, there might be a tendency for late neurotoxicity in this  setting.  The  MAH  was  requested  to  provide  further  analysis  on  the  potential  causes  of  such  late toxicities, and to provide an in-depth analysis of late neurotoxicity incidence across all patients treated with axicabtagene ciloleucel and brexucabtagene autoleucel. The analysis provided did not identify a consistent pattern in either the time to onset or common etiology for these neurologic events. It is considered though unlikely, that the toxicity from previous lines of chemotherapy would cause these late neurotoxicites, as alluded to by the MAH. Nonetheless, the MAH should further explore this in the future. It is agreed that the SmPC does not need to be modified at this stage, as the late neurotoxicities were reported as low grade toxicities.

Among the important potential risks, no secondary malignancies were attributed to axicabtagene ciloleucel, no confirmed cases of immunogenicity were identified, no subjects tested positive for RCR, no cases of TLS or GvHD were identified.

There was a slight tendency toward a higher incidence of hypogammaglobulinemia (14% vs 27%), worst Grade 3 or higher axicabtagene ciloleucel-related AEs (52% vs 65%), infections (47% vs 59%), and worst Grade 3 or higher infections (10% vs 24%) in females. This trend was already observed for axicabtagene ciloleucel in the previous indication; however, no potential causes were identified so far, and seems to occur irrespective of the indication.

Compared with subjects who had relapsed, subjects with refractory disease showed a trend toward a higher incidence  of  axicabtagene  ciloleucel-related  SAEs  (23%  vs  35%)  and  serious  CRS  (5%  vs  15%). Additionally, compared with subjects who were not in the double refractory subgroup, subjects in the double refractory  subgroup  showed a trend towards a higher incidence of SAEs (42% vs 56%), axicabtagene ciloleucel-related SAEs (24% vs 47%), worst Grade 3 or higher axicabtagene ciloleucel-related SAEs (18% vs 28%), and serious neurologic events (11% vs 25%). These aspects seem to be specific for these disease subgroups and dependent of disease status.

## 2.6.2. Conclusions on clinical safety

The  important  identified  risks  for  axicabtagene  ciloleucel  in  the  FL  indication  are  CRS,  neurotoxicity, cytopenias, infections, hypogammaglobulinemia. There are some potential risks linked to the use of this product: secondary malignancy, immunogenicity, RCR, tumor lysis syndrome, and aggravation of GvHD.

Essentially, the AEs and risks are similar to what has been described for other CAR T cell therapies and for axicabtagene ciloleucel in the previous indication. No further risks and AEs could be identified which would be specific for axicabtagene ciloleucel or for the indication to be treated with axicabtagene ciloleucel.

## 2.6.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7. Risk management plan

The MAH submitted/was requested to submit an updated RMP version 7.0 with this application. The (main) proposed RMP changes are summarized in the below sections.

<div style=\"page-break-after: always\"></div>

## General comments:

RMP Part I 'Product overview' section 'indication(s) in the EEA' has been amended to include the new indication of axicabtagene ciloleucel. Since the current indications (DLBCL and PMBCL) have been added as proposed indications, amendments to this section are warranted. Only the new applied indication should be mentioned as 'proposed'.

## Safety Specification

## Epidemiology of the indications and target population

Module SI 'Epidemiology of the indication and target population' was updated satisfactorily to include epidemiology data for the proposed new indication of adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.

## Clinical trial exposure

Module SIII 'Clinical trial exposure' was adequately updated with regard to exposure information about e.g. dosage, duration, age group, gender, dose, ethnic origin for the proposed FL indication of axicabtagene ciloleucel.

## Populations not studied in clinical trials

Module SIV 'Populations not studied in clinical trials' - SIV.1 was updated with the ZUMA-5 study exclusion criteria. Additionally, section SIV.2 and SIV.3 were updated to include data from the ZUMA-5 study. The proposed changes are considered acceptable.

## Post-authorisation experience

Module SV 'Post-authorisation experience' was adequately updated with a new estimate of the postmarketing exposure.

## Identified and potential risks

In the Module SVII, section SVII.3.1 'Details of important identified risks, important potential risks, and missing information' has been updated with data from the ZUMA-5 study. The proposed changes are considered acceptable.

## Missing information

In the Module SVII, the subsection 'Use in non-Caucasian patient populations' under section SVII.3.2 'missing information' was updated to include data from the ZUMA-5 study. The proposed changes are considered acceptable.

<div style=\"page-break-after: always\"></div>

## Summary of the safety concerns

No changes were proposed by the MAH to the summary of safety concerns. This is considered acceptable as initially no new safety concerns were identified from the submitted data.

| Important Identified Risks   | Serious neurologic adverse reactions including cerebral oedema                    |
|------------------------------|-----------------------------------------------------------------------------------|
| Important Identified Risks   | CRS                                                                               |
| Important Identified Risks   | Cytopenias including aplastic anaemia                                             |
| Important Identified Risks   | Infections                                                                        |
| Important Identified Risks   | Hypogammaglobulinaemia                                                            |
| Important Potential Risks    | Secondary malignancy                                                              |
| Important Potential Risks    | Immunogenicity                                                                    |
| Important Potential Risks    | RCR                                                                               |
| Important Potential Risks    | TLS                                                                               |
| Important Potential Risks    | Aggravation of GvHD                                                               |
| Important Potential Risks    | Transmission of infectious agents via product                                     |
| Important Potential Risks    | Decrease in viability of the product due to inappropriate preparation of infusion |
| Important Potential Risks    | CD19 negative relapse                                                             |
| Important Potential Risks    | CAR-T persistence in relapsed patients                                            |
| Important Potential Risks    | Failure to produce a viable CAR-T cell product                                    |
| Missing Information          | Use in pregnancy and lactation                                                    |
| Missing Information          | Use in non-Caucasian patient populations                                          |
| Missing Information          | New occurrence or exacerbation of an autoimmune disorder                          |
| Missing Information          | Long term safety                                                                  |

## Pharmacovigilance plan

## Routine pharmacovigilance activities

## Specific Adverse Reaction/Adverse Event Follow-up Questionnaires

| Name of Questionnaire   | Description                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Neurologic events       | Targeted follow-up questionnaires for neurologic AEs (including serious neurologic adverse reactions) will be utilized as follow up to AE reports to determine start and stop dates of the event, severity and seriousness, outcome, diagnostic results, whether alternative causes for signs and symptoms were ruled out, treatment provided, relevant medical history, additional medications. |

<div style=\"page-break-after: always\"></div>

| Name of Questionnaire                                                         | Description                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CRS                                                                           | Targeted follow-up questionnaires for CRS will be utilized as follow up to an ADR report to determine start and stop dates of the event, severity and seriousness, outcome, diagnostic results, whether alternative causes for signs and symptoms were ruled out, treatment provided, relevant medical history, additional medications. This questionnaire will also collect information on patients with underlying organ impairments (e.g., hepatic, renal, cardiac, pulmonary) who experience CRS. |
| New malignancy                                                                | Targeted follow-up questionnaires for new malignancy will be utilized as follow up to AE reports to obtain further information regarding start and stop dates of the event, severity and seriousness, diagnostic results, pre-existing factors that may have contributed to the development of the new malignancy, relevant medical history and additional medications.                                                                                                                               |
| CD19 and CAR T Levels after Recurrence Following Initial Response to Yescarta | Targeted follow-up questionnaires for 'CD19 and CAR T levels after recurrence following initial response to Yescarta' will be utilized as a follow-up to AE reports to obtain further information regarding date of diagnosis, diagnostic results (CD19 status in tissue biopsy, presence of CAR T post infusion and at recurrence in blood), and additional information in case of CD19 negativity.                                                                                                  |

The RMP was updated to include new targeted follow-up questionnaire of CD19 and CAR-T Levels after Recurrence Following Initial Response to Yescarta for the important potential risks of CD19 Negative Relapse and CAR-T Persistence in Relapsed Patients. The proposed targeted follow-up questionnaire is endorsed.

## Additional pharmacovigilance activities

| Study Status                                                                                                                                                                                                               | Summary of Objectives                                                                                                                                                                                                      | Safety Concerns Addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due Dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                                 |
| KT-EU-471-0117 (PASS): Long-term, non- interventional study of recipients of Yescarta for treatment of relapsed or refractory DLBCL and PMBCL Ongoing                                                                      | Additional characterization of the identified risks, further evaluation of potential risks and missing information.                                                                                                        | Identified risks, potential risks, and missing information                                                                                                                                                                 | Final Report Submission                                                                                                                                                                                                    | 14 Nov 2040                                                                                                                                                                                                                |
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| None                                                                                                                                                                                                                       |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| KT-EU- 471 -0116 (Prescriber survey): Quantitative testing of HCP knowledge about YESCARTA (axicabtagene ciloleucel) risk minimization measures Ongoing                                                                    | To assess the prescribers' understanding of the risks of Yescarta                                                                                                                                                          | Serious neurologic adverse reactions including cerebral edema CRS Infections Secondary malignancies Decrease in viability of the product due to inappropriate preparation of infusion                                      | Final study report                                                                                                                                                                                                         | Submitted on 24 June 2021                                                                                                                                                                                                  |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                              | Summary of Objectives                                                                              | Safety Concerns Addressed                                                                                                                                                                                                                                                                                                                                                   | Milestones                                                   | Due Dates   |
|-------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------|-------------|
| KTE-C19-101 (ZUMA- 1) A Phase 1/2 multicenter study evaluating the safety and efficacy of KTE- C19 in subjects with refractory aggressive | To assess safety and efficacy of axicabtagene ciloleucel in refractory aggressive NHL              | Serious neurologic adverse reactions including cerebral edema CRS Cytopenias including aplastic anemia Infections Hypogammaglobulinemia Secondary malignancy Immunogenicity RCR TLS Aggravation of GvHD CD19 negative relapse CAR T persistence in relapsed Failure to produce a viable CAR T cell product                                                                  | Safety updates in the nearest PSUR to the annual anniversary | Annual      |
| NHL                                                                                                                                       |                                                                                                    |                                                                                                                                                                                                                                                                                                                                                                             | Final report Cohort 1 and 2                                  | 31 Aug 2031 |
| Ongoing                                                                                                                                   |                                                                                                    | patients Use in non-Caucasian patient populations New occurrence of an autoimmune                                                                                                                                                                                                                                                                                           | Final report Cohort 3                                        | 31 Oct 2032 |
| KTE-C19-105 (ZUMA- 5): A Phase 2 multicenter study of axicabtagene ciloleucel in subjects with relapsed/refractory iNHL                   | To assess efficacy and safety of axicabtagene ciloleucel in subjects with relapsed/refractory iNHL | Serious neurologic adverse reactions including cerebral edema CRS Cytopenias including aplastic anemia Infections Hypogammaglobulinemia Secondary malignancy                                                                                                                                                                                                                | Safety updates in the nearest PSUR to the annual anniversary | Annual      |
| Ongoing                                                                                                                                   | and safety of axicabtagene ciloleucel in combination with                                          | Immunogenicity RCR TLS Aggravation of GvHD CD19 negative relapse CAR T persistence in relapsed patients Failure to produce a viable CAR T cell product Use in non-Caucasian patient populations New occurrence of an autoimmune disorder Long term safety Serious neurologic adverse reactions including cerebral edema CRS Cytopenias including aplastic anemia Infections | Final report                                                 | 30 Apr 2036 |
| KTE-C19-106 (ZUMA- 6): A Phase 1-2 multi- center study evaluating the safety and efficacy of KTE C19 in                                   | To assess efficacy                                                                                 |                                                                                                                                                                                                                                                                                                                                                                             | Safety updates in the nearest PSUR to the annual anniversary | Annual      |

<div style=\"page-break-after: always\"></div>

| Study Status                                                            | Summary of Objectives                     | Safety Concerns Addressed                                                                                                                                                                                                                                                                            | Milestones   | Due Dates   |
|-------------------------------------------------------------------------|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------------|
| combination with Atezolizumab in subjects with refractory DLBCL Ongoing | atezolizumab in refractory DLBCL subjects | Hypogammaglobulinemia Secondary malignancy Immunogenicity RCR TLS Aggravation of GvHD CD19 negative relapse CAR T persistence in relapsed patients Failure to produce a viable CAR T cell product Use in non-Caucasian patient populations New occurrence of an autoimmune disorder Long term safety | Final report | 31 Aug 2033 |

## Overall conclusions on the PhV Plan

The proposed post-authorisation PhV development plan is sufficient to identify and characterise the risks of the product.

The study(ies) in the post-authorisation development plan are sufficient to monitor the effectiveness of the risk minimisation measures.

## Plans for post-authorisation efficacy studies

There are no planned or ongoing post-authorization efficacy studies.

## Risk minimisation measures

## Routine risk minimisation measures

| Safety concern                                                | Routine risk minimization activities                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Serious neurologic adverse reactions including cerebral edema | Routine risk communication : SmPC sections: 4.2, 4.4, 4.7 and 4.8 PL section: 2, 4 Routine risk minimization activities recommending specific clinical measures to address the risk : Recommendations for monitoring and management of serious neurologic adverse reactions, including treatment algorithms, are included in the SmPC sections 4.2 and 4.4. Other routine risk minimization measures beyond the Product Information : |

<div style=\"page-break-after: always\"></div>

| Safety concern                       | Routine risk minimization activities                                                                                                                                                                                                                                                                                                                              |
|--------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| CRS                                  | Use restricted to physicians experienced in the treatment of hematological cancers. Routine risk communication : SmPC sections: 4.2, 4.4 and 4.8 PL section: 2, 4                                                                                                                                                                                                 |
| Cytopenias including aplastic anemia | Routine risk communication : SmPC sections: 4.4 and 4.8 PL section: 2, 4 Routine risk minimization activities recommending specific clinical measures to address the risk : Recommendation for blood count monitoring is included in SmPC sections 4.4. Other routine risk minimization measures beyond the Product Information :                                 |
| Infections                           | Use restricted to physicians experienced in the treatment of hematological cancers. Routine risk communication : SmPC sections: 4.2, 4.4 and 4.8 PL section: 2, 4 Routine risk minimization activities recommending specific clinical                                                                                                                             |
| Hypogammaglobulinemia                | Routine risk communication : SmPC sections: 4.4 and 4.8 PL section: 4 Routine risk minimization activities recommending specific clinical measures to address the risk : Recommendations for monitoring immunoglobulin levels and management using infection precautions, antibiotic prophylaxis and immunoglobulin replacement are included in SmPC section 4.4. |

<div style=\"page-break-after: always\"></div>

| Safety concern       | Routine risk minimization activities                                                                                                                                                                                                                                                                                                                                                                                 |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                      | Other routine risk minimization measures beyond the Product Information : Use restricted to physicians experienced in the treatment of hematological cancers.                                                                                                                                                                                                                                                        |
| Secondary malignancy | Routine risk communication : SmPC sections: 4.4 Routine risk minimization activities recommending specific clinical measures to address the risk : Recommendation for life-long monitoring for secondary malignancies is included in SmPC section 4.4. Other routine risk minimization measures beyond the Product Information : Use restricted to physicians experienced in the treatment of hematological cancers. |
| Immunogenicity       | Routine risk communication : SmPC sections: 4.8 Routine risk minimization activities recommending specific clinical measures to address the risk : None Other routine risk minimization measures beyond the Product Information : Use restricted to physicians experienced in the treatment of hematological cancers.                                                                                                |
| RCR                  | Routine risk communication : None Routine risk minimization activities recommending specific clinical measures to address the risk : None Other routine risk minimization measures beyond the Product Information : Use restricted to physicians experienced in the treatment of hematological cancers                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Safety concern                                                                    | Routine risk minimization activities                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TLS                                                                               | Routine risk communication : SmPC section: 4.4 PIL section 2 Routine risk minimization activities recommending specific clinical measures to address the risk : Recommendations that patients with elevated uric acid or high tumor burden receive treatment prior to infusion, and for monitoring and management of TLS are included in SmPC section 4.4. Other routine risk minimization measures beyond the Product Information : |
| Aggravation of GvHD                                                               | Routine risk communication : SmPC section 4.4 PL section 2 Routine risk minimization activities recommending specific clinical measures to address the risk : None Other routine risk minimization measures beyond the Product Information : Use restricted to physicians experienced in the treatment of hematological cancers.                                                                                                     |
| Transmission of infectious agents via product                                     | Routine risk communication : SmPC Sections 4.2 PL Section 3 Routine risk minimization activities recommending specific clinical measures to address the risk : None Other routine risk minimization measures beyond the Product Information :                                                                                                                                                                                        |
| Decrease in viability of the product due to inappropriate preparation of infusion | Routine risk communication : SmPC section 4.2 Routine risk minimization activities recommending specific clinical measures to address the risk : None Other routine risk minimization measures beyond the Product Information :                                                                                                                                                                                                      |
| CD19 negative relapse                                                             | risk communication : risk minimization activities recommending specific clinical to address the risk :                                                                                                                                                                                                                                                                                                                               |
|                                                                                   | Routine None Routine measures                                                                                                                                                                                                                                                                                                                                                                                                        |

<div style=\"page-break-after: always\"></div>

| Safety concern                                           | Routine risk minimization activities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|----------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                          | None Other routine risk minimization measures beyond the Product Information : None                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| CAR T persistence in relapsed patients                   | Routine risk communication : None Routine risk minimization activities recommending specific clinical measures to address the risk : None Other routine risk minimization measures beyond the Product Information : None                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Failure to produce a viable CAR T cell product           | Routine risk communication : None Routine risk minimization activities recommending specific clinical measures to address the risk : None Other routine risk minimization measures beyond the Product Information : None                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Use in pregnancy and lactation                           | Routine risk communication : SmPC sections: 4.6 PL section: 2 Routine risk minimization activities recommending specific clinical measures to address the risk : Requirement for verification of pregnancy status of women of child-bearing potential included in SmPC section 4.6. Recommendation to refer to information for lymphodepleting chemotherapy for information on the need for effective contraception in patients who receive the lymphodepleting chemotherapy in SmPC section 4.6 and PL section 2. Other routine risk minimization measures beyond the Product Information : Use restricted to physicians experienced in the treatment of hematological |
| Use in non-Caucasian patient populations                 | Routine risk communication : None Routine risk minimization activities recommending specific clinical measures to address the risk : None Other routine risk minimization measures beyond the Product Information :                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| New occurrence or exacerbation of an autoimmune disorder | Routine risk communication : SmPC section 5.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| Safety concern   | Routine risk minimization activities                                                                                                                                                                                                                                                                    |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  | Routine risk minimization activities recommending specific clinical measures to address the risk : None Other routine risk minimization measures beyond the Product Information : Use restricted to physicians experienced in the treatment of hematological cancers.                                   |
| Long term safety | Routine risk communication : None Routine risk minimization activities recommending specific clinical measures to address the risk : None Other routine risk minimization measures beyond the Product Information : Use restricted to physicians experienced in the treatment of hematological cancers. |

Only minor editorial amendments have been executed for the routine risk minimization measures. The proposed changes to RMP Part V are considered acceptable.

## Additional risk minimisation measures

## Additional Risk Minimization Activity: HCP Educational Material

| HCP Educational Material                                | HCP Educational Material                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|---------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Objective(s)                                            | To inform HCPs on how to monitor and manage symptoms associated with CRS and serious neurologic adverse reactions and provide guidance on reporting these serious adverse reactions associated with Yescarta.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Rationale for the additional risk minimization activity | The HCP educational material will be provided at launch of the product and at the time of updates in each member state and will highlight the risks of Yescarta and will help ensure that the HCPs using Yescarta are made aware of the risks and will be able to monitor for them. The HCP educational material will also help HCPs ensure that they have access to a minimum of 1 dose of tocilizumab prior to Yescarta infusion. The treatment center must have access to an additional dose of tocilizumab within 8 hours of each previous dose. CRS is not commonly observed with most anti-cancer medications. Therefore, HCPs may not be as experienced in managing these adverse reactions. CRS occurred in 93% of patients in ZUMA-1 Phase 1 and Phase 2 Cohorts 1 and 2, and 82% of patients in ZUMA-5. The median time to onset for CRS was 2 days for patients in ZUMA-1 and 4 days for patients in ZUMA-5, whilst the median time to onset for neurologic events was 5 days for patients in ZUMA-1 Phase 1 and Phase 2 Cohorts 1 and 2, and 7 days for patients in ZUMA-5. It is anticipated that HCP educational material will enhance early diagnosis and proper evidence-based management of these events, including information on when and how to use tocilizumab and/or steroids. The expected result is improvement in the outcomes of or mitigating severe, life-threatening, and fatal CRS and/or neurologic adverse reactions. |
| Target audience and planned distribution path           | The HCP educational material targets HCPs who are likely to prescribe Yescarta. The method of delivery of the HCP educational material is determined on a Member State basis to align with local clinical organization.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

## HCP Educational Material

| Plans to evaluate the effectiveness of the interventions and criteria for success   | The evaluation of the effectiveness of HCP educational material will include the following:  Evaluations of HCPs' understanding of the risks of Yescarta by means of a prescriber survey. The objective of the prescriber survey is to assess the prescribers' understanding of the risks of Yescarta.  To meet this objective, the prescriber survey will: o Assess whether every prescriber received the HCP educational material. o Measure the prescribers' understanding of known important identified risks associated with Yescarta. o Assess whether prescribers understand how to identify and treat CRS or serious neurologic adverse reactions.  A post-marketing registry will assess the incidence of serious neurologic adverse reactions and CRS and will thus provide an outcome measure of the effectiveness of the risk minimization program.  A summary of all reported severe, life-threatening CRS and serious neurologic adverse reactions with an analysis of AEs outcomes and treatment. This will be presented within periodic safety reports. These activities will assess whether the HCP educational material is meeting its objectives. If the conclusion is that it is not, Kite Pharma will discuss with the Agency ways that this additional risk minimization activity can be modified.   |
|-------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Abbreviations: AE = adverse event; CRS = cytokine release syndrome; HCP = healthcare professional.

Additional Risk Minimization Activity: PAC

## PAC

<div style=\"page-break-after: always\"></div>

| Objective(s)                                                                      | To inform patients of the risks of CRS and serious neurologic adverse reactions, associated with Yescarta. For patients to share the information in the PAC with their HCPs.                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rationale for the additional risk minimization activity                           | Easy and immediate patients' access to information about the common signs and symptoms of CRS, and serious neurologic adverse reactions will promote early medical attention and treatment that will help mitigating the risks.                                                                                                                                                                                                                                                                                                                                                             |
| Target audience and planned distribution path                                     | The target audience is patients who will be treated with Yescarta. The PAC will be part of the health care professional kit and will be provided to the patient by the hematologist/heme oncologist or nursing staff.                                                                                                                                                                                                                                                                                                                                                                       |
| Plans to evaluate the effectiveness of the interventions and criteria for success | The evaluation of the effectiveness of the PAC will include the following:  Prescriber survey to assess the physicians' understanding of the key risks associated with Yescarta (e.g., CRS, serious neurologic adverse reactions).  Collection of evidence that the PAC has been provided to patients treated with Yescarta. These activities will assess the effectiveness of the PAC in meeting its objective. If the conclusion is that the objective is not being met, Kite Pharma will discuss with the Agency ways that this additional risk minimization activity can be modified. |

Abbreviations: CRS = cytokine release syndrome; HCP = healthcare professional; PAC = patient alert card.

<div style=\"page-break-after: always\"></div>

Additional Risk Minimization Activity: Controlled Distribution Program

| Controlled Distribution Program                                                   | Controlled Distribution Program                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Objective(s)                                                                      | To ensure that Yescarta is only administered in a qualified clinical setting.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Rationale for the additional risk minimization activity                           | To minimize the important risks of CRS and neurologic adverse reactions, clinical facilities are required to complete a formal site qualification process prior to ordering Yescarta.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Target audience and planned distribution path                                     | The controlled distribution program targets clinical facilities in which Yescarta is administered. The process of qualification is carried out by the QA Site Qualification EU team at Kite Pharma EU BV. The site qualification process includes the following steps:  Introduction to key Yescarta processes  Quality Audit  Training of HCPs  'Dry-run exercise'  Continued monitoring of compliance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Plans to evaluate the effectiveness of the interventions and criteria for success | The evaluation of the effectiveness of the controlled distribution program will include the following:  Collection of evidence for the training delivered to HCPs and other relevant site personnel during site qualification.  A post-marketing registry will assess the incidence of serious neurologic adverse reactions and CRS and will thus provide an outcome measure of the effectiveness of the risk minimization program.  A summary of all reported severe, life-threatening CRS and serious neurologic adverse reactions with an analysis of AE outcomes and treatment. This will be presented within periodic safety reports. These activities will assess whether the Controlled Distribution Program is meeting its objectives. Effectiveness of the controlled distribution program will be reported in the PSUR. If the conclusion is that it is not, Kite Pharma will discuss with the Agency ways that this additional risk minimization activity can be modified. |

Abbreviations: AE = adverse event; CRS = cytokine release syndrome; HCP = healthcare professional; PSUR = periodic safety update report; QA = quality assurance.

<div style=\"page-break-after: always\"></div>

## Additional Risk Minimization Activity: Guide to Handling, Method of Administration and Sampling Recommendations for Secondary Malignancies

## Guide to Handling, Method of Administration and Sampling Recommendations for Secondary Malignancies

| Objective(s)                                                                      | To ensure the appropriate handling, preparation and administration of Yescarta, and raise awareness of the SmPC recommendations for additional testing in case of secondary malignancy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Rationale for the additional risk minimization activity                           | To minimize the potential risks of decrease in viability of the product due to inappropriate preparation of the Yescarta infusion and secondary malignancy, HCPs will receive training materials which include instructions on the appropriate handling, preparation and administration of Yescarta and on sampling and management recommendations for secondary malignancies.                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Target audience and planned distribution path                                     | The Guide to Handling, Method of Administration and Sampling Recommendations for Secondary Malignancies will target HCPs who are likely to be involved in the preparation of the Yescarta infusion and to the prescriber. The exact method of delivery of the HCP educational material will be determined on a Member State basis to align with local clinical organization.                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Plans to evaluate the effectiveness of the interventions and criteria for success | The evaluation of the effectiveness of the Guide to Handling, Method of Administration and Sampling Recommendations for Secondary Malignancies includes the following:  Collection of evidence that the training was delivered to HCPs and other relevant site personnel during site qualification.  Prescriber survey will assess understanding of the key risk minimization messages associated with handling and administration of Yescarta. These activities will assess the effectiveness of the Guide to Handling, Method of Administration and Sampling Recommendations for Secondary Malignancies in meeting its objective. If the conclusion is that the objective is not being met, Kite Pharma will discuss with the Agency ways that this additional risk minimization activity can be modified. |

The section 'Additional Risk Minimization Activity: Healthcare Provider (HCP) educational Material Rationale for the additional risk minimization activity' has been updated to include median time to onset and frequency for events of cytokine release syndrome (CRS) from both ZUMA-1 and ZUMA-5.

Section V.3 'Summary of risk minimization measures' has been updated with minor editorial amendments. Additionally, updates to this section were made in accordance with the updates to Part III (PV Plan) to include event follow-up questionnaire as routine pharmacovigilance activity beyond adverse reactions reporting and signal detection for the important potential risks of CD19 negative relapse and CAR-T persistence in relapsed patients, and to align information on additional PhV activities with RMP Part III.2 and III.3.

## Summary of risk minimisation measures

| Safety Concern                                                | Risk Minimization Measures                                                                | Pharmacovigilance Activities                                                                                                 |
|---------------------------------------------------------------|-------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------|
| Important identified risk(s)                                  | Important identified risk(s)                                                              |                                                                                                                              |
| Serious neurologic adverse reactions including cerebral edema | Routine risk minimization measures : SmPC sections 4.2, 4.4, 4.7 and 4.8 PL sections 2, 4 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : Event follow-up questionnaire |

<div style=\"page-break-after: always\"></div>

| Safety Concern                       | Risk Minimization Measures                                                                                                                                                                                                                                                         | Pharmacovigilance Activities                                                                                                                                                                                                                                                         |
|--------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                      | Use restricted to physicians experienced in the treatment of hematological cancers Additional risk minimization measures :  HCP educational material  PAC  Controlled distribution program                                                                                      | Additional pharmacovigilance activities : KT-EU-471-0117: 14 Nov 2040 KT-EU-471-0116: Submitted on 24 June 2021 ZUMA-1: 31 Oct 2032 ZUMA-5: 30 Apr 2036 ZUMA-6: 31 Aug 2033                                                                                                          |
| CRS                                  | Routine risk minimization measures : SmPC sections 4.2, 4.4 and 4.8 PL sections 2, 4 Use restricted to physicians experienced in the treatment of hematological cancers Additional risk minimization measures :  HCP educational material  PAC  Controlled distribution program | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : Event follow-up questionnaire Additional pharmacovigilance activities : KT-EU-471-0117: 14 Nov 2040 KT-EU-471-0116: Submitted on 24 June 2021 ZUMA-1: 31 Oct 2032 ZUMA-5: 30 Apr 2036 |
| Cytopenias including aplastic anemia | Routine risk minimization measures : SmPC sections 4.4 and 4.8 PL sections: 2, 4 Use restricted to physicians experienced in the treatment of hematological cancers Additional risk minimization measures : None                                                                   | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None Additional pharmacovigilance activities : KT-EU-471-0117: 14 Nov 2040 ZUMA-1: 31 Oct 2032 ZUMA-5: 30 Apr 2036 ZUMA-6: 31 Aug 2033                                                |
| Infections                           | Routine risk minimization measures : SmPC sections 4.2, 4.4 and 4.8 PL sections: 2, 4 Use restricted to physicians experienced in the treatment of hematological cancers Additional risk minimization measures : None                                                              | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None Additional pharmacovigilance activities : KT-EU-471-0117: 14 Nov 2040 KT-EU-471-0116: Submitted on 24 Jun 2021 ZUMA-1: 31 Oct 2032 ZUMA-5: 30 Apr 2036 ZUMA-6: 31 Aug 2033       |

## Safety Concern

## Risk Minimization Measures

## Pharmacovigilance Activities

Hypogammaglobulinemia

## Routine risk minimization measures :

SmPC sections 4.4 and 4.8

PL section: 4

Use restricted to physicians experienced in the treatment of hematological cancers

## Additional risk minimization measures :

None

## Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection :

None

## Additional pharmacovigilance activities :

KT-EU-471-0117: 14 Nov 2040

ZUMA-1: 31 Oct 2032

ZUMA-5: 30 Apr 2036

ZUMA-6: 31 Aug 2033

## Important potential risk(s)

Secondary malignancy

## Routine risk minimization measures :

SmPC sections 4.4

Use restricted to physicians experienced in the treatment of hematological cancers

## Additional risk minimization measures :

Guide to Handling, Method of Administration and Sampling Recommendations for Secondary Malignancies

## Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection :

Event follow-up questionnaire

## Additional pharmacovigilance activities :

KT-EU-471-0117: 14 Nov 2040

KT-EU-471-0116: Submitted on 24 Jun 2021

ZUMA-1: 31 Oct 2032

ZUMA-5: 30 Apr 2036

ZUMA-6: 31 Aug 2033

Immunogenicity

## Routine risk minimization measures :

SmPC sections 4.8

Use restricted to physicians experienced in the treatment of hematological cancers

## Additional risk minimization measures :

None

## Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection :

None

## Additional pharmacovigilance activities :

ZUMA-1: 31 Oct 2032

ZUMA-5: 30 Apr 2036

ZUMA-6: 31 Aug 2033

RCR

## Routine risk minimization measures :

Use restricted to physicians experienced in the treatment of hematological cancers

## Additional risk minimization measures :

None

## Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection :

None

## Additional pharmacovigilance activities :

KT-EU-471-0117: 14 Nov 2040

ZUMA-1: 31 Oct 2032

ZUMA-5: 30 Apr 2036

ZUMA-6: 31 Aug 2033

<div style=\"page-break-after: always\"></div>

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                    | Risk Minimization Measures                                                                                                                                                                          | Pharmacovigilance Activities                                                                                                                                                                                                |
|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TLS                                                                               | Routine risk minimization measures : SmPC sections 4.4 PL section 2 Use restricted to physicians experienced in the treatment of hematological cancers Additional risk minimization measures : None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None Additional pharmacovigilance activities : KT-EU-471-0117: 14 Nov 2040 ZUMA-1: 31 Oct 2032 ZUMA-5: 30 Apr 2036           |
| Aggravation of GvHD                                                               | Routine risk minimization measures : SmPC section 4.4 PL section 2 Use restricted to physicians experienced in the treatment of hematological cancers Additional risk minimization measures : None  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None Additional pharmacovigilance activities : KT-EU-471-0117: 14 Nov 2040 ZUMA-1: 31 Oct 2032 ZUMA-5: 30 Apr 2036           |
| Transmission of infectious agents via product                                     | Routine risk minimization measures : SmPC Sections 4.2 PL Section 3 Additional risk minimization measures : None                                                                                    | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None Additional pharmacovigilance activities : None                                                                          |
| Decrease in viability of the product due to inappropriate preparation of infusion | Routine risk minimization measures : SmPC Sections 4.2 Additional risk minimization measures : Guide to Handling, Method of Administration and Sampling Recommendations for Secondary Malignancies  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None Additional pharmacovigilance activities : KT-EU-471-0116: Submitted on 24 June                                          |
| CD19 negative relapse                                                             | Routine risk minimization measures : None Additional risk minimization measures : None                                                                                                              | 2021 Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : Event follow-up questionnaire Additional pharmacovigilance activities : KT-EU-471-0117: 14 Nov 2040 ZUMA-1: 31 Oct 2032 |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                 | Risk Minimization Measures                                                             | Pharmacovigilance Activities                                                                                                                                                                                                               |
|------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                |                                                                                        | ZUMA-5: 30 Apr 2036 ZUMA-6: 31 Aug 2033                                                                                                                                                                                                    |
| CAR T Persistence in relapsed patients         | Routine risk minimization measures : None Additional risk minimization measures : None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : Event follow-up questionnaire Additional pharmacovigilance activities : KT-EU-471-0117: 14 Nov 2040 ZUMA-1: 31 Oct 2032 ZUMA-5: 30 Apr 2036 |
| Failure to produce a viable CAR T cell product | Routine risk minimization measures : None Additional risk minimization measures : None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None Additional pharmacovigilance activities : KT-EU-471-0117: 14 Nov 2040 ZUMA-1: 31 Oct 2032 ZUMA-5: 30 Apr 2036 ZUMA-6: 31 Aug 2033      |

## Missing information

Use in pregnancy and lactation

Use in non-Caucasian patient populations

## Routine risk minimization measures :

SmPC sections 4.6

PL section 2

Use restricted to physicians experienced in the treatment of hematological cancers

Additional risk minimization measures

:

None

Routine risk minimization measures

None

Additional risk minimization measures

:

None

:

Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection :

None

Additional pharmacovigilance activities

:

KT-EU-471-0117: 14 Nov 2040

Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection :

None

Additional pharmacovigilance activities :

ZUMA-1: 31 Oct 2032

ZUMA-5: 30 Apr 2036

ZUMA-6: 31 Aug 2033

<div style=\"page-break-after: always\"></div>

| Safety Concern                                           | Risk Minimization Measures                                                                                                                                                            | Pharmacovigilance Activities                                                                                                                                                                                                          |
|----------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| New occurrence or exacerbation of an autoimmune disorder | Routine risk minimization measures : SmPC section 5.1 Use restricted to physicians experienced in the treatment of hematological cancers Additional risk minimization measures : None | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None Additional pharmacovigilance activities : KT-EU-471-0117: 14 Nov 2040 ZUMA-1: 31 Oct 2032 ZUMA-5: 30 Apr 2036 ZUMA-6: 31 Aug 2033 |
| Long term safety                                         | Routine risk minimization measures : Use restricted to physicians experienced in the treatment of hematological cancers Additional risk minimization measures : None                  | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection : None Additional pharmacovigilance activities : KT-EU-471-0117: 14 Nov 2040 ZUMA-1: 31 Oct 2032 ZUMA-5: 30 Apr 2036 ZUMA-6: 31 Aug 2033 |

All changes are considered acceptable.

## Overall conclusions on risk minimisation measures

The proposed risk minimisation measures are sufficient to minimise the risks of the product in the proposed indication(s).

## Elements for a public summary of the RMP

The Part VI: summary of the risk management plan has been updated to include the new indication. The updates made in RMP Parts I through IV have been reflected satisfactorily in the RMP summary.

## Annexes

The annexes have been updated as follows:

## Part VII Annexes:

- Annex 4: Added new targeted follow-up questionnaires of CD19 and CAR- T Levels after Recurrence Following Initial Response to Yescarta for the important potential risks of CD19 Negative Relapse and CAR-T Persistence in Relapsed Patients. Annex 4 is considered acceptable as it is.
- Annex 6: Updated HCP Educational Material to include follicular lymphoma (FL) and the incidence of CRS and neurologic adverse reactions from ZUMA-5. Annex 6 is considered acceptable as it is.

<div style=\"page-break-after: always\"></div>

The following further changes are requested in the next warranted RMP update:

- Annex 8: The MAH updated annex 8 with the changes in this RMP.

## Overall conclusion on the RMP

The changes to the RMP in version 7.0 are acceptable.

## 2.8. Update of the Product Information

As a consequence of this new indication, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 of the SmPC have been updated. The Package Leaflet has been updated accordingly.

## 2.8.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Yescarta The bridging report submitted by the MAH has been found acceptable.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The agreed indication is: 'Yescarta is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy'.

FL is one of the second most common type of lymphomas representing about 10-20% of all NHL. The clinical course of the disease is characterised by relapses, with progressively diminishing remission periods. The majority of patients are diagnosed in advanced stage (III-IV according to Ann Arbor staging). One of the characteristics of the FL immunophenotype is the expression on the surface of tumour cells of CD19, which is a common target for different therapeutic modalities in patients with B-cell malignancies.

## 3.1.2. Available therapies and unmet medical need

Although newly diagnosed FL of low grade is an indolent disease and patients respond well to first-line chemoimmunotherapy, most of patients relapse and received several treatments with different mechanisms of action in second and third line, including chemoimmunotherapy, immunomodulating agents and PI3K inhibitors. For a small proportion of selected patients stem cell transplant (auto- or allo-SCT) is an option. After 3, 4, 5 and 6 lines of therapy the overall survival is respectively 1.1, 0.9, 0.6 and 0.5 years (Batlevi et al., 2020). The disease remains incurable and there is a risk of histologic transformation to high grade NHL. An unmet need for therapeutic options with novel mechanisms of action and manageable toxicity, especially in late lines of relapsed and/or refractory disease, is recognised in this late clinical setting.

<div style=\"page-break-after: always\"></div>

## 3.1.3. Main clinical studies

The main clinical study supporting this application is the single arm trial ZUMA-5 (KTE-C19-105), a Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL), which is ongoing in the US. The study includes patients with two histological types of indolent NHL (iNHL): FL and marginal zone lymphoma (MZL). With regard to the indication R/R FL, only subjects classified FL Grade 1-3a have been included, since FL Grade 3b is treated as de novo DLBCL.  The results of the primary (cut-off date 12March 2020) and follow-up 18-month (cut-off date 14Sept 2020), and upon request, follow-up 24-month (cut-off date 31Mar2021) analyses have been submitted.

## 3.2. Favourable effects

Objective response rate (ORR), defined as complete response (CR) plus partial response (PR) per Lugano classification and central assessment, was 91% (95% CI; 82%, 96%) in FL subjects after 3 or more prior lines of therapy (FAS, leukapheresed patients). The CR rate was 79% in this population corresponding to the intended indication. Median DOR is 38.6 months (95% CI: 24.7, NE)

## 3.3. Uncertainties and limitations about favourable effects

The treatment benefit cannot be comprehensively and comparatively assessed as it was only studied in a single-arm trial.

The major initial uncertainty was related to the discrepancy in the number of patients with histologically confirmed FL by local and retrospective central histopathological diagnosis. Confirmation of FL by central assessment in all subjects, relevant for the intended marketing authorisation, would be ideal situation. However, the Applicant's approach to provide new sets of populations under consideration of a more recent data cut-off date (31 March 2021), as required, and to revise the data sets for FAS, IAS and SAS by excluding subjects with centrally confirmed non-FL (n=5 subjects), is considered acceptable, given that the following revision of the gathered efficacy and safety results in the intended target population did not indicate  clinically  significant  changes.  It  is  known  from  scientific  literature  that  a  reliable  pathological diagnosis of FL depends largely on size and quality of the tissue sample, and that discordant histological findings across different biopsies are often observed.

## 3.4. Unfavourable effects

The AEs reported are similar to what has been described for other CAR T cell therapies and for axicabtagene ciloleucel in the other indications.

The most significant and frequently occurring adverse reactions were CRS (77%), infections (59%) and encephalopathy (47%).

Serious  adverse  reactions  occurred  in  45%  of  patients.  The  most  common  serious  adverse  reactions included encephalopathy (16%), unspecified pathogen infections (12%), CRS (12%), bacterial infections (5%), fever (4%), viral infection (4%) and thrombosis (3%).

The most common (≥5%) Grade 3 or higher non -haematological adverse reactions included encephalopathy (14%), unspecified pathogen infections (11%) and CRS (6%).

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

The safety database included 124 FL patients treated with axicabtagene ciloleucel in the ZUMA-5 trial. Yet, the potential follow-up time of 18 months is still rather short. While this period would be enough to identify the earlier and immediate AEs, there are certain potential risks for which conclusive data could not be obtained  due  to  the  limited  follow-up  time.  Therefore,  aspects  regarding  secondary  malignancies, replication  competent retrovirus analysis will be collected in the PASS registry study for the long-term follow-up.

The number of late neurologic toxicities gave additional uncertainties. Similarly, the higher incidence of toxicities in females remains an uncertainty for this product.

## 3.6. Effects Table

Table 24. Effects Table for Yescarta in follicular lymphoma (FL) excluding centrally confirmed non-FL subjects (data cut-off: 31 March 2021); FAS (n=75) for efficacy and SAS for safety

| Effect                                       | Short description    | Unit                 | Treatment            | Control              | Uncertainties / Strength of evidence                                            | References           |
|----------------------------------------------|----------------------|----------------------|----------------------|----------------------|---------------------------------------------------------------------------------|----------------------|
| Favourable Effects                           | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects   | Favourable Effects                                                              | Favourable Effects   |
| ORR                                          |                      |                      | 91% (82, 96)         |                      | Single-arm trial, no comparison possible                                        |                      |
| CR (after 3 or more prior therapy lines)     |                      |                      | 77% (66%, 86%)       |                      | Single-arm trial                                                                |                      |
| DOR (KM-median estimate)                     |                      |                      | 38,6 months          | N/A                  | Single-arm trial, no comparison possible                                        |                      |
| Unfavourable Effects                         | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects | Unfavourable Effects                                                            | Unfavourable Effects |
| Cytokine Release Syndrome (CRS)              | ≥ Grade 3            | % (n/n)              | 6% (8/124)           | N/A                  | Strong evidence for relationship to the treatment with axicabtagene ciloleucel  |                      |
| CART-related encephalopat hy syndrome (CRES) | ≥ Grade 3            | % (n/n)              | 14% (17/124)         | N/A                  | Strong evidence for relationship to the treatment with axicabtagene ciloleucel. |                      |
| Infections                                   | ≥ Grade 3            | % (n/n)              | 11%                  | N/A                  | Possibly related to conditioning chemotherapy                                   |                      |

Abbreviations: N/A= not applicable

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The observed high ORR and CR rates supported by DOR data designate that clinically meaningful benefit could be achieved at long term in the intended population of relapsed or refractory follicular lymphoma (FL) patients in 4L+ setting with poor prognosis and progressively increasing refractoriness to prior therapeutic modalities.

The most important unfavourable effects of axicabtagene ciloleucel as a CAR T cell product in general are CRS, neurotoxicity,  cytopenias,  infections  and  hypogammaglobulinaemia.  Generally  these  unfavourable effects  are  either  treatable  or  have  a  self-limiting  course  and  are  reversible.  The  potential  serious consequences of CRS have been recognised and treatment algorithms have been developed that are still being refined according to further experience. Overall considering the life-threatening disease the safety profile of KTE-X19 seems to be acceptable for the target population. Since the unfavourable effects are in line with the experience made with this drug class, the identified uncertainties and limitations are of limited relevance.

## 3.7.2. Balance of benefits and risks

While compelling ORR and CR were reported and the depth of responses appears to be accompanied by their durability, uncertainty remains regarding the true magnitude of the effects, especially at long term, i. e. after Month 24. The currently limited follow-up does not allow to fully contextualise response data based on PFS/OS results. The safety database is considered sufficiently characterised due to data available in other patient populations, the toxicity is manageable and no new safety signals have been reported.

## 3.7.3. Additional considerations on the benefit-risk balance

## 3.8. Conclusions

The overall B/R of axicabtagene is positive for adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy.

<div style=\"page-break-after: always\"></div>

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CAT considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, IIIA and IIIB   |

Extension of indication to include the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy. Consequently, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC and Package Leaflet are proposed to be updated. As a consequence, the RMP (version 7.0) has been updated to align with the indication extension.

In addition, the applicant has taken the opportunity to make minor editorial corrections throughout the SmPC and package leaflet. Lastly, the newly assigned ATC code has been included in the SmPC.

The variation leads to amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I, IIIA and IIIB and to the Risk Management Plan are recommended.

## Similarity with authorised orphan medicinal products

The CAT by consensus is of the opinion that Yescarta is not similar to Gavyzaro and Kymriah within the meaning of Article 3 of Commission Regulation (EC) No. 847/200 (See appendix 1).

## Additional market protection

Furthermore, the CAT reviewed the data submitted by the MAH, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies (see appendix 2).

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module 8 \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

<div style=\"page-break-after: always\"></div>

## Summary

Please refer to Scientific Discussion 'Yescarta-H-C-004480/II/0042'